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ABSTRACT 
 
Rhesus macaques represent a valuable model in biomedical research and in development 
of vaccines and therapeutics. Due to the lack of reagents, the general properties of IgG and 
corresponding cellular receptors (FcγR) in this species are poorly characterized. We engineered 
recombinant IgGs containing each of the four rhesus macaque heavy constant region (CH) 
subclasses. To define FcγRs that mediate IgGs, we identified and characterized three FcγR 
classes, and generated recombinant cDNA constructs. cDNA IgH constructs were created by 
fusing – by sequence overlap extension PCRs – a gene segment encoding the murine variable 
heavy domain specific for the hapten NIP, an established specificity system for assessing 
antibody effector functions, with rhesus macaque CH fragments. The complete IgH constructs 
were transfected into J558L cells, a murine IgH-lost myeloma cell line expressing anti-NIP light 
chain. Secretion of engineered IgGs was determined by ELISAs using NIP-BSA and anti-
monkey IgG-specific antibodies. Molecular cloning methods were applied to identify and clone 
FcγR genes, and recombinant FcγR cDNA constructs were created by the recombinant DNA 
method. Four engineered IgH cDNA constructs were successfully created. Recombinant IgGs, in 
the intact Ig form and retaining the original anti-NIP specificity, were successfully produced. 
Compared to those in humans, FcγRs in rhesus macaques share high homology, yet also feature a 
relatively high level of intra-species polymorphism and possess different N-linked glycosylation 
patterns. FcγR constructs and expression vectors were successfully generated. The chimeric 
recombinant IgGs are powerful tools for defining IgG functional properties and studying CH 
structure/function relationship. These molecules can also be used as immunogens for generation 
of antibodies capable of unequivocally detecting individual IgG subclasses. The findings on 
FcγRs validate rhesus macaques as a model for studying antibody responses, and underscore the 
need to take into account of the genetic heterogeneity. The FcγR constructs and vectors serve as 
a tool for further studies of IgG/FcγR interactions. 
We also reported here our findings from a separate study that the main female hormone, 
17β-estradiol, is capable of restoring antibody responses to an influenza vaccine in a 
postmenopausal mouse model, suggesting that immunogenicity and efficacy of influenza 
vaccines should be evaluated in postmenopausal women. 
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CHAPTER 1                                                                                                             
INTRODUCTION AND STUDY OBJECTIVES 
 
1.1. Rhesus macaques as a biomedical research model for human diseases 
1.1.1. Rhesus macaques are widely modeled for human diseases and are considered the best 
animal model for HIV/AIDS-related studies 
The macaque model has been in the past century used for over 70 human infectious 
diseases (Gardner and Luciw, 2008). From pandemics and notable global infections, such as 
acquired immunodeficiency syndrome (AIDS), influenza, hepatitis, and tuberculosis, to a variety 
of infections typically seen in pediatrics or in tropics, as well as diseases caused by newly 
emergent infectious or other viral, bacterial, fungal, or parasitic pathogens, including potential 
bioterrorism diseases, and oncogenic and chronic degenerative neurologic disorders, have been 
studied in these animals. Other non-infectious diseases, such as Parkinson’s and Alzheimer’s 
diseases and age-related disorders (Herodin et al., 2005; Carlsson et al., 2004), have also been 
modeled in this versatile model. 
Studies using animal models, including those with macaques, are crucial part for 
understanding human disease mechanisms so as to improve diagnostics, to rationally design 
vaccines, and to develop therapies. Use of the macaque model has proved to be an invaluable 
resource for understanding pathogenesis of human diseases. This model has also represented 
essential tools in vaccinology and passive immunization studies, such as for assessing the safety 
and efficiency of new vaccines, including these properties of different adjuvants being used to 
boost vaccine-induced immune responses (Sibal and Samson, 2001). Furthermore, macaques 
have served as models for evaluation of efficacy of novel therapeutic applications, the 
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mechanisms of action and pharmacokinetics of therapeutic antibodies, as well as strategies to 
prevent allograph rejection in transplantation research. 
The macaque species most commonly used as human disease models is rhesus macaques 
(Macaca mulatta). Rhesus macaque animals are extensively available and are closely related 
anatomically, physiologically, and phylogenetically to humans (Shedlock et al., 2009; Gardner 
and Luciw, 2008). As a nonhuman primate (NHP) model, rhesus macaques are further valued by 
their capacity of being naturally infected (and expressing disease symptoms) with NHP 
etiologies similar to those causing related diseases that are difficult to study in humans (Gardner 
and Luciw, 2008). In particular, rhesus macaques experimentally infected with simian 
immunodeficiency virus (SIV) [considered the viral substitute of the AIDS-causing human 
immunodeficiency virus (HIV), which does not replicate in most animal species (Lackner and 
Veazey, 2007)], were shown to recapitulate human HIV infection immunologically, 
virologically, and pathologically, as well as to develop AIDS-like disease (Shedlock et al., 2009; 
Thomas, 2009). Rhesus macaque species, to date, is considered the most suitable model for 
studying HIV pathogenesis as well as for testing potential therapies and developing vaccines 
against HIV/AIDS (Shedlock et al., 2009; Nath et al., 2000). Indeed, this species has played a 
key role in characterizing HIV viral immunobiology and in correlating the host innate and 
adaptive immune responses with in vivo protection induced by HIV/AIDS vaccine candidates 
(Shedlock et al., 2009; Gardner and Luciw, 2008). The recent availability of the rhesus macaque 
genome sequence (Gibbs et al., 2007) and microarray chips of macaque-specific genes has 
certainly increased the potential use of rhesus macaques in biomedical research. 
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1.1.2. The rhesus macaque model: Incomplete characterizations of Ig/FcR immune system 
components and mechanisms 
When using the rhesus macaque model, particularly for evaluation of vaccines and 
antibody (Ab)-based therapeutic applications, much of the attention has been focused on 
assessing the host immune responses. In such responses, the two main molecular players are Ab 
[also known as immunoglobulin (Ig)], and their cellular Fc receptor (FcR). These molecules 
together carry out the various so-called cell-killing effector functions that aim to destroy and 
“clear” pathogens. Indeed, Ab responses, particularly those of neutralizing Abs, correlate with in 
vivo protection and represent the major protective components against SIV and HIV infections 
(Schmitz et al., 2003). Many therapeutic agents directed at Igs or FcRs are under development 
for treatment of various human diseases, including cancer and autoimmune disorders. 
Nevertheless, apart from the general similarity of the overall biology of infection between SIV-
infected rhesus macaques and HIV-infected humans, as well as the evolutionary relatedness 
between these two species, the Ig/FcR immune system components and mechanisms of rhesus 
macaque model relevant to studies of human diseases are not completely characterized. In the 
absence of known human disease mechanisms, the design and interpretation of experimental data 
generated from the rhesus macaque model are based on the similarity of the disease pathogenesis 
and manifestation between these two species (Shedlock et al., 2009). It is the scientific 
assumption that crucial immune molecules in rhesus macaques could be highly conserved with 
those of humans, both structurally and genetically, and that their interactions could generally 
mimic those in humans. However, this premise has not been fully evaluated. 
Early studies show that rhesus macaque Igs share a high degree of homology with their 
human counterpart (Calvas et al., 1999). This finding suggests that these molecules would be less 
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immunogenic (at least compared to murine counterpart) in humans, and consequently, might 
induce a low level of the so-called human anti-mouse antibody (HAMA) response (Laffly and 
Sodoyer, 2005). Indeed, rhesus macaque monoclonal Abs (mAbs) have been proposed as an 
alternative to humanized rodent mAbs, which causes a high HAMA response when used for 
therapeutic purposes (Ehrlich et al., 1988; van Meurs and Jonker, 1986). On the other hand, anti-
human Ab reagents in many cases poorly or rarely cross-react with rhesus macaque effector 
cells, suggestive of less conserved antigenic determinants (epitopes) between the corresponding 
molecules of the two species. Some immune cell surface molecules between the two species, 
while structurally similar, are even sufficiently distinct antigenically to invoke an immune 
response. For instance, rhesus macaques elaborate specific humoral immune responses against 
the human CD4 cell surface molecule (Lodgberg et al., 1994; Newman et al., 1992). Indeed, it 
had been suggested that rhesus macaques had the potential to be employed for production of 
specific Abs recognizing antigens and receptors on the surface of human immune cells 
(Lodgberg et al., 1994). Subsequently, several “primatized” mAbs containing variable regions 
from a macaque species (although it was not rhesus, but cynomolgus macaque) and an IgG 
human constant region have been developed. Among these mAbs are anti-CD4 [Keliximab; for 
rheumatoid arthritis (Newman et al., 2001; Reddy et al., 2000)], anti-CD23 [for allergies 
(Nakamura et al., 2000)], and anti-CD80 [Galiximab; for autoimmune and inflammatory 
diseases, like psoriasis (Gottlieb et al., 2004; Schopf 2001)]. 
Like with Abs, studies of murine Ig Fc cell surface receptors (FcRs) have traditionally 
provided important insights for better understanding human FcR biology. However, the human 
FcR system is complicated and extensively different from that of mice. Humans possess several 
FcRs with which no homologues are found in mice, such as FcγIIa, FcγRIIc, FcγIIIb, and FcαR 
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(Pleass and Woof, 2001). As FcR biology varies greatly among species, insights from a more 
“human” FcR model system – such as those from an NHP species instead of mice – would be 
more practically translatable into human FcRs. As discussed above, owning to their close 
anatomical, physiological, and phylogenetical relatedness to humans (Gardner and Luciw, 2008), 
rhesus macaque species is already used extensively for immunological research. Rhesus macaque 
FcR biology research, however, is largely unexplored (Rogers et al., 2008, 2006, and 2004). 
Indeed, several FcγRs found in mice, including FcRs for IgA and IgM, have not even been fully 
characterized in NHP species (Rogers et al., 2004). 
Therefore, the various Ig and FcR systems and related pathogen-clearance mechanisms 
are still largely unexplored in the rhesus macaque model. In particular, little is presently known 
about the structure of Ig and FcR molecules in rhesus macaques, and the extent of similarity to 
their human counterpart is not completely defined. No current information about the functional 
properties and structure-function relationships that characterize rhesus macaque IgG molecules, 
as well as interaction of IgG subclasses and corresponding FcγR classes, is available. It is not 
known at what extent the various components of the rhesus macaque immune system mimic 
corresponding components of the human immune system upon antigen exposure, particularly 
that directing against HIV and SIV. Also, the relative level of IgG subclasses present in rhesus 
macaque serum is not known. As many therapeutic Abs – either approved or in trials or 
development – are of IgG Ab class, comprehensive understanding of interaction between IgG 
subclasses and corresponding FcγRs would enable the rational design and production of novel 
therapeutic Abs, as well as prognosis for treatment success. 
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1.1.3. The need for comprehensive characterization of rhesus macaque Ig/FcR immune system 
components and mechanisms 
Owing to almost 25 million years of evolution (Shedlock et al., 2009), human and rhesus 
macaque species might possess important structural and thus, functional, differences related to 
their Ig and FcR components that have not been completely characterized. The incomplete 
characterization has limited the scope of biomedical research performed with this model. 
Importantly, these differences might mislead data interpretation and translation to human 
diseases. Indeed, recent studies suggest that the safety and performance of drugs or vaccines 
observed in NHP animals, particularly rhesus macaques, are not necessarily similar to or 
translatable into humans. For instance, while the CD28 super-agonist Ab TGN1412 had showed 
no adverse effects in macaques, it caused, with 500 times less in dose and within an hour of 
administration, life-threatening conditions in healthy human volunteers in a 2006 clinical study 
(Attarwala, 2010). More recently, a leading HIV vaccine candidate that demonstrated apparent 
protection in rhesus macaques appeared to fail to protect humans (Thomas, 2009). Molecularly, 
recent studies revealed that there are more active immune genes in rhesus macaques than in 
humans (Gibbs et al., 2007). Several key differences that exist between rhesus macaques and 
humans related to their major histocompatibility complex (MHC), as well as Ig and FcR 
molecules, both structually and functionally, have also been recently revealed (Rogers et al., 
2008; Gibbs et al., 2007; Rogers et al., 2006; Scinicariello et al., 2006; Daza-Vamenta et al., 
2004; Scinicariello et al., 2004). 
Collectively, these findings suggest that interspecies differences between rhesus 
macaques and humans regarding immune gene expression and immune responses might 
contribute – by means that are currently not fully understood – to pathogenesis and progression 
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of infection (Shedlock et al., 2009). Failure to recognize these differences may lead to erroneous 
expectations or confounding interpretation of data generated by using this model for evaluation 
of vaccines or therapeutic Abs. 
 
1.2. Antibody molecules: Overview, structural and functional features, genetic basis, 
classification, and IgG class and subclasses 
1.2.1. Antibody molecules: Overview 
Antibodies (Abs), or Igs, are host glycoproteins naturally produced in vertebrates in 
response to invading foreign particles or organisms (antigens), or to, in abnormal or pathological 
circumstances, other agents in the body. Igs are the antigen-specific and multifunctional adaptor 
molecules expressed by B lymphocytes as either membrane-bound or secreted products. 
Membrane-bound Igs, also known as B cell receptors, act as cell-surface receptors for specific 
antigens, which mediate cell signaling and cell activation (like activation of phagocytes, natural 
killer cells, or the complement cascade). Secreted Igs, which are synthesized by antigen-
specifically proliferated and terminally differentiated B cell clones (Parham, 2000), circulate in 
the blood. These circulating Igs serve as the soluble effector molecules, which are capable of 
individually and specifically binding and neutralizing pathogens/toxins at a distance, or marking 
them for elimination through activating mechanisms that effect their destruction and clearance 
(effector functions). Igs, therefore, play a critical role in the protection and defense of a host 
organism against pathogens and malignancies. 
Every individual Ig recognizes and binds to just one single antigen, which could be 
protein and/or carbohydrate particles present on microorganisms and viruses, or could be 
distinctive molecules expressed on the surfaces of tumor cells. Because of this exquisitely-
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specific and high-affinity binding characteristics, Igs are ideal molecular tools for basic research 
and diagnostics. Igs have been widely used, both in vitro and in vivo, for detecting, localizing, 
and purifying both known and unknown molecular targets. As will be discussed further, Igs have 
also greatly been increasingly used as therapeutic agents over the last several decades. Indeed, 
Igs are among the most powerful immune-therapeutic agents currently available, and neutralizing 
Igs are the most sought-after molecules of actions induced from vaccinating against a variety of 
infectious pathogens. 
 Igs belong to the eponymous Ig “superfamily” (IgSF) that constitute the humoral branch 
of the immune system in most vertebrates, including fishes, amphibians, reptiles, birds, and 
mammals (Clark, 1997). IgSF molecular members adopt a tertiary globular structural motif 
known as IgSF domain, or Ig domain, that result from independent folding of their polypeptide 
chains, as their basic building block (Schroeder and Cavacini, 2010). In an Ig molecule, the 
variable domains localize at the amino termini and confer the antigenic specificity, whereas the 
constant domains reside  within the carboxyl terminus and define the different effector functions. 
The recognition of this domain structure/function property of Igs has facilitated the manipulation 
of the Ig genes and thus, their recombinant protein products of predefined specificity and/or 
desired species (Clark, 1997). Indeed, generation and production of chimeric recombinant 
molecules used for therapeutic purposes or for basic research studies, including those of the 
structural basis of Ig functions, have been great success. 
 
1.2.2. Structural features and Ig L and H domains 
All Igs, independent of their antigenic specificity, generally have a common structure that 
has been conserved through evolution. It is a Y-shaped symmetrical structure composed of four
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Fig. 1.1. Schematic representation showing two-dimentional general structure of a conventional 
antibody, or immunoglobulin (Ig), molecule. This representation displays both amino acid (A) 
and nucleotide level (B), showing the structure and arrangement of Ig heavy and light chains, the 
relative positioning of inter-chain disulfide bonds, the paired domains and the classical Ab 
fragments, as well as illustrating germ-line genetic organization of separate gene segments 
(exons) encoding for Ig heavy-chain constant domains (not drawn to scale). (A) This diagram 
depicts the four-chain structure of an Ig molecule, a dimeric protein composed of two identical 
light (L) chains (IgL) and two identical heavy (H) chains (IgH), each consisting of a variable (V) 
region and a constant (C) region. Individual IgL and IgH chains are folded into domains (also 
known as Ig folds), which are discrete and compactly folded protein regions. Ig domains have 
similar structures and, by themselves or through interactions with other domains, form functional 
units of the Ig molecule. Each IgL comprises two domains, a variable (VL) and a constant (CL), 
and each IgH comprises four (or five) domains, a V domain (VH) and three followed C domains 
(CH1, CH2, and CH3). Each Ig domain, V or C, comprises about 110 amino acid residues and  
an intra-chain disulfide bond (-S-S-) between two cysteine residues, forming a loop of about 60 
amino acids. Individual IgL and IgH chains are held together by inter-chain disulfide bonds and 
form a flexible Y shape of the molecule. The VH region, which is adjacent to the CH1 region, is 
located at the amino terminus (NH2), and the CH3 (some have a CH4) region is positioned at the 
carboxy terminus (COOH), which is at the 3’ end of the IgH [which can be either membrane-
bound, mIg (or B-cell receptors, BCRs) or secreted, sIg]. The CH1 domain contributes to the 
stability of V regions and to the diversity of Igs. In between the CH1 and CH2 domains is the 
hinge portion, which contributes in the flexibility of the molecule. Based on the similarity level 
of amino acid sequences, two major IgL types, namely κ and λ (encoded at different genetic loci 
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and referred as Igκ and Igλ, respectively), and five major IgH classes isotypes), namely μ, γ, α, δ, 
and ε (referred as Igμ, Igγ, Igα, Igδ, and Igε, respectively), are classified. IgHs in IgG, IgA, and 
IgD classes contain four Ig domains and a hinge region, whereas those in the IgM and IgE 
contain an additional Ig domain that replaces the hinge region. The five IgH isotypes also vary in 
function, serum concentration, and serum stability. IgL type is not a determinant of the Ig class 
(isotype) nor known to be associated with specific effector functions of the molecule. Each IgH 
class Ig molecule has only one type of IgL. Ig chains can also be associated with carbohydrate 
moieties (Ig CH2 has conserved glycosylation sites). Igs and BCRs are for antigen recognition 
and destruction and also illustrated in this diagram are the regions that participate in antigen 
recognition/binding (Fab; two identical sites constituted by the V regions and capable of binding 
essentially any macromolecule, including proteins, carbohydrates, lipids, and nucleic acids, with 
most binding proteins or carbohydrates), and the regions that mediate different effector functions 
(Fc; constituted by the CH2 and CH3 domains of dimerized IgH chains and capable of recruiting 
cells/molecules of effector functioning for destruction of antigens and pathogens), which include 
interacting with complement (binding C1q), activating macrophage, polymorphonuclear 
leukocytes (PMN), platelets, and binding Fc receptors, as indicated. Igs themselves are also 
antigens. The hydrophobic leader sequence of both H and L chain is removed immediately after 
synthesis and is not present in the mature Ig molecule. (B) This diagram depicts germ-line (non-
rearranged) organization of human IgH chain gene segments (exons). Shown is for an Igγ3 (to be 
used as an example), which consists of three exons (represented by red-filled, enlarged boxes; 
numbered as indicated) encoding the corresponding C domains, and one exon (Hg; represented 
by the purple-filled, enlarged box) encoding the hinge region. Due to sequence repetition, human 
Igγ3 can have two to four hinge exons. Straight black lines indicate introns. Long and colorful 
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arrows indicate the correspondence between the DNA exon segments and the different domains 
of the IgH polypeptide that is encoded. Ig gene components are widely scattered through 
different chromosomes (chromosomes 2 and 22 for Igκ and Igλ, respectively, and chromosome 
14 for IgHs) and to assemble an intact Ig molecule, they are first rearranged/spliced at the DNA 
level (i.e. not RNA splicing), as illustrated. Ig genetic organization, which contains individual 
exons that encode for different functional domains of the protein products in which binding 
specificity resides within V domains while subclass effector functions reside within C domains 
makes it possible for generation of recombination Igs combining different binding specificity and 
effector functions.
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polypeptide subunits – two identical heavy (H) and two identical light (L) chains. These four 
polypeptide chains are held and stabilized together by covalent disulfide bonds between the H 
and L chains and between the two H chains, as well as by non-covalent intra- and inter-chain 
binding forces (such as salt linkages, hydrogen bonds, and hydrophobic bonds). Each of these 
chains comprises of two distinct regions – a variable (V) region, which is found at the amino 
terminal portion and has the greatest amino acid sequence variation among Ig molecules of 
different specificity, and a constant (C) region, which is found at the carboxyl terminal portion 
and, in contrast to the V region, is of relatively constant (i.e. more conserved) sequence. Fig. 1.1 
shows the structure and arrangement of H and L chains and the relative positioning of inter-chain 
disulfide bonds. 
Being IgSF protein members, Igs utilize a globular, fairly constant motif structure known 
as Ig domain (also called IgSF domain or Ig fold) as their basic building block (Fig. 1.1). Each Ig 
domain is a specific tertiary homologous structural polypeptide unit consisting of from 110 to 
130 amino acids and weighting approximately 12-13 kD. Regardless of amino acid differences 
among Ig molecules of different classes, subclasses, or specificity, each Ig L and H chains 
independently fold into homologous domains, where each contains of two sandwiched β-pleated 
sheets linked together and stabilized by an intra-chain disulfide bond between the two conserved 
cysteine residues and by hydrophobic interactions between the sheets (Schroeder and Cavacini, 
2010; Williams and Barclay, 1988; Amzel and Poljak, 1979). Each L chain consists of one V 
(VL) and one C (CL) domain, whereas each H chain contains one V (VH) and three to four C 
(CH) domains (CH1-CH4), depending on the Ig class (as will be discussed below). In general, Ig 
CH domains are defined as CH1-CH2-CH3 (IgG, IgA, and IgD), or with an additional domain 
(CH4) (for IgM and IgE) (Schroeder and Cavacini, 2010). The two L chains and the two H 
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chains weight ~25 kD and ~50-55 kD, respectively. The classical folding pattern of Ig molecules 
remains intact in all of regions and fragments (Attanasio et al., 1994). 
The entire L chains, VH, and CH1 domains together constitute two identical fragments 
that recognize and bind antigens, known as Fab (Fragment – antigen binding), represented by the 
arms of the symmetrical Y shape (Fig. 1.1). The rest of the Ig molecule [i.e. the remaining CH 
domains (i.e. CH2 and CH3; also CH4 in IgM and IgE)] form a fragment that specify effector 
functions, termed Fc (Fragment – crytallizable), represented by the tail (the stem) of the Y shape. 
The V domains of both chains, which provide the structural basis of antigenic specificity, 
unsurprisingly, localize to the Fab. As described previously, the CH1 domains localize to the 
Fab, whereas the remaining CH domains (CH2-CH3 or CH2-CH3-CH4) constitute the Fc 
(Schroeder and Cavacini, 2010). Fig. 1.1 also illustrates the paired domains and the classical Ab 
fragments. 
In addition to the relatively “constant”, or highly conserved, CH domains, the C region of 
the IgH chains also contains between its CH1 and CH2 domains a nonglobular helical, extended 
“spacer” region of  12-15 amino acids [an exception exists with human IgG3 hinge: it contains 
up to 62 amino acids, dependent upon the number of repetitive sequences (Lefranc and Lefranc, 
2001)] that has the highest Ig class/subclass sequence variability, both intra-species and inter-
species. The region also varies in length between different Ig classes within a species. This 
flexible region is called the hinge, and is characterized by evolutionary instability (Scinicariello 
et al., 2004; Attanasio et al., 2002; Sumiyama et al., 2002; Scinicariello and Attanasio, 2001). 
The hinge is rich in Cys and Pro residues and can be structurally split, based on crystallographic 
data and the intermolecular interactions, into three discrete segments: the upper, the core (the 
middle), and the lower hinges (Burton and Woof, 1992; Oi et al., 1984). The upper hinge is 
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towards the amino terminal segment and exhibits the least homology of all sections, followed by 
the core. The hinge can also be exposed to enzymatic or chemical cleavage, a characteristics that 
has facilitated early studies of Ig structure/function relationships. For instance, papain cuts an 
IgG molecule into two Fab and one single Fc, whereas pepsin digests it into one single dimeric 
F(ab)2 and one single Fc (Schroeder and Cavacini, 2010). 
 
1.2.3. Functional features and Ig V and C regions 
Ig molecules serve many and varied functions through binding antigens and targeting 
them to other components of the immune system (Fig. 1.2). On the basis of Ig forms of 
existence, these functions can be separated into two purposes: those of circulating soluble 
effector molecules, which recognize antigens at a distance and neutralize them, and those of 
cellular receptors for antigen, which trigger cell activation and signaling (Schroeder and 
Cavacini, 2010). On the structural basis, Igs can be subdivided into two distinct functional units: 
the paired V domains (i.e. Fab, a combined property of VH and VL domains) that bind antigens 
and confer antigenic specificity, and the Ig CH domains (i.e. Fc) that mediate effector functions 
and define Ig isotypes (Schroeder and Cavacini, 2010). Igs, therefore, eliminate pathogens and 
toxins by both cellular and non-cellular mechanisms through specific binding to them with their 
V domains, followed by activating cell-killing effector mechanisms via their C domains. Because 
of the domain structure of Ig molecules, for many purposes, the antigen-binding properties of the 
whole Ab and the Fab are usually considered equal (Burton, 1991). 
The key Ig Fab-mediated functional activity of Ig molecules is to neutralize, or directly 
inactivate, toxins and infectious pathogens, particularly viruses (Fig. 1.2). For in vivo anti-virus 
protection, directly neutralizing virion infectivity is considered the most important activity of Igs 
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(Burton, 2002). Mechanistically, these functional activities are carried out by blocking of 
pathogenic functional sites through enzymic or receptor binding activity: thank to their relatively 
large molecular size (similar to the size of a typical virus envelope spike), Igs block virus entry 
into host target cells through binding to free virus particles and occupying virion sites necessary 
for attachment or fusion to the cells (cell receptors) (Parren and Burton, 2001). In this case, Igs, 
or more specifically, neutralizing Abs, can act alone, without cellular effector immune 
mechanisms, to protect vertebrates from viral pathogens. As described above, a single, intact Ig 
molecule contains two identical Fab fragments (antigen binding sites), the so-called “bivalency”. 
A single Ig molecule, therefore, although capable of recognizing only one type of antigen, can 
bind and neutralize two antigens simultaneously. Furthermore, this bivalency characteristics 
allows Igs to bind antigens possessing repeating antigenic determinants or aggregated antigens 
with higher avidity (Clark 1997; Janeway et al., 1996). Due to the domain structure of Ab, the 
antigen-binding properties of Fab are typically considered those of entire Ab. 
The Ig Fc regions typically act through the interactions between their various Ig Fc 
receptors (FcRs) and the Ab-antigen complexes (or immune complexes; ICs), which induce 
diverse and potent immune responses that are critical for healthy immunity (Fig. 1.2). Following 
the formation of ICs, the Fc regions can activate different cell-killing immune effector 
mechanisms that effect the destruction and clearance of antigens and pathogens through their 
binding to FcRs, which are expressed on various immune cells, or through recruiting other 
immune mediators, such as complement (Schroeder and Cavacini, 2010). In normal immune 
systems, three major mechanisms for the destruction and clearance of the antibody-coated (also 
known as opsonized) antigens – all result in lysis of the pathogens by lytic enzymes – are known:
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Fig. 1.2. Functional features of Ig V and C regions and Ig domain structure/function properties. 
See texts for details. Figure is modified from Weiner et al., 2010, Casadevall et al., 2004, and the 
internet.
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1) Antibody-dependent cell cytotoxicity (ADCC), in which the ICs activate effector cells 
[through the Fc-FcR (specifically, FcγRIIIa) binding], such as natural killer cells or monocytes; 
2) Complement-dependent cytotoxicity (CDC; through C1q binding), in which the complement 
pathway is recruited and the complement cascade is activated; and 3) Fc-mediated phagocytosis, 
or Ab-dependent cellular phagocytosis (ADCP), in which phagocytic cells (i.e. macrophages 
neutrophils, and dendritic cells) are activated [through the Fc-FcR (FcγRII/I) binding] (Fig. 1.2). 
Other Ig functional activities and responses that assist in directing appropriate immune responses 
include opsonizing, inducing respiratory burst, releasing inflammatory mediators (inflammation), 
antigen presentation, degranulation of cytotoxic cells, mast cell degranulation, as well as other 
antigen-independent functions, such as crossing the placenta [placental transport; through 
binding to the neonatal FcR (FcRn)], maintaining half-life (through binding to FcRn), 
multimerizing, regulating lymphocyte proliferation and differentiation, including B cell 
activation, secreting cytokines and chemokines, and being secreted on mucosal surfaces 
(Schroeder and Cavacini, 2010; Smith and Clatworthy, 2010; Weiner et al., 2010; Jefferis et al., 
1998; Burton and Woof, 1992). Therefore, through the binding of ICs to specific FcRs, the Ig Fc 
regions can provide humoral immunity with a cell-based effector functional system (Smith and 
Clatworthy, 2010). 
In addition to being capable of inducing Ab-dependent killing of target cells, the Fc 
regions can also affect V domain binding affinity and specificity (Torres and Casadevall, 2008) 
and suppress humoral immunity (Smith and Clatworthy, 2010) (will be discussed in more details 
later). Also, in abnormal immune circumstances, such as autoimmunity or allergies, the IC-FcR 
interactions might cause adverse consequences, like development of tissue injury, or might even 
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be involved in pathogenesis of immunological disorders and diseases, including rheumatoid 
arthritis and systemic lupus erythematosus (SLE) (Takai 2005; Hogarth 2002). 
  
1.2.4. Functional features and the role of the hinge and glycosylation 
As discussed previously, the Ig hinge region contains several conserved Cys residues and 
can be divided into three sections. The core hinge is rich in Cys (and Pro) residues that form the 
IgH inter-chain disulfide bonds and is thus relatively inflexible (i.e. rigid). The upper and the 
lower hinges can mediate Ig segmental (Fab-Fc) and rotational (Fab-Fab) flexibility by directly 
allowing the two Fab portions of the Y-shaped molecule to “open” or “close” (for two Fab arms 
as a whole), and rotate (for each individual Fab arm) – relative to the Fc position (Clark, 1997). 
The ability of Fab arms to be differently positioned improves Ig access and accommodation, and 
thus allows differently spaced and/or distinctly oriented antigens or antigen determinants to be 
bivalently recognized by the two binding sites (Clark, 1997; Kim et al., 1994; Burton and Woof, 
1992). 
In addition to playing a role in intermolecular covalent assembly and flexibility (the core 
hinge), the hinge also plays a crucial role in IC formation (the upper hinge), may be required for 
FcR binding and complement activation (the lower hinge) (Coloma et al., 1997; Roux et al., 
1997), as well as may affect signal transduction (Clark, 1997; Rudich et al., 1988). The 
flexibility of Fc portion, relative to Fab fragments, can influence interactions of Igs with 
coresponding FcRs or other molecules. As a consequence, the extended human IgG3 hinge is 
believed to have better flexibility, and thus be more effective in antigen binding and in triggering 
effector mechanisms (Burton and Woof, 1992). The hinge of IgG subclasses will be described 
further in the following sections. Distinct structures of the hinge in different species might, 
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therefore, alter molecular flexibility, neutralizing ability, reactivity with and binding affinity to 
FcRs, the capability to activate the complement cascade, susceptibility to proteolytic enzymes, or 
other Ig functional properties of Igs (Torres and Casadevall, 2008; Thommesen et al., 2000; 
Michealsen et al., 1990, Tan et al., 1990). 
As mentioned above, Igs are glycoproteins in their nature. While IgL chains are 
aglycosylated, IgH chains (in particular, Fc portions) are integrally attached covalently with 
oligosaccharide groups (i.e. carbohydrate moieties), usually at CH2 domain (Sutton and Phillips, 
1983). The extent of glycosylation varies, dependent upon Ig isotype
 
(Arnold et al., 2007). 
Carbohydrates are important for proper Ig folding and for stabilizing IgG-FcγR binding 
(Schroeder and Cavacini, 2010; Lund et al., 1995). Fc-associated glycans are also capable of 
affecting Ab functions, including mediating complement activation and influencing FcR binding 
(Schroeder and Cavacini, 2010; Miletic and Frank, 1995). Changes in glycosylation of IgH 
chains can, therefore, result in alteration of Ig functions, including effector functions 
(particularly complement activation) (Schroeder and Cavacini, 2010). Indeed, more effective 
therapies might be obtained from differential or modified glycosylation patterns engineered in 
passive immunotherapy or in vivo treatment (Collin et al., 2008; Smith et al., 2004). 
Collectively, Abs are extremely versatile molecules, structurally and functionally. The 
globular domain structure of Ab molecules is facilitative of genetic engineering (as will be 
discussed later). Changes in the Fc may influence the end result of Ab-antigen interactions, 
including the affinity and/or kinetics of the Fab-mediated antigen recognition and binding 
(Schroeder and Cavacini, 2010; Torres and Casadevall, 2008). 
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1.2.5. Gene organization, DNA rearrangement, and production of Ig 
Higher vertebrates feature with a humoral immune system that is uniquely characterized 
by its ability to generate a vast diversity of Abs to respond to virtually unlimited array of 
antigens or pathogens sharing little or no similarity. This unique characteristics relies largely on 
the Ig gene organization and DNA rearrangement mechanisms. In humans, IgH and IgL chains 
are encoded by separate multi-gene families
 
located on three different chromosomes (Schroeder 
and Cavacini, 2010; Tonegawa, 1983). Specifically, IgL κ and λ families are located on 
chromosomes 2 and 22, respectively, whereas IgH family is located on chromosome 14 (Lefranc 
and Lefranc, 2001). Each multi-gene family contains different, independent gene segments that 
encode individual V and C domains of each Ig H or L chain. In particular, IgL  and  families 
consist of V, J (for joining), and C gene segments, whereas IgH family contains V, D (for 
diversity), J, and C gene segments. Each V gene segment generally contains its own promoter, a 
leader exon, an intervening intron, an exon encoding V domain, and a recombination signal 
sequence (RSS) (Schroeder and Cavacini, 2010). The IgH C gene (IGHC) segments consist of 
nine functional and two pseudo (Ψ), non-functional, C genes. Each Ig isotype is encoded by a 
separate CH gene region, namely or which correspond to the five IgH isotypes. 
These CH region gene segments are aligned in the same transcriptional orientation on 
chromosome 14, in the IgH locus, downstream of V region genes (IGHV) (Bengten et al., 2000). 
Generally, each CH gene region consists of three main exons, each individually encoding CH1, 
CH2, and CH3 IgH domains, and of one or more additional exons encoding the hinge (Schroeder 
and Cavacini, 2010; Bengten et al., 2000). 
Ig V and C domains are produced through two independent DNA rearrangement and 
recombination events. VL and VH domains are expressed by the so-called rearranged VJ and 
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rearranged VDJ gene segments, respectively. These VJ and VDJ rearranged gene segments result 
from a number of gene rearrangement events that occur in B cells during their early development 
in the bone marrow – in the absence of antigens. They are expressed in association with the Ig μ 
chain (to produce IgM) and following antigen exposure, can undergo somatic hypermutation that 
allow maturation and increase of affinity for the antigens. Ig CL and CH domains are expressed 
by the C gene segments in the L and H multi-gene families, respectively. Different CH domains 
(i.e. or ) can be produced in response to antigenic stimulation (such as by immunization or 
infection) and cytokine regulation by activated B cells in their late development – in the spleen 
or lymph nodes. They can then be subjected to the so-called class switch recombination event 
(i.e. from IgM to IgG, IgA, or IgE), a process in which effector functions may be altered but 
antigen-binding specificity remains unchanged (Schroeder and Cavacini, 2010). Not only the 
antigen and the signaling pathways, but also the local microenvironment may have influence on 
which Ig isotype is to be chosen during class switch (Schroeder and Cavacini, 2010). 
Therefore, a vast Ig repertoire with a great number (~10
16
) of structurally distinct 
molecules (that is, against virtually any antigenic structure) can be generated through a number 
of molecular mechanisms that alter the DNA of individual B cells. These mechanisms include 
genetic organization by individual gene segments, somatic variation and random combinatorial 
rearrangement of these segments, as well as combinatorial association between different L and H 
chains – and all processes are without the presence of antigens (or further diversification by 
hypermutation) (Schroeder and Cavacini, 2010). Thus, although an individual Ig molecule can 
only bind a limited set of ligands, as discussed previously, Igs as a population can bind to an 
almost unlimited array of antigens or chemical structures. 
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1.2.6. Ig classification: Ig L and H chain classes (isotypes) 
Humans Igs are categorized into five major classes (or isotypes), IgM, IgG, IgA, IgD, and 
IgE, which are defined by and correspond to the five main classes of their low-variability CH 
regions, designated , , , , and , respectively (Clark, 1997). IgL high-variability regions can 
be grouped into two types, κ and λ. In a complete Ig molecule, each class (or isotype) of the five 
H chains (i.e. , , , , or ) is associated to either – but not both – a κ or a λ chain. In some 
species, these classes are further split into subclasses, which suggest their recent evolution (i.e. 
recent gene duplication events) (Clark, 1997; Bruggemann, 1988). The ratio of Igs with κ or λ 
chains represented in human serum is about 60:40, whereas it is 95:5 in mouse serum. The 
numbers of Ig classes also vary among species. 
It is the CH regions that distinguish the five different Ig classes and define their specific 
effector mechanisms (Clark, 1997). In addition to exhibiting distinct characteristic patterns of 
functional effector activities, classes also differ in some other properties, including size and 
subclass response to antigen (Schroeder and Cavacini, 2010). Amino acid substitution or 
polymorphism in Ig CH regions may also affect effector functions of Abs. 
 
1.2.7. IgG: General functional activities and subclass classification  
Human IgG represents the most abundant Ig class found in the body, including in serum 
[constituting ~80% of the total serum Igs (Clark, 1997)], extracellular fluid, and lymph nodes 
(Fig. 1.3). IgG exists as monomers and has the longest Ig serum half-life and is also most 
extensively studied. This Ig class also represents the most frequently used Ig isotype in cancer 
immunotherapy. IgG can be used as a model for considering many key Ig functional features, 
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including binding antigen through V domains and, at the same time, interacting with conserved 
effector systems through C domains. 
IgG may contribute directly to an immune response, such as neutralizing toxins, viruses, 
and other infectious pathogens. Patients diagnosed with low levels of IgG (hypogamma-
globulinaemia) exhibit increased susceptibility to infections (Smith and Clatworthy, 2010). IgG 
is capable of carrying out all the Ig cell-killing effector functions necessary for removal of 
pathogens. Such functional activities include ADCC, CDC, ADCP, opsonization, as well as 
sensitization and activation of other (than natural killer cells and macrophages) immune effector 
cells, such as neutrophils, basophils, and mast cells, as discussed previously (Fig. 1.3). IgG that 
coats antigens can bind FcRs through its Fc and trigger signaling through immunoreceptor 
tyrosine-based activation motifs (ITAMs) or immunoreceptor tyrosine-based inhibitory motifs 
(ITIMs). In addition to these antigen-dependent functions, this Ig class can also bind neonatal Fc 
receptors (FcRn) on endothelial cells to maintain serum IgG levels or to define Ab half-life. The 
binding to tumor cells of two or more IgG molecules can lead to subsequent recruitment and 
binding of complement component 1q (C1q) to IgG Fc, which can then initiate the complement 
cascade, resulting in tumor cell lysis by the membrane attack complex (MAC) (Weiner et al., 
2010). Regardless of subclasses (see below), IgG is also able to be transferred from the maternal 
plasma to the fetus through the placenta to provide fetal immunity (trans-placental transport) 
(Parham, 2000; Clark, 1997), as well as to participate in the secondary immune responses 
(Schroeder and Cavacini, 2010). 
Based on structural, antigenic, and functional differences in CH region, human IgG is 
split into four subclasses, IgG1, IgG2, IgG3, and IgG4, designated 1, 2, 3, and 4, respectively 
(Schroeder and Cavacini, 2010) (Fig. 1.3). This numbering of IgG subclasses is referred to the
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Fig. 1.3. Human IgG: most common in serum, classified into four subclasses, possessing slight 
structural yet significant functional differences. See texts for details. Figure is modified from 
Murphy et al., Immunobiology, 7th Edition, Garland Publishing, 2008, and Burmester and 
Pezzutto, Color Atlas of Immunology, Georg Thieme Verlag, 2003.
28 
 
 
decreasing order (i.e. IgG1, IgG2, IgG3, and then IgG4) of their serum concentration level 
(Schroeder and Cavacini, 2010). The production of IgG subclasses may be influenced by various 
factors, including properties of antigens (i.e. structure and quantity, route of administration, and 
duration of stimulation) and characteristics of individual host (such as age and the genetic 
background) (Bachmann and Zinkernagel, 1996). Like with the class definition, the identity of 
subclass of an individual IgG is determined by variations in its CH regions. Indeed, due to recent 
gene duplication events (as described above), the four human IgG subclasses share high 
homology in CH domain sequences (>90%; Clark, 1997). By contrast, the hinge, which is unique 
to each subclass and most diverse among subclasses by amino acid composition and structure, 
exhibits the greatest sequence variations among IgG subclasses within an individual species 
(~56-60% identity among subclasses, compared to >90% homology shared by CH domains). 
Therefore, the hinge can be used to rapidly differentiate the four subclasses (Papadea et al., 
1989) (the four subclasses, indeed, also differ in the number and arrangement of their interchain 
disulfide bonds). Consequently, as will be described later, while the high identity within IgG 
subclasses has facilitated studies of the key Ab functional residues, the heterogeneity of the 
hinge can obscure investigating amino acids crucial for Ab intermolecular interactions (Clark, 
1997; Roux et al., 1997). 
As previously discussed, glycosylation pattern varies among Ig classes and subclasses. 
Although glycosylation variation is also observed among IgG molecules (Schroeder and 
Cavacini, 2010), the N-linked glycosylation site located at Asn297 on each CH2 domain is 
highly conserved throughout IgG evolution. In addition, not only forming extensive contacts 
with amino acid residues within CH2 domains and subjected to posttranslational modifications, 
but also the N-glycan at Asn297 is involved in IgG-FcγR recognition and binding. These 
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findings suggest that this N-linked carbohydrate moiety plays an important role in Ig domain 
stabilization and may even be capable of optimizing IgG in vivo effector functions (Schroeder 
and Cavacini, 2010; Burton and Woof, 1992). 
The CH region genes of the four IgG subclasses (IGHG) are designated as IGHG1, 
IGHG2, IGHG3, and IGHG4, according to the IMGT nomenclature (Lefranc and Lefranc, 2001). 
Each of the four IGHG genes consists of four individual exons, namely CH1, the hinge, CH2, 
and CH3, each individually encoding the corresponding CH domain (i.e. CH1,  the hinge, CH2, 
and CH3 domains, respectively). An exception exists in human IgG3, where its hinge, due to 
sequence repeats, is encoded by two to five exons (Lefranc and Lefranc, 2001; Burton and Woof, 
1992), as previously discussed. The IgG lower hinge, which is defined based on the 
intermolecular interactions, is, nevertheless, encoded by partial CH1 (C-terminus) exon and 
partial CH2 exon (Burton and Woof, 1992). 
 
1.2.8. IgG subclasses: Distinct characteristic patterns of effector functions 
While the four IgG subclasses exhibit light differences in sequence and structure, they 
express significant differences in function. Each subclass is characteristic of its own patterns and 
properties of functional activities, including in clearance mechanisms of opsonized antigens that 
are carried out upon antigen exposure, and at level of expression in response to specific antigenic 
stimulation (Schroeder and Cavacini, 2010). Generally, IgG1 and IgG3 are the most efficient 
activators, followed by IgG2 which is moderately potent, whereas IgG4 is only marginally active 
or inactive (Morrison et al., 1994). In particular, IgG1 and IgG3 are most effective with ADCC 
and CDC, whereas IgG2 is only moderately efficient in and IgG4 is incapable of carrying out 
CDC. Also, within the secondary immune response, while IgG1 and IgG3 are predominantly 
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produced against protein antigens, IgG2 and IgG4 are generally induced by polysaccharide 
antigens (Schroeder and Cavacini, 2010). 
The four IgG subclasses also differ in their binding capability and affinity to the three 
major IgG FcR (FcγR) classes: IgG1 and IgG3 are capable of binding and have the highest 
affinity for all three FcγR classes, IgG2 fails to bind FcγRI and FcγRIII, whereas IgG4 can bind 
FcγRII and FcγRIII but only with low affinity (Schroeder and Cavacini, 2010) (Fig. 1.3). 
Binding of IgG subclasses can further be influenced by other factors, such as their hinge 
structural diversity and flexibility, as well as the attached carbohydrates (glycans). Typically, 
ligand IgG molecules bind coressponding FcγRs in the lower hinge through an extensive contact 
surface. This area contains overlapping but not identical residues from the two IgH (Fc) chains, 
thus the binding is asymmetrical. Also, the length and flexibility extent of IgG subclass hinge 
regions are as from the greatest to the least as IgG3, IgG1, IgG4, and IgG2 (Clark, 1997; 
Roux et al., 1997; Brekke et al., 1995). Early studies have recognized a correlation between 
effector function efficiency (including complement activation) and flexibility patterns of IgG 
subclasses (Clark, 1997; Burton and Woof, 1992). More recent data suggest that IgG subclasses 
differ in their efficiency of neutralizing viruses and toxins, and that the hinge structure may 
influence the in vitro neutralizing activity of Abs (Cavacini et al., 2003; Liu et al., 2003; Scharf 
et al., 2001; Cavacini, 1995). In these studies, IgG3 appeared be more efficient than IgG1 at 
neutralizing virus antigens (Schroeder and Cavacini, 2010). IgG3 is also highly susceptible to 
proteolytic endonuclease cleavage (Clark, 1997). As previously discussed, the advantage of IgG3 
in virus neutralizing capability may lie in its unique, extended hinge structure, which can 
increase the segmental flexibility and improve the accessibility of the molecules onto the 
antigens, thus enhance effector functions (Cavacini et al., 2003; Scharf et al., 2001). These 
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findings imply the possibility of designing Ab molecules with improved functions through 
manipulating their hinge region. 
Taken as a whole, specific IgG subclass responses, amino acid residues involved in 
specific FcγR binding and effector functions, and interactions with different antigenic 
stimulations, can therefore all be associated with healthy immune responses (and, similarly, 
individual disease processes). Understanding these specific responses and properties, particularly 
different types of clearance mechanisms, will improve efficiency in the control and prevention of 
diseases and infections, as well as in development of vaccines and therapeutic Abs (Schroeder 
and Cavacini, 2010). 
 
1.3. Ig and IgG Fc receptors: Overview, classification, structural and functional features, 
and allelic polymorphism 
1.3.1. Ig Fc receptors (FcRs) and IgG Fc receptors (FcγRs): Overview 
To carry out their cell-killing effector functions, Igs, upon binding specific antigens with 
their paired V domains and forming the Ab-antigen immune complexes (ICs), interact with 
different innate immune effector cells through binding to their cell-surface receptors with their C 
domains. Fc receptors (FcRs), as they are termed, are transmembrane glycoproteins that 
specifically recognize and bind the multifunctional Fc portion of Igs. FcRs bind to Igs that are 
attached to pathogens (antigens) or infected cells, or that are bound to tumor cells (i.e. Ig-
opsonized particles, or ICs). This binding triggers the cell signal transduction events and initiates 
various immune cell-killing effector functions (such as ADCC, CDC, and ADCP, as previously 
described), resulting in cellular activation or inhibition of other immune-competent (phagocytic 
or cytotoxic) cells (Ravetch and Bolland, 2001). Ultimately, activated phagocytic or cytotoxic 
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Fig. 1.4. Mechanisms of action of FcRs: Binding of FcRs with Ig-opsonized particles triggers the 
cell signal transduction events and initiates various cell-killing immune effector functions, 
resulting in cellular activation or inhibition of other immune-competent cells. See texts for 
details. Figure is reproduced from Sondermann and Oosthuizen, 2002.
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cells destroy and remove invading pathogens or infected cells, and promote tumor cell lysis 
(Ravetch and Bolland, 2001) (Fig. 1.4). FcRs, therefore, form a bridge between the humoral and 
cell-based immunity and couple the potency of cellular effector activities with the specificity of 
Ig binding responses. 
In addition to fulfilling such protective effector functions, FcR-mediated immunity also 
plays an important role in the regulation of normal, healthy immune responses, including 
modulation of Ig production by B cells (Fig. 1.5). It is also involved in a variety of diverse 
disease groups, including autoimmune disorders (in particular, systemic lupus erythematosus), 
allergies, infectious diseases, as well as in inflammatory diseases, hypersensitivity, and cancer. 
Because of their involvement in diseases and capability to act as activators or inhibitors (i.e. 
regulators) of the immune system, FcRs have been considered excellent targets for therapies. 
Indeed, particular FcγR allelic variations that are associated with disease susceptibility and/or 
severity, or that can influence the outcome of Ig-based treatments, have been documented (van 
Sorge et al., 2003; Cartron et al., 2002). FcR-derived immunotherapies, particularly the 
technology for enhancement of therapeutic monoclonal Ig potency through optimizing the Ig-
FcR interactions, have risen as a promising approach for the treatment in numerous clinical 
situations, including those named above (Sondermann and Oosthuizen, 2002). 
FcRs, as a population, are expressed on the surface of many immune cells, virtually all 
immunologically active and competent cells (called effector cells), or in other words, of almost 
every cells of the immune system (Smith and Clatworthy, 2010; Sondermann and Oosthuizen, 
2002) (Fig. 1.5). Due to several reasons, including encoding gene organization, multiple 
transcripts (isoforms), and polymorphic forms, as discussed below, the cellular expression of 
FcγR classes is complex. In humans, FcRs are classified based on the class of Igs that they
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Fig. 1.5. Activating and inhibitory FcRs and the regulatory functions of immune complexes. 
See texts for details. Figure is reproduced from Nimmerjahn and Ravetch, 2008.
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recognize. FcRs for IgG, the most common serum and extracellular fluid Ig, are termed FcγRs. 
FcγRs play an important role in promotion and regulation of the immune and inflammatory 
responses to Ab-antigen immune complexes (Smith and Clatworthy, 2010). FcγRs have also 
been most extensively studied among FcRs, and will be the only focus to be discussed hereafter. 
The neonatal Fc receptor (FcRn), an IgG Fc receptor that mediates the transcytosis of maternal 
IgG to the neonate and regulates serum IgG level (i.e. half-life) (Schroeder and Cavacini, 2010), 
is neither included from consideration in this dissertation. 
 
1.3.2. FcγRs: Classification, structural features, and effector cell distribution patterns  
Human FcγRs are classified, based on sequence and molecular structure, into three 
classes with eight members, FcγRI (CD64; consisting of three members a, b, and c), FcγRII 
(CD32; consisting of three members a, b, and c), and FcγRIII (CD16; consisting of two members 
a, and b) (Jefferis and Lund, 2002; Clark, 1997) (Fig. 1.6). Not only these classes exhibit 
considerable genetic, structural, and functional diversity, but also they differ significantly in 
binding affinity (due to ditinct molecular structure) and specificity for ligands (i.e. IgG 
subclasses) (Smith and Clatworthy, 2010). These molecules also have unique cell type 
distribution patterns (cell-specific distribution) and effector functions (Smith and Clatworthy, 
2010; Jefferis and Lund, 2002; Ravetch and Kinet, 1991). 
Structurally, all FcγRs represent typical type I transmembrane glycoproteins and are 
members of the Ig superfamily (IgSF), which comprised of a unique ligand (IgG)-binding α-
chain consisting of Ig C-like extracellular domains (ectodomains) (D), followed by a short 
cytoplasmic tail (CYT) that links the receptor to the cellular plasma membrane (transmembrane; 
TM), and a signaling chain (Daeron, 1997) (Fig. 1.6). In general, FcγR classes either have CYT 
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domains that are capable of delivering signal transduction or associate with signaling co-receptor 
complexes (Ravetch, 1994). However, an exception exists in CD16b: it is attached by 
glycophosphatidylinositol (GPI) tail instead of the TM/CYT (i.e. lacking a transmembrane 
domain and being GPI-linked to the outer membrane) (Clark, 1997; Ravetch, 1994). CD32 and 
CD16 contain two conserved ectodomains, N-terminal (membrane-distal) D1 and C-terminal 
(membrane-proximal) D2, whereas CD64 has a third ectodomain, D3 (Ravetch and Bolland, 
2001). These receptors are also composed of a signal/leader (L) peptide that allows their 
transport to the cell surface. 
All FcγR classes are encoded by a gene family located on chromosome 1. These genes 
share common overall intron-exon genetic organization consisting of five or six exons: two 
encoding leader (L) peptide, two or three encoding D ectodomains, and one encoding the 
TM/CYT tail (van de Winkel and Capel, 1993). Individually, each of these three FcγR classes is 
encoded by a cluster of closely related genes: the three human CD64 or CD32 isoforms are 
encoded by three closely related genes, FcγRIa, FcγRIb, and FcγRIc, or FcγRIIa, FcγRIIb, and 
FcγRIIc, respectively; similarly, the two human CD16 isoforms are encoded by two separate 
highly homologous genes, FcγRIIIa and FcγRIIIb (Clark, 1997). 
FcγRs also differ in their cellular expression profiles, as discussed above (Fig. 1.6). In 
general, CD64 and CD32a are produced by both myeloid and granulocyte cells, whereas CD16a 
or CD16b is expressed by myeloid cells or granulocyte cells, respectively (Smith and 
Clatworthy, 2010). In particular, CD64 and CD32a are constitutively expressed, to varying 
degrees, on innate immune cells capable of fulfilling multiple effector functions, including 
phagocytosis and ADCC, which include macrophages, monocytes, neutrophils (granulocytes), 
and dendritic cells (Schroeder and Cavacini, 2010; Nimmerjahn et al., 2008; Clark, 1997).
39 
 
 
    
 
40 
 
 
Fig. 1.6. Activating and inhibitory IgG FcRs: Structure, function, binding affinity, and cellular 
expression profiles. See texts for details. Figure is reproduced from Smith and Clatworthy, 2010.
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CD32b is mainly expressed on B-cells. Indeed, CD32b is the only FcγR expressed by B cells 
(Smith and Clatworthy, 2010), and is also found on other immune effector cells, including 
macrophages, dendritic cells, activated neutrophils, mast cells, and basophils (Smith and 
Clatworthy, 2010; Nimmerjahn et al., 2008). CD16a is nearly exclusively expressed on natural 
killer (NK) cells (which is also the only FcγR expressed on these cells), which are the principal 
cell type carrying out ADCC. However, CD16a is also found on other effector cells such as 
macrophages, monocytes, neutrophils, and dendritic cells, while CD16b, which has only been 
described in humans, is exclusively present on neutrophils (Clark, 1997). Of immune effector 
populations, NK cells, macrophages, neutrophils, and dendritic cells are most potent. 
 
1.3.3. FcγRs: Functional activities, IgG isotype-binding affinity, and signal transduction of 
activating and inhibitory FcγRs 
Binding of ICs to FcγRs can induce potent and diverse immune responses. In healthy 
immunity systems, the binding to activating FcγRs (see below for the concept) mediates 
pathogen clearance – directly by various effector functional activities of Ab-dependent killing of 
target cells, as well as indirectly through other antigen-dependent and antigen-independent 
mechanisms, such as the release of cytokines and other inflammatory mediators (Smith and 
Clatworthy, 2010; Nimmerjahn et al., 2008) (Fig. 1.5). The binding to inhibitory FcγRs, on the 
other hand, can suppress humoral immunity (Smith and Clatworthy, 2010). FcγRs also mediate 
neutralization of pathogen- or toxin-bound IgG complexes (Perez et al., 2009; Verma et al., 
2009). In abnormal immunity status, such as in autoimmunity, however, the binding to FcγRs 
(especially FcγRIIa) might induce robust inflammatory responses with adverse consequences in 
diseases or disorders like rheumatoid arthritis and SLE (Takai, 2005; Hogarth, 2002), as 
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previously disccussed. Moreover, CD16-mediated ADCC responses are important for killing 
tumor cells and thus, for the efficacy of therapeutic Abs in treating cancers (such as in follicular 
lymphoma and Waldenstrom's macroglobulinemia patients). 
As discussed previously, FcγRs differ in binding affinity to different IgG subclasses (Fig. 
1.6). In general, they have the highest affinity for IgG1, then IgG3 and IgG4, whereas mostly 
they do not bind IgG2 (Schroeder and Cavacini, 2010; Smith and Clatworthy, 2010). 
Furthermore, upon ligand binding, they also exhibit differences in the signaling pathway (which 
is associated with the initiation, amplification, and termination of both innate and adaptive 
immune responses). In particular, an activating signal is transmitted upon IgG binding of CD64, 
CD32a, or CD16a, an inhibitory signal is associated with binding of CD32b, whereas no signal is 
delivered when IgG binds CD16b (Schroeder and Cavacini, 2010; Smith and Clatworthy, 2010; 
Weiner et al., 2010). The five activating FcγRs, CD64, CD32a, CD32c, CD16a, and CD16b, are 
thus referred as activating (or stimulatory) FcγRs, whereas CD32b is the only FcγR that has an 
inhibitory function (referred as inhibitory FcγR) (Smith and Clatworthy, 2010). These opposite 
FcγR functional activities must be appropriately coordinated to ensure healthy effector immune 
responses. The exclusively B cell-expressed CD32b, thus, as the only inhibitory FcγR capable of 
negatively modulating cell activation state previously initiated by an activating FcγR through ICs 
formed upon antigen exposure, plays a unique role in these responses (Smith and Clatworthy, 
2010). 
Among the three FcγR classes, CD64 exhibits high IgG binding affinity, whereas the 
other two are capable of only medium- to low-affinity binding (Fig. 1.6). Consequently, CD64 is 
the only FcγR able to bind monomeric IgG with high affinity and functions during early immune 
responses. In contrast, for efficient binding, CD32 and CD16 (CD16a) require the formation of 
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ICs or IgG aggregates (i.e. IgG polymeric forms) surrounding multivalent antigens during late 
immune responses (Schroeder and Cavacini, 2010; Nimmerjahn et al., 2008). Thus, CD64 is 
referred as the high-affinity FcγR, whereas CD32 (i.e. CD32a and CD32c) and CD16 (i.e. 
CD16a and CD16b) are referred as low-affinity FcγRs (Smith and Clatworthy, 2010). 
Different FcγR classes may also differ in their N-glycosylation patterns, which play an 
important role in the molecule folding, structure, degradation, and cell-cell adhesion (van Sorge 
et al. 2003). N-glycosylation is also capable of influencing ligand binding and leukocyte 
expression patterns of FcγRs (including the case of CD16 on ligand binding and cellular 
expression) (Rogers et al., 2006; van Sorge et al. 2003). 
FcγRs transduce activating or inhibitory signals through intrinsic immunoreceptor 
tyrosine-based activation motifs (ITAMs) or inhibitory motifs (ITIMs), respectively (Smith and 
Clatworthy, 2010) (Fig. 1.4 and 1.6). The ITAMs are present in either the CYT tail/domains (for 
CD32a and CD32c) or the associated FcR common accessory γ-chain (for CD64 and CD16a), 
whereas the ITIMs are present in CYT tail/domain (for CD32b) (Smith and Clatworthy, 2010) 
(thus, each CD32 molecule possesses an ITAM or an ITIM of its own and has no additional 
signaling chains). Mechanistically, cross-linking by Ab-antigen/pathogen ICs of activating or 
inhibitory FcγRs results in the ITAM or ITIM phosphorylation, respectively (Smith and 
Clatworthy, 2010). Such phosphorylation of ITAMs or ITIMs leads to signal transduction and 
cell activation (i.e. the activating signaling cascade) or to inhibition of the activating signaling 
cascade, respectively (Smith and Clatworthy, 2010). In addition, several FcRs expressed on a 
single type of leukocytes may cooperate to modulate many cellular functional effects of IC 
binding and cellular effector functions (Daëron, 1997). For instance, when on human neutrophils 
CD16b is cross-linked to CD32a through a divalent antigen, the neutrophil cells can be 
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synergistically activated (Green et al. 1997). Similarly, cross-linking on human B cells of CD32b 
with B cell receptor (BCR) may result in an increase of the “threshold” (i.e. the ratio of binding 
of an IgG subclass to activating FcγRs and inhibitory CD32b; also known as A/I ratio) for B cell 
activation and a decrease of Ab production by these B cells (Smith and Clatworthy, 2010). Also, 
CD16b, the GPI-linked receptor that has no CYT domain and does not contain the associated 
FcR common γ-chain (Smith and Clatworthy, 2010), is also believed to modulate cellular 
neutrophil responses to pathogens/antigens through interactions with other neutrophil FcRs. 
The final outcome (end result) of IC-FcR interactions is, therefore, complex and hard to 
predict – it is dependent upon the functional activities of the bound FcγR, the effector functions 
of a particular IgG subclass, the FcγR-expressing effector cell type, and applicable contributory 
(inhibitory or stimulatory) signals
 
(Schroeder and Cavacini, 2010; Weiner et al., 2010). 
 
1.3.4. Intra-species (inter-individual) allelic polymorphism (allotypic variation) of FcγRs 
Adding to the complexity of distinct expression pattern, recognition, and activation 
profiles of FcγRs, each class of these receptors contains multiple isoforms and furthermore, a 
number of those isoforms exist as allelic dimorphisms (biallelic polymorphisms) (Takai, 2005; 
Jefferis and Lund, 2002). Correlation between allelic polymorphism and function has been 
demonstrated. Furthermore, a number of naturally-occurring single variations have established 
their functional and even clinical significance. In particular, R131 (CD32a) ([D2] R80, IMGT 
unique numbering), F158 (CD16a) ([D2] F108, IMGT unique numbering), and NA2 (CD16b) 
have been shown to exhibit higher affinity and functional activity compared to their 
corresponding alleles (H131, V158, and NA1, respectively) (Binstadt et al., 2003; van de Winkel 
and Capel, 1993). As a result, these allelic FcγR variants have the ability to affect susceptibility 
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and/or severity of certain autoimmune disorders, especially systemic lupus erythematosus, as 
well as inflammatory and infectious diseases (Takai, 2005; Binstadt et al., 2003; van Sorge et al., 
2003). Moreover, these variations have been shown to influence the outcome of monoclonal 
antibody treatment (Cartron et al., 2002). For instance, CD16 polymorphisms have been recently 
shown to be associated with the therapeutic success in treatment of Waldenstrom’s 
macroglobulinemia by the rituximab mAb. These polymorphisms, therefore, can serve as high-
risk factors or genetic markers for certain diseases or IgG-based immunotherapies (van Sorge et 
al., 2003). Characterization of these allelic polymorphisms and their relations with two-
dimensional and three dimensional structures are, thus, important for the understanding of their 
physiological effects. In this context, the IMGT Collier de Perles graphical two-dimensional 
representations may provide useful information for relating structure to potential function 
(Bertrand et al., 2004). 
Thus, even a single amino acid substitution in FcγRs could result in significant 
differences in functional properties and ultimately, might establish clinical relevance. 
Consequently, on one hand, it might in a distant future be possible for a particular FcγR allelic 
isoform to be selectively regulated – and on specific cell types – for individualized 
immunotherapies (Jefferis and Lund, 2002). On the other hand, the efficiency of future or 
potential FcγR-directed immunotherapies might vary from individual patient to one another. 
 
1.4. Monoclonal antibodies, molecularly-engineered (recombinant) IgG and FcγR 
molecules, and recombinant DNA method 
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1.4.1. Monoclonal antibodies (mAbs) as basic research and diagnostic tools as well as 
prophylactic and therapeutic agents 
The capability of Abs to bind with exquisite discrimination and high affinity to virtually 
all possible arrays of diverse antigens and chemical structures has placed them to a special 
position in both biological sciences and practical medicine (Clark, 1997). Nowadays, 
recombinant mAbs represent important biomedical and pharmaceutical products. These 
molecules are utilized not only as valuable tools in basic research and diagnostic areas, but also 
as powerful agents in prophylaxis and therapeutics. More than two dozen therapeutic mAbs have 
to date been approved for use in the clinic, and hundreds (~350) more mAbs are in development 
or trials (Reichert, 2012; An, 2010). 
MAbs, owning to their desirable safety profiles and high efficiency, have proved to 
improve human health, fight diseases, and even save lives. MAbs have been widely used in basic 
research and diagnostic tests such as Western blot, ELISA, immune dot blot, immune-
histochemistry, immune-fluorescence, and flow cytometry, to name a few. Passive 
immunotherapy with mAbs, which initially introduced mAbs into practical medicine, still retains 
a powerful prophylactic and therapeutic strategy. It is routinely used for the control of hepatitis 
B, rabies, and cytomegalovirus infections (Sawyer, 2000). It also has the potential use for 
efficient control and treatment of other infectious diseases, such as the lethal influenza 
H5N1virus infection  (Simmons et al., 2007). MAb treatment of infections caused by bacteria 
resistant to antibiotics may provide a lifesaving strategy (Keller and Stiehm, 2000). Not only 
being utilized in infectious diseases and antiviral prophylaxis, but also mAb-based strategies for 
treatment have been applied for a wide variety of other diseases and disorders, ranging from 
cancer and malignancies to rheumatoid arthritis, inflammatory diseases, as well as from 
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autoimmune disorders, to cardiovascular, asthma, poisoning, and organ transplantation 
(transplant rejection) (Laffly and Sodoyer, 2005; Brekke and Thommesen, 2003; Park and 
Smolen, 2001; Schulze- Koops and Lipsky, 2000; Zeitlin et al., 2000). 
MAbs, including those produced from recombinant DNA molecules (i.e. recombinant 
mAbs), are produced by a single cell clone and are all structurally and functionally identical (An, 
2010). Due to the availability of the murine hybridoma technology in the early time (see below), 
most therapeutic mAbs currently used in humans are of murine origin (An, 2010). Over the last 
three decades, advances in recombinant Ab technology that promotes production of genetically 
engineered mAbs has greatly driven the use of Abs, both as basic research and diagnostic tools 
as well as prophylactic and therapeutic agents. 
 
1.4.2. The hybridoma technique: The traditional method for production of mAbs 
Traditionally, mAbs are produced in vitro by immortalizing antibody-producing cells 
created through fusing myeloma (tumor) cells with the spleen cells from a mouse immunized 
with the wanted antigen. This method, termed hybridoma technique, was developed nearly four 
decades ago (Kohler and Milstein, 1975). It has been proven to be the most reproducible method 
for generating murine mAbs. 
The method, however, has a number of limitations. Not only murine mAbs produced by 
this method consist of only ﬁxed (unchangeable) CH class and subclass regions, have short 
serum half-life, and lack the capability to activate sufficient effector functions (including Ab-
dependent killing of target cells, ADCC and CDC), but also the created hybridoma clones may 
be genetically unstable (Nielsen et al., 2006). In addition, the technique itself is time-consuming 
and laborious. More importantly, murine mAbs have poor pharmacokinetics in humans. When 
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used as therapeutic agents, murine mAbs are recognized by the human immune system as 
allogeneic proteins, resulting in a rapid removal of them from the blood, as well as in systemic 
inflammatory effects and human anti-mouse antibody (HAMA) immune responses (Steinitz, 
2009; Laffly and Sodoyer, 2005).  
The problems associated with murine mAbs produced by the hybridoma method have 
recently been overcome largely, owning to the advent of the recombinant DNA technology (i.e. 
the genetic engineering technique). This advanced technology allows reducing HAMA 
immunogenicity responses by making or modifying mAbs so as they are  less “murine” or more 
“human”, such as chimerizing murine/human mAbs, humanizing murine mAbs, or completely 
human mAbs (An, 2010; Kipriyanov and Le Gall, 2004). 
 
1.4.3. The recombinant DNA method for production of mAbs and molecularly-engineered 
IgGs and FcγRs: Overview 
Recombinant DNA method, or recombinant DNA technology, is a molecular technique 
for engineering recombinant proteins. The technique is widely used in biological and biomedical 
sciences, biopharmaceutical and biotechnology, as well as medicine. It takes advantage of the 
fact that production of proteins can be accomplished using cloned DNA sequences or 
recombinant DNA molecules to create plasmid constructs capable of growing and being 
expressed by cell culture (i.e. expressing recombinant genes). Thus, in this method, a 
recombinant DNA fragment (or gene segment) is first created by several molecular cloning steps, 
and is subsequently inserted into a cloning vector, which is then transformed into and 
multiplicated in competent cells (bacteria; such as E. coli competent cells). Prior to transfection, 
the recombinant DNA constructs must be directionally inserted into an expression plasmid vector 
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containing genetic sequences necessary for expression, including promoter, translational 
initiation signal, and transcriptional terminator. Upon transfection into the host organism, the 
recombinant foreign DNA molecule that is contained within the recombinant DNA plasmid 
construct may be transcribed and translated by the host cell translational apparatus. Finally, 
colonies producing the recombinant protein product were detected and isolated. These 
procedures, thus, utilize a number of molecular techniques, including cloning vector, restriction 
endonuclease digestion, DNA ligation (with DNA ligase), and selection of clones with desired 
DNA inserts by appropriate antibiotics-supplemented culture medium. 
The recombinant DNA technology for production of recombinant antibodies (rAbs) (also 
called recombinant Ab technique) is a fully in vitro method for creating highly-specific and high-
affinity mAbs. As discussed previously, it is the globular domain structure and genetic 
organization of Abs, in which specificity-determined Fab is formed by V domains while different 
effector functions Fc is constituted by C domains, that have greatly facilitated the manipulation 
of Ig genes for Ab genetic engineering. In particular, the Ig domain structure enables exchange 
and replacement of domains specializing in antigen-binding activities (Fab or partial Fab), or 
those responsible for cell-killing effector functions (Fc) among Abs (Kipriyanov and Le Gall, 
2004). In this method, recombinant Abs are created in a way that V region is made of a particular 
species and C region is of another species. For instance, mouse V domains can be merged with 
(or fused to) human C domains to yield partially-mouse, partially-human ("humanized") mAbs. 
Among available mouse V gene segment sequences that have enabled rapid production of 
recombinant Abs, murine V gene sequence specifically directed against the hapten 5-iodo-4-
hydroxy-3-nitrophenyl acetyl (NIP) has been established as a specificity system that has 
facilitated studies of Ab effector functions. Traditionally used as a haptenic determinant, NIP 
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may be further radiolabeled and used as salts or derivatives. Additionally, production of NIP-
specific recombinant Abs is relativey straightforward. Various Ab variants possessing anti-NIP 
specificity have been produced and used to assess the Fc-related structural basis of Ig effector 
functions (Loset et al., 2004; Furebring et al., 2002; Redpath et al., 1998; Clark, 1997). A variety 
of pre-designed expression vectors enabling rapid construction and driving expression of 
complete and fragmental recombinant Ab molecules, such as pLNOH2 (Norderhaug et al., 
1997), have been also established. 
 
1.4.4. The recombinant DNA method for production of mAbs and molecularly-engineered 
IgGs and FcγRs: Advantages and limitations 
Recombinant Ab technique offer many advantages over the conventional hybridoma Ab 
production method. In the recombinant Ab method, mAbs can be produced in in vitro by cloning 
entire Ig V region gene repertoire, and no immunization nor experimentation with animals are 
needed (thus less time would be required). Indeed, the hybridoma cell lines are sometimes 
genetically unstable and in such cases, immortalization of unique Abs by cloning corresponding 
genes would be greatly useful. For many applications, only partial Ab molecules (i.e. Ab 
fragments, instead of whole Ab molecules) are needed. Here the recombinant Ab method has 
proved advantageous with its ability to genetically engineer Abs in bacterial expression systems, 
which is rapid and straightforward. 
More importantly, given the availability of enormous Ab gene sequences and a variety of 
advanced molecular biology techniques, isolation and cloning of Ig genes can be rapidly carried 
out. These sequences can be readily amenable to genetic manipulation and fusion. Genetic 
manipulations, chemical modifications, or other intervening methods of the properties of 
51 
 
 
expressed mAb – owing to V and/or C regions – can greatly enable the design of novel Abs with 
predetermined effector functions or other desired functional activities (Fig. 1.7). Such 
manipulations can be done through a variety of genetic engineering methods and using various 
different strategies, such as "inserting" or "swapping-out" Ab portions, introducing mutations, 
and adding markers, cytotoxic agents, cytokines, or other labeling or functional conjugates, 
among other approaches (Carter, 2001; Clark, 1997). These modifications have enabled creation 
or alteration of recombinant Abs with additional desired antigen binding specificity, enhanced 
binding affinity, optimized or additional natural effector functions, or removal of unwanted 
functional activities (such as placenta transfer or complement activation) for particular 
applications (Carter, 2001; Clark, 1997). For instance, IgG Abs that are capable of binding FcRs 
but not complement – or vice versus (i.e. those with only complement activation potential) – can 
be designed. Engineering of recombinant Abs can also be further improved by manipulating 
amino acid composition (sequences) within individual Ig domains to obtain particular Abs for 
studying the structure basis and functional properties (such as binding, folding, stability, 
catalysis, and effector functions) (Clark, 1997). 
Advances in the recombinant Ab techniques have allowed production of Abs to virtually 
any antigen, and facilitated generation of Abs never been made in vivo. Nevertheless, despite the 
large diversity of potential applications ascribed to recombinant Abs, the method lacks of an 
appropriate strategy for determining and selecting the desired high affinity Ab products that 
would be effective in vivo. 
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1.4.5. Creation of recombinant Ig gene constructs: Sequence overlap extension polymerase 
chain reaction (SOE-PCR)  
As discussed above, the recombinant Ab techniques rely on the rapid cloning of isolated 
Ig gene segments before these genes can be cloned into cells that can grow and express 
recombinant Ab products. Cloning of Ig Ab genes can be done by either isolating these 
genesfrom the relevant genetic materials of a hybridoma cell line, or by synthesizing them using 
polymerase chain reaction (PCR) amplification with degenerate primers on a pool of Ab-
producing cells obtained from an immunized animal or immunized human donor(s). The PCR 
method has indeed allowed amplification of the entire Ig genes (or some of their components). 
Subsequently, these genes can be introduced into a variety of cells for production of recombinant 
Abs. At present, the PCR method is commonly used to amplify genes encoding Abs with desired 
specificity. It can even be utilized to produce the entire Ab gene repertoire of immunized or non-
immunized animals for cloning purposes. 
Recombinant Ig gene constructs can be created from individual Ig gene segments by a 
method for splicing two pieces of DNA segments, known as sequence overlap extension PCR 
(SOE-PCR) (Yolov and Shabarova, 1990; Yon and Fried, 1989; Ho et al., 1989). This technique 
is a powerful tool for fusing two short DNA fragments whose total length is not greater than 3-4 
kb at a time (Kuwayama 2002; Pont-Kingdon, 1997), which is ideal for creating Ig gene 
constructs. Fig. 1.8 illustrates the principle of SOE-PCR to assemble a gene construct from two 
DNA fragments. Two pairs of primers, the flanking and the internal pairs, are used. The overlap 
(homologous or complementary) sequence is incorporated in the two internal primers, which 
serve two functions: priming and overlapping, by their priming and overlap regions, respectively. 
In particular, the 5’ end sequence of the internal reverse primer (to be used for amplifying the
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Fig. 1.7. Among the advantages of engineering Abs: Strategies for enhancing the potency and 
activity of antitumor antibodies. See text for details. Figure is reproduced from Carter, 2001.
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first PCR fragment) is complementary to a short sequence of the second PCR fragment – and 
thus, to the 5’ end sequence of the internal forward primer (to be used for amplifying the second 
PCR fragment). 
The theoretical stages of SOE-PCR amplification are also summaried in Fig. 1.8. Firstly, 
two overlapping fragments are amplified in separate PCRs using the forward flanking and 
reverse internal primer pair – as well as the forward internal and reverse flanking primer pair – 
on the target sequence. In some cases, these two resultant PCR product fragments anneal to each 
other through their complementary sequences. Since these two DNA template fragments were 
introduced at their adjacent end an overlapping sequence, each of these overlap strands can act as 
a giant “primer” on the other to extend its 3’ end by DNA polymerase. These reactions result in 
the fused DNA species created in the mixture of early SOE-PCR products. The intact mixed 
DNA strands are finally generated when the overlap is extended and co-ordinately amplified 
with the outside forward and reverse flanking primer pair (i.e. hybridizing and amplifying the 3’ 
end of the upper strand of forward fragment and the 5’ end of the lower strand of the reverse 
fragment). In all reactions, a PCR cycle comprises steps of denaturation, annealing, and 
extension of the primed 3’ ends. Although SOE-PCR fusion offers greater speed and flexibility 
for construction of recombinant DNA molecules than traditional RE and ligase cloning, it is, 
however, expected to introduce errors, as any other PCR reactions. 
Several sequential runs of SOE-PCR, with each run combining two DNA pieces at a 
time, can assemble more than two short segments and generate a final constructs with the desired 
length. Modifications of reaction parameters and/or conditions, such as designing longer 
chimeric primers, optimizing molar ratios and DNA concentrations, adjusting annealing 
temperature, and running with no primers for several first PCR cycles and using nested primers,
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Fig. 1.8. Diagrammatic overview of the sequence overlap extension polymerase chain reaction 
(SOE-PCR) procedure to assemble a chimeric/mixed gene fragment. The procedure is also called 
by various other names, such as overlap extension PCR, splice overlap extension PCR, overlap 
PCR, overlapping PCR, two-step PCR, two-step overlap extension PCR, or three-part PCR. (A) 
Individual strands of a DNA fragment displaying their 5’ and 3’ ends are illustrated as enlarged 
boxes. Two pairs of primers are used: FW flanking primer/RV internal primer and FW internal 
primer/RV flanking primer. The overlap (homologous or complementary) sequence is 
incorporated in the FW and RV internal primer. Primer direction is indicated as arrows. The two 
internal primers serve two functions, priming and overlapping, by their priming and overlap 
regions, respectively. Complementary ends are shown by different colors boxes (i.e. small green-
filled and yellow-filled boxes). (B) Theoretical stages of formation of a SOE-PCR chimeric 
product. See text for details. Overlapping ends of identical sequences of fragments are indicated 
with the same color filled; complementary ends are shown by different colors boxes (i.e. small 
green-filled and yellow-filled boxes). A PCR cycle comprises steps of denaturation, annealing, 
and extension of primed 3’ ends.
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might be needed during the procedures in order to improve the success of reamplification and 
generate the best products, as well as to minimize non-specific bands (as will be discussed in 
more details later). 
 
1.4.6. Mammalian expression systems for production of recombinant IgGs and FcγRs 
Molecular engineering of Abs or Ab fragments enables manipulation and production of 
Igs in various eukaryotic and prokaryotic cell types, including bacteria, yeast, plant cells, insect 
cells, and mammalian cells (Kipriyanov and Le Gall, 2004). However, to be fully functional, 
recombinant Ig products that are expressed must be correctly folded, wholly assembled, and 
post-translationally modified. In particular, to form intact molecules, the two IgH chains must be 
disulfide bound (and to be able to carry out effector functions), CH2 domains must be correctly 
glycosylated, and CH3 domains must be paired (Kipriyanov and Le Gall, 2004; Brekke and 
Thommesen, 2003). Glycosylation is also crucial for efficacy of Abs and protein drugs targeted 
as human therapeutic agents. Expression systems possessing the mechanisms necessary for these 
processes and events have been seen in various mammalian cell lines, including nonsecreting 
myeloma, hybridoma, and nonlymphoid cells (Kipriyanov and Le Gall, 2004). Like with Igs, a 
mammalian cell line system (rather than prokaryotic cell types) should also be considered for 
expressing recombinant FcRs, as FcRs also contain conserved disulfide bridge (some FcR 
members also consist of unpaired Cys residues) in each of their IgSF domain. 
Dependent upon the quantity of the recombinant Ab products needed, transient or stable 
expression of Abs in mammalian expression systems can be performed. In contrast to transient 
production which is rapid, stable expression of Abs is time consuming. The reason is that stable 
production is based on the stable integration of recombinant Ig genes into the host cell 
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chromosomes, which is a largely random event. To facilitate successfully transfected cell clones 
to be isolated from a heterogeneous population, the interested gene is integrated together with a 
selection marker during engineering of the recombinant constructs. Among common types of 
selection marker genes are those encoding resistance to antibiotics (such as neomycin gene, 
which encodes resistance to G418) and enzyme analogs [such as dihydrofolate reductase 
(DHFR) gene, which encodes methotrexate resistance]. 
Several mammalian expression cell lines capable of highly producing Ig molecules have 
been developed. The murine IgL lambda (λ)-producing, IgH-defective, myeloma (i.e. cells that 
produce Abs) J558L cell line is one of such cellular systems (details will be described later) 
(Howard et al., 2002; Oi et al., 1983). Intact, glycosylated Abs that are fully functional and 
capable of antigen-binding, have been successfully expressed and secreted by J558L cells 
transfected with vectors expressing IgH chains and carrying the G418 selectable marker (Howard 
et al., 2002; Fell et al., 1989; Oi et al., 1983). 
 
1.5. Structural and functional features of rhesus macaque IgG and FcγRs: Current status 
of knowledge 
1.5.1. Presence of four IgG subclass genes, each with similar length and organization as that 
of humans   
Like humans, rhesus macaques express five Ig classes. Early studies had identified both 
in serum and in genomic DNA in healthy rhesus macaques only three IgG subclasses, IgGl, IgG2, 
and IgG3 (Calvas et al., 1999; Shearer et al., 1999). Later data obtained from genomic DNA 
analysis, however, show that this primate species possess four IGHG genes, based on their 
sequence similarity with the four corresponding human genes IGHG1, IGHG2, IGHG3, and 
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IGHG4 (Scinicariello et al., 2004). These genes are expressed at least at the mRNA level, 
including the lately-identified IGHG4, whose protein product (i.e. IgG4) may be present at 
almost undetectable levels in rhesus macaque serum (Scinicariello et al., 2004). The early 
serological failure of identifying the rhesus macaque IgG4 homologue of humans might also 
indicate the possibility that differences between human and rhesus macaque IgG4 had 
circumvented its detection and identification. 
The intron-exon genomic organization of the four IGHG genes is similar between rhesus 
macaques and humans. Each of the four rhesus macaques IGHG genes is composed of four 
exons, individually encoding CH1, the hinge, CH2, and CH3 domains, and three introns, which 
take place in-between the exons. Each rhesus macaque CH domains contains a similar number of 
amino acids as that found in their human counterparts, which is 98, 109-110, and 107, in CH1, 
CH2, and CH3 domains, respectively. The length of the introns is also similar to that of the 
corresponding human introns (~390, ~120, and ~100 nucleotides for the intron located between 
CH1-the hinge, the hinge-CH2, and CH2-CH3 exons, respectively) (Scinicariello et al., 2004). 
 
1.5.2. A single exon encoding the IgG3 hinge region and key amino acid differences of IgGs 
compared to human counterpart 
IgG V region genes between rhesus macaques and humans are highly homologous and 
their IgG C region genes are generally homologous. Indeed, rhesus macaque IgG1, IgG2, IgG3, 
and IgG4 CH domains  exhibit 89.9%, 88.0%, 92.9% and 91.4% amino acid identity to their 
human counterpart (Scinicariello et al., 2004). The deduced amino acid sequence of each of four 
rhesus macaque IgG subclasses differs from that of their human counterpart – generally for a few 
amino acids (Scinicariello et al., 2004) – yet they share most amino acid residues known to be 
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functionally conserved. Perhaps the most striking difference between rhesus macaque and human 
IgG subclass genes is at the IgG3 hinge. Rhesus macaque IgG3 contains only one hinge exon 
(Scinicariello et al., 2004), whereas, as previously described, the human IgG3 hinge most often 
consists of four exons (can be two to five exons; with repetitive sequences and separated by short 
introns) (Lefranc and Lefranc, 2001). In addition, it is deficient in Cys residues, which is 
important for Ig stability through formation of disulfide bonds. 
Some other key amino acid differences in IgGs of rhesus macaques and their human 
counterparts have also been revealed. The upper hinge region of macaques contains several Pro 
residues [known to be involved in stabilization or maintaince of the IgG tertiary structure and 
might influence the hinge flexibility (Thommesen et al., 2000, Greenwood et al., 1993)] that are 
not present in the human counterpart. Chinese rhesus macaque IgG4 also possesses Ala instead 
of Pro at position 13 of the hinge. Also, rhesus macaque IgG4 has Pro at position 101 of CH2 
domain, where in human IgG4 it is Ser. Moreover, in humans, unlike IgG4, other IgG subclasses 
capable of activating complement contain Pro at position 101. The inefficiency in complement 
activation of human IgG4 is thought to be associated with lack of Pro at the position 101 (Xu et 
al., 1994). The presence of Cys-to-Ser substitution at position 10 in rhesus macaque IgG4 CH1 
domain as compared to humans might affect the formation of interchain disulfide bridges 
involved in this Cys residue (Scinicariello et al., 2004). Interestingly, a Ser exists at this position 
in IgG1 in both species. 
Although characterized by evolutionary instability, as discussed previously, the structural 
distinctions of the IgG hinges in rhesus macaques as compared to human counterparts might lead 
to alterations in the formation of disulfide bridges and functional properties of IgG molecules, 
including molecular flexibility (Thommesen et al., 2000; Roux et al., 1997), neutralizing ability, 
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binding affinity to FcRs, capability of complement activation (Burton and Woof, 1992; 
Michealsen et al., 1990, Tan et al., 1990), and susceptibility to proteolytic enzymes. The single-
hinge IgG3 in rhesus macaques (and other macaque species) might exhibit unique properties 
and/or carry out different effector functions when compared to human IgG3. 
 
1.5.3. Intra-species IgG H chain genes: Relatively high level of heterogeneity (polymorphism) 
and variability of disease susceptibility 
As previously mentioned, rhesus macaques are characterized by a high level of 
polymorphism of MHC genes (Shedlock et al., 2009). Like several other NHP species, rhesus 
macaques also feature a relatively high degree of intraspecies CH gene heterogeneity (allelic 
polymorphism) for IgGs, particularly IgG2 and IgG4, as compared to humans (Scinicariello et 
al., 2004; Scinicariello et al., 2001). Although IgG (i.e. IGHG) polymorphism level is less 
extensive than that of IgA in this animal species (Sumiyama et al., 2002; Scinicariello et al., 
2001), many IgG substitutions are located in CH2 domains, the place that is responsible for most 
IgG effector functions and properties (Radaev and Sun, 2002). 
In addition to species-specific differences from humans, individual rhesus macaque 
animals originated from different geographical areas also show considerable variation in immune 
conding genes and disease susceptibility. Examples of such variations include those observed 
with IGHG2 and IGHG4 genes of Chinese- versus Indian-originated macaques (Scinicariello et 
al., 2001). These geographically different rhesus macaque animals also vary in their 
susceptibility to infectious diseases, especially SIV infection: when inoculated with the same 
infectious challenge virua stock, some animals progressed disease – and at different extents – 
while others remained relatively unaffected (Reimann et al., 2005; Ling et al., 2002; Marthas et 
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al., 2001; Joag et al., 1994). Some rhesus macaque individual animals may thus be better than 
others to be used as a research model. 
The extensive polymorphism in IgG CH genes might be involved in the presence of 
structurally, and thereby functionally, variable IgG molecules in different rhesus macaque 
animals. This relatively high level of allelic polymorphism might also reflect an alternative 
strategy developed by rhesus macaques to clear invading pathogens, however. Also, 
polymorphisms might explain the poor (cross)reactivity or inactivity of anti-human reagents to 
different rhesus macaque IgG subclasses. Moreover, these Ig allelic forms, with different 
functional properties, might contribute to different susceptibility, progression, or severity to 
infections. These differences should be taken into account when designing experimental 
strategies and protocols with various model systems – as well as to select appropriate animals for 
studying pathogenesis of human infectious diseases, immunization, and vaccine strategies. 
Theoretically, substitutions in rhesus macaques of individual amino acid residues known 
in humans to be functionally important may lead to changes in Ig effector functions (such as 
ADCC, CDC, ADCP, or IgG half-life), as well as in Ig structure-function relationships. 
However, polymorphisms that occur co-locally in both IgG Fc ligand and their native FcγR 
molecules within their binding areas would, under natural evolutionary selection, have the 
potential to optimize functional activity and increase the binding fitness of both interacting 
players (Kim et al., 2001). Furthermore, because of the extensive contact surface and multiple 
residues interacting with receptors, the interactions between IgG (ligand) subclasses and different 
FcγRs and are complex. In addition, interaction of the homodimeric Fc fragment with its 
receptors is asymmetrical (i.e. overlapping but not identical residues in both Fc fragments may 
take part in binding). Therefore, in order to adequately assess the binding properties and the 
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ability to mediate effector functions of IgG molecules in rhesus macaques or other NHP animals, 
not only heterogeneity (polymorphism) of ligand IgGs themselves need to be considered, but 
also structure of corresponding FcγRs in those species must also be taken into account. 
 
1.5.4. Rhesus macaque FcγR biology system and related pathogen-clearance mechanisms are 
largely uncharacterized 
Although the information available on rhesus macaque Ab molecules and corresponding 
receptors is steadily increasing (Rogers et al., 2008, 2006a, and 2004; Scinicariello et al., 2004; 
Scinicariello and Attanasio, 2001; Calvas et al., 1999), basic characterization is still lacking for 
the majority of Fc receptors. Indeed, research on NHP FcR biology is still in its nascent stage. 
Rhesus macaque FcRs have only been described recently and are limited to few classes (Rogers 
et al., 2008, 2006b, and 2004). Within FcγRs in this species, only gene sequences for FcγRIII 
(CD16) have to date been identified (Rogers et al., 2008; Miller et al., 2007; Rogers et al., 2006b 
and 2004), whereas the genes encoding CD32 and CD64-“like” sequences have been only 
computationally predicted. Rhesus macaque CD16 gene shows 91.7% identity to human CD16a 
(Rogers et al., 2006b). Although CD16 molecules in NHP species (including rhesus macaques) 
and humans share an extensive similarity in sequence and genetic organization – with nearly 
complete conservation of residues known to be critical for IgG binding – they have been found to 
be different in some key aspects. In particular, while human CD16 consists of two isoforms 
encoded by two separate genes, only a single CD16 gene homologue, which encodes a protein 
with over 90% homology to human CD16, was identified in rhesus macaques and other NHP 
animals (Rogers et al., 2006b). CD16 cell-type expression patterns on the leukocyte population 
differ not only between humans and NHP scpecies, but also among different NHP species 
65 
 
 
(Warncke et al., 2012; Rogers et al., 2006). Also, in contrast to corresponding human FcγR, 
recombinant NHP CD16 exhibits different binding specificity to different NHP and human IgG 
subclasses (Rogers et al., 2006). Difference in functional properties of different cynomolgus IgG 
subclasses has also been recently characterized (Warncke et al., 2012; Jacobsen et al., 2011). 
The findings about a high degree of inter-individual genetic heterogeneity of NHP IgSF 
molecules such as IgG and CD16 [as well as IgA and IgD (Rogers et al., 2006a)] characterized to 
date raise the question whether such diversity might also be reflected in other IgSF members, 
including other classes of FcγR, in these species. Although CD16 is known to be polymorphic in 
humans and its inter-individual allelic variants have recently been reported in rhesus macaques 
(Miller et al., 2007), we do not know at what extent these molecules are heterogeneous. More 
importantly, CD16 allelic variants appear to influence the host responses to mAb treatment 
(Miller et al., 2007). As discussed previously, CD16 also plays an important role in destruction 
of HIV-infected NK cells and malignancies via ADCC mechanism. The fact that the neutrophil 
expression profile of CD16 differs among several macaque species usually used in evaluation of 
therapeutic Abs based on IgG-FcγR interactions (Rogers et al., 2006), should be considered in 
experimental design and data interpretation. 
As mentioned previously, even a single amino acid change in FcγR amino acid sequences 
might result in the possibility of significantly altering ligand binding affinity of a particular FcγR 
(Rogers et al., 2006a; Scinicariello et al., 2004; Scinicariello et al., 2001). Particular FcγR allelic 
variations might also be associated with disease susceptibility and/or severity, or can even 
influence the outcome of Ig-based treatments (van Sorge et al., 2003; Cartron et al., 2002). Thus, 
specific sequence alleles or variations indentified in individual animals might be assessed for 
their potentially altered binding affinity or specificity – or even clinical relevance as needed. In 
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addition, discrepancy should be considered when using NHP models in the evaluation of Ig-
based or, in the near future, FcγR-derived, immunotherapies. These observations highlight the 
need to further characterize FcγRs in rhesus macaques. 
Taken together, on one hand, rhesus macaque IgGs and associated FcγR systems 
characterized to date are conserved and extensively homologous compared to those in humans. 
This similarity suggests that immune responses and mechanisms of protection modeled from this 
species can be translated into humans. On the other hand, rhesus macaque IgGs are highly 
polymorphic and have several key differences from their human counterparts. This distinction 
suggests that efffector functional activities of IgG subclasses, including their interactions with 
corresponding FcγRs, between these two species may not be directly equal or simply similar. 
The presence of allelic forms of rhesus macaque IgG CH region and FcγR genes might result in 
production of IgGs and FcγR molecules exhibiting different functional properties, thus 
potentially contributing to individual immune responsiveness profiles. These differences should 
be clarified in order to correctly interpret and evaluate experimental results generated using the 
rhesus macaque model. Additionally, as discussed previously, amino acid changes in FcγRs 
might have the potential to influence the possible effects caused by IgG substitutions (due to 
relatively high polymorphism of IGHG genes), leading to the unique properties and functions of 
their IgGs in rhesus macaques. Comprehensive characterization of FcγR structures is, thus, 
necessary in order to adequately assess the binding properties and the ability to mediate effector 
functions of their IgG ligands. The first steps towards definition of all such functional activities 
and properties in rhesus macaques would, therefore, be the creation of their genetically 
engineered IgG subclasses. 
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1.6. Study objectives and specific aims 
Taken together, rhesus macaques are used widely in immune-related research and vaccine 
studies, yet their immune system components and mechanisms are largely uncharacterized. 
Although extensively similar as compared to humans, IgGs and corresponding FcγRs in this 
species possess several key structural and functional differences that must be considered when 
interpreting experimental data and evaluating therapeutic strategies. To validate and improve the 
use of a rhesus macaque model for human diseases, comprehensive characterization of the 
elements responsible for the humoral immune responses and the mechanisms for elimination of 
invading pathogens is imperative. Previous work in our laboratory has successfully identified the 
IgG CH region genes in rhesus macaques. The presence of several allelic forms of IgG CH genes 
(and some other IgSF members identified to date) might result in production of Ab molecules 
exhibiting different functional properties. However, the effector functions and clearance 
mechanisms associated with rhesus macaque IgG CH regions are presently undefined. 
Information on IgG responses, including the preferential usage of certain IgG subclasses during 
various immune responses to pathogens or vaccination, is also currently unavailable. In addition, 
the structure-function relationship of molecules encoded by recently identified IgG CH region 
genes are uncharacterized.  
These gaps of knowledge are mainly due to lack of specific reference reagents (Abs) 
capable of specifically recognizing and unequivocally differentiating rhesus macaque IgG 
subclass molecules. Such Abs represent a valuable tool to further characterize IgG immune 
responses and vaccine efficacy in this species. Also, although rhesus macaque CD16 genes have 
recently been described, other important FcγR classes, including CD64 and CD32, have not been 
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defined. The needs for complete characterization of various IgG and FcγR genes and for 
generation of their recombinant molecules are, therefore, widely recognized. 
The present study was designed to fill some of these gaps. Specifically, the goal of this 
study is to define and further characterize the two major components of the humoral immune 
system, IgG and FcγR molecules, in rhesus macaques, focusing on the following aims: 
 
1. To generate recombinant Abs for each of the four rhesus macaque IgG1, IgG2, IgG3, 
and IgG4 subclasses – to be utilized for defining IgG functional properties and 
immune response patterns in this species as well as for generation of reference Abs. 
2. To identify and characterize FcγR genes and protein products existing within rhesus 
macaques, including identifying CD64 and CD32 genes, defining intraspecies 
variations of CD64, CD32, and CD16 genes, as well as determining their genetic 
polymorphisms and similarity with their human counterpart. 
3. To generation of recombinant cDNA cloning and expression vectors for rhesus 
macaques CD64 and CD32 – to be utilized for expression of protein products for 
studying IgG/FcγR interactions and functional activities. 
 
 Accomplishment of these specific aims will add into the long-term goals of providing a 
well-defined rhesus macaque model for understanding IgG-mediated protective and pathogenetic 
mechanisms, as well as for evaluating efficacy of novel immune intervention strategies. 
Apart from the findings about IgGs and FcγRs in rhesus macaques, we also reported in 
this study our data demonstrating that the main female hormone substance, 17β-estradiol, is 
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capable of restoring Ab responses to an influenza vaccine in a postmenopausal mouse model. 
These findings suggest that immunogenicity and efficacy of influenza vaccines should be 
evaluated in postmenopausal women, which belong to an age group that is highly susceptible to 
influenza infection and its most serious complications.
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CHAPTER 2                                                                                                             
ENGINEERING OF CHIMERIC MOUSE-RHESUS MACAQUE                                  
IGG1, IGG2, IGG3, AND IGG4 SUBCLASS RECOMBINANT ANTIBODIES 
RECOGNIZING THE HAPTEN 5-IODO-4-HYDROXY-3-NITROPHENACETYL 
 
2.1. Summary 
Four IgG subclass homologues, corresponding to the four human IgG subclass genes, 
were discovered and characterized in rhesus macaques, an important non-human primate 
research model for human diseases. The functional properties that distinguish these IgG 
subclasses, however, is largely unexplored. The obvious reason for such unavailability of 
information is lack of specific reagents. To fill this gap, we engineered all four chimeric mouse-
rhesus macaque IgG1, IgG2, IgG3, and IgG4 subclass recombinant antibodies (Ab) specifically 
recognizing the hapten 5-iodo-4-hydroxy-3-nitrophenacetyl (NIP), an established specificity 
system for studying IgG effector functional properties. We first created recombinant IgG heavy 
chain (IgH) cDNA gene fragments encoding each rhesus macaque IgG class using sequence 
overlap extension (SOE)-PCRs, where murine VH anti-NIP and Chinese rhesus macaque CH 
region genes were PCR-amplified and joined together as single fragments. The resultant 
fragments were then cloned into specialized expression vectors. The IgH expression vectors were 
subsequently transfected into the murine IgH-loss-variant myeloma cell line, J558L, which 
synthesizes and secrets an IgL λ but does not produce murine intact Ig molecules. G418-selected 
cells were tested for IgG production and binding by ELISA with NIP coupled to BSA-coated 
microtiter plates and goat anti-monkey purified IgGs. Horseradish peroxidase (HRP)-conjugated 
anti-mouse IgL λ or HRP-conjugated goat anti-monkey IgG-specific was used as the detection 
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Ab. We successfully produced recombinant rhesus macaque IgG chimeras of the four subclasses, 
which would represent both the foundations and the tools for further studies on IgG effector 
functions and Ab structure-function relationship in the rhesus macaque model. 
 
2.2. Materials and Methods 
Fig. 2.1. represents the steps involved in the construction, production, and detection of 
the NIP-rhIGHG chimeras/chimeric molecules using recombinant DNA technology, which 
include the following precedures.  
 
2.2.1. Construction of NIP-specific murine VH–rhesus macaque IgG CH (rhIGHG) cDNA 
hybrids (NIP-rhIGHG): DNA sources, SOE-PCR, and primer design 
NIP-rhIGHG cDNA hybrids, including NIP-rhIGHG1, NIP-rhIGHG2, NIP-rhIGHG3, 
and NIP-rhIGHG4 IgG subclass gene cassettes, were constructed by sequential sequence overlap 
extension PCRs (SOE-PCRs). Firstly, separate PCRs were used to amplify cDNAs encoding 
NIP-specific mouse variable heavy (VH) and rhesus macaque (rh) constant heavy (CH) IgG gene 
segments (exons) of each of the four subclasses (referred to as rhIGHG1, rhIGHG2, rhIGHGH3, 
and rhIGHG4, according to the IMGT nomenclature). cDNA encoding VH, which has 
specificity for 4-hydroxy-3-iodo-5-nitrophenylacetic acid (NIP; a hapten that can be used for 
studying specific effector immune responses), was cloned from pLNOH2 “RNA-Chinese” vector 
(see below), which was available in our laboratory plasmid repository (Rogers et al., 2008), 
using primer set FVH5FW and FVH3G4R (Table 2.1). The resultant VH PCR product contains a 
BsmI restriction endonuclease (RE) recognition site at the 5’ end, and a 42-bp sequence at the 3’ 
end that is homologous to the 5’ end of rhCH1 IgG gene segment.
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Fig. 2.1. Flowchart representation summarizing the major steps involved in construction, 
production, and detection of NIP-rhIGHG chimeras using recombinant DNA technology (genetic 
engineering). Individual DNA gene fragments were first isolated and amplified from the rhesus 
macaque Ab-producing cells by PCR/RT-PCR using primers that were designed based on known 
conserved regions of the publicly available rhesus macaque and corresponding human IgG 
sequences. These fragments were then used as DNA templates in SOE-PCRs to generate in in 
vitro the complete cDNAs, which contain a mouse VH in combination with rhesus macaque CH 
sequences. The resulting chimeric cDNA gene constructs were cloned into pCR2.1 TOPO TA 
cloning vector containing a selectable marker sequence. Selection for transformed clones that 
picked up the constructs and replicated in competent bacterium cells was made by culturing the 
cells in medium containing X-gals and ampicillin. The constructs were then amplified from the 
cloning vector by PCR using the primers that incorporated appropriate restriction sites which 
were used to transfer the desired constructs into an expression vector, where it fit exactly 
between the two defined restriction sites. To make a large quantity of the constructs, the resulting 
recombinant expression vector was transformed back into competent bacterium cells so that they 
were multiplicated by these cells following their division and replication. An appropriate amount 
of recombinant DNAs were then transfected into the appropriate recipient cell lines (murine 
myeloma J558L cells), where the cellular machinery directed the cells to synthesize, assemble, 
and secret protein products. Stable transfectants synthesizing the genes of interest are 
subsequently identified. The resulting chimeric IgGs now contained NIP-specific V domains 
derived from mice that was fused to rhesus macaque C domains. The secreted recombinant IgGs 
were detected from supernatants of cell cultures by ELISAs. Mammalian cell lines (not bacteria 
or yeast) must be used as the four chains of the molecules have to assemble correctly, as well as 
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the glycosylation and the large number of disulfide bonds have to be made correctly. Some 
figure pieces are reproduced from the internet.
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Next, cDNAs encoding each of IGHG gene segments, rhCH1, rhCH2, and rhCH3, of 
each of the four subclass molecules of rhesus macaques were isolated and PCR-amplified from 
the appropriate plasmid vectors that contain IGHG genes identified in the genomic DNAs 
isolated from a Chinese rhesus macaque [available in our laboratory plasmid repository 
(Scinicariello et al., 2004)]. The primer sets used in these PCRs were designed so that short 
homologous or complementary nucleotide sequences were introduced at the joint of any two 
adjacent gene segments (Fig. 2.2). For example, for IgG2 molecule, the resultant rhCH1 PCR 
product contains a 30-bp sequence on the 3’ end that is homologous to the 5’ end of the resultant 
rhCH2 PCR product. Similarly, the resultant rhCH2 PCR product has a 43-bp and 30-bp 
sequence on the 5’ end that is homologous to the 3’ end of the resultant rhCH3 PCR product in 
IgG2 and IgG3 molecules, respectively (Table 2.1). The resultant rhCH3 PCR product further 
contains a BamHI or a XhoI RE recognition site at the 3’ end. 
Unlike in humans where IgG3 has three hinge segments due to sequence repetition (Roux 
et al., 1997), one hinge segment is identified in this IgG subclass of rhesus macaques 
(Scinicariello et al., 2004). To ascertain this feature in generation of rhesus macaque IgG3, a 
primer pair specific for the hinge, namely G3CHF (forward direction) and G3CHR (reverse 
direction), was designed. These IgG3 hinge primers, G3CHF and G3CHR, shares a 33-bp and 
36-bp identical sequence with the forward primer for the IgG3 gene segment rhCH2 (i.e. G3C2F) 
and the reverse primer for the IgG3 gene segment rhCH1 (i.e. G3C1R), respectively (Table 2.1). 
For other IgG subclasses, primer sets specific for the hinge were embedded in the reverse primer 
for the rhCH1 gene segment and the forward primer for the rhCH2 gene segment. 
All primers were designed to flank known conserved regions of human and NHP IgG 
gene sequences, and were subsequently optimized (such as increasing the length of overlaps in
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Fig. 2.2. Schematic representation illustrating the separate exons that encode for individual 
heavy-chain constant domains of an Ig molecule, as well as diagrammatic representation 
depicting organization of a complete IgG3 heavy chain gene fragment with name and location of 
a pair of primers at the CH2-CH3 boundary, shown as an example for overlap primer sequences. 
(A) Separate exons encoding individual heavy-chain constant domains of an Ig protein molecule 
(not drawn to scale). Shown is the organization of IgG3 H chain genes with CH1, hinge (Hg), 
CH2, and CH3 exons, represented in the 5’ to 3’ orientation. Purple and red boxes indicate exons 
and straight black lines indicate introns. Lightly purple shaded areas indicate the correspondence 
between the DNA segments and the different domains of the Ig polypeptide chain that they 
encode. The intron-exon organization of the IGHG genes was inferred from the human and 
rhesus macaque sequences publicly available. (B) Organization of a complete IgG3 heavy chain 
gene fragment and name and location of a pair of primers at the CH2-CH3 boundary, shown as 
an example for overlap primer sequences. The Ig intron-exon genetic segmental organization 
facilitates the design of primers for amplification of mRNA without interfering the DNA. 
Primers should flank the spliced regions where two exons are fused and contain the homologous 
annealing sequences that are seen in mRNA but not in the DNA. Individual IgG exons encoding 
corresponding CH domains is demonstrated by enlarged boxes. The necessary splice sites found 
at intron boundaries and the sequences of the introns  were removed. Name and relative location 
(indicated by vertical bars) of primers used to amplify the appropriate fragments are illustrated. 
The red arrow indicates the direction of the forward primer and the green arrows indicates that of 
the reverse primer. The primer sequences shown in the dot-line box are the overlap sequence of 
these two middle (internal) primers. Alignment of these primer sequences were performed using 
BioEdit sofware. Code: rc, reverse complementary.
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internal primers to reduce the background of non-specific products) following analysis of PCR 
and sequencing reactions. All primers were synthesized by Sigma–Aldrich Co. (St. Louis, MO). 
All primers have specificity to the corresponding 5’ and 3’ ends of all rhesus macaque domain 
coding regions and, as indicated above, were incorporated with RE recognition sites located 
outside V and C gene coding regions to allow subsequent cloning (see below). To all primers, 
ambiguous bases were introduced to make them compatible with the primer sets previously 
published. The final sequences of the primers are shown in Table 2.1. 
 
2.2.2. Construction of the NIP-rhIGHG cDNA hybrids: Optimization of SOE-PCRs and 
amplification strategies 
cDNA encoding the heavy chain rhCH fragment of each of the four rhesus macaque IgG 
subclasses was PCR-annealed together by SOE-PCRs using the resultant rhCH1, rhCH2, and 
rhCH3 cDNA gene segments as DNA templates, and by different strategies that were optimized 
and dependent upon each subclass (Fig. 2.3). By separate SOE-PCRs using appropriate primer 
pairs on the four gene segment PCR products, VH, rhCH1, rhCH2, and rhCH3, as DNA 
templates, immediate ligation fragments, including [VH+rhCH1], [rhCH1+rhCH2], and 
[rhCD2+rhCH3], were generated. These immediate fragments, together with the rhCH1, rhCH2, 
and rhCH3 segments, were subsequently used as DNA templates in additional SOE-PCRs to 
create rhIGHG fragments ([rhCH1+rhCH2+rhCH3]) using primers 3FCG4F and FCG4R. The 
final whole chimeric IgG fusion fragments, [VH+rhCH1+rhCH2+rhCH3] (NIP-rhIGHG), were 
constructed by annealing the VH gene segment with the rhIGHG fragment – or the [VH+rhCH1] 
fragment with the [rhCH2+rhCH3] fragment – by SOE-PCRs using primers FVH5FW and 
FCG4R. The size in base pairs (bp) of the whole chimeric recombinant constructs NIP-rhIGHG1,
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Table 2.1. Primers used for generation of rhesus macaque IgG gene fragments and recombinant constructs by PCR and SOE-PCR 
amplifications. 
Primer 
namea 
Sequence (5’-3’ direction)b 
Specificity 
(region of genes; species)c 
Sequence 
characteristics 
FVH5FW GGTGTGCATTCCCAGGTCCAATTGCAGCAGCCT 5’; murine anti-NIP VH 
Containing BsmI site (5’-TGCATTC-3’) 
Contained in full (33-bp sequence) in IgNotI 
FCG4R AGTGGATCCATTACTAGTAGCAGGTGCCGTCCACCTCCGCCATGATCTGCGTGTAGTGGTTGTGCAGA 3’; rhesus macaque IgG CH3 
Containing BamHI site (5’-GGATCC-3’) 
22-bp homologous to IGC2 
Contained in part (65-bp sequence) in IgXhoI 
IGC2 TCTGCGTGTAGTGGTTGTGCAG 3’; rhesus macaque IgG CH3 
22-bp homologous to FCG4R 
Contained in full (22-bp) in IgXhoI 
FVH3G4R GACCGATGGGCCCTTGGTGGAGGCTGAAGAGACTGTGAGAGTGG 3’; murine anti-NIP VH 
42-bp homologous to 3FCG4F 
21-bp homologous to IGF 
3FCG4F ACTCTCACAGTCTCTTCAGCCTCCACCAAGGGCCCATCGGTC 5’; rhesus macaque IgG CH1 
42-bp homologous to FVH3G4R 
21-bp homologous to IGF 
IGF TCCTCAGCCTCCACCAAGGGCCCA 5’; rhesus macaque IgG CH1 
21-bp homologous to FVH3G4R 
21-bp homologous to 3FCG4F 
IgG1R GACGGTCCCCCCAGGAG 3’; rhesus macaque IgG1 CH1 14-bp homologous to G2C1RN 
G2C1RN GATGGTCCCCCCAGGAGTTCAGCTGGGCACGGTGGGCACGTGGAACGACATGGGAGCCCAACTGTCTTGTCCACCTTGG 3’; rhesus macaque IgG2 CH1 
79-bp homologous to G2C2FN 
14-bp homologous to IgG1R 
G2C2FN CCAAGGTGGACAAGACAGTTGGGCTCCCATGTCGTTCCACGTGCCCACCGTGCCCAGCTGAACTCCTGGGGGGACCATC 5’; rhesus macaque IgG2 CH2 79-bp homologous to G2C1RN 
G2C2R CACCTGTGGCTCTCGGGGCTGCCCTTTGGTTTTGGAGACAGTTTTCT 3’; rhesus macaque IgG2 CH2 43-bp homologous to G2C3F 
G2C3F AACTGTCTCCAAAACCAAAGGGCAGCCCCGAGAGCCACAGGTG 5’; rhesus macaque IgG2 CH3 43-bp homologous to G2C2R 
G3C1R ATGGGGGTGTGAACTCAACTCTCTTGTCCACCTTGG 3’; rhesus macaque IgG3 CH1 
36-bp homologous to G3CHR 
15-bp homologous to G3CHF 
G3CHR CTGGGCATGGTGGGCATGGGGGAGTTGTGTCACCACATGGGGGTGTGAACTCAACTCTCTTGTCCACCTTGG 3’; rhesus macaque IgG3 hinge 
36-bp homologous to G3C1R 
51-bp homologous to G3CHF 
12-bp homologous to G3C2F 
G3CHF AGTTCACACCCCCATGTGGTGACACAACTCCCCCATGCCCACCATGCCCAGCACCTGAACTCCTGGGGGGAC 5’; rhesus macaque IgG3 hinge 
33-bp homologous to G3C2F 
51-bp homologous to G3CHF 
15-bp homologous to G3C1R 
G3C2F CACCATGCCCAGCACCTGAACTCCTGGGGGGAC 5’; rhesus macaque IgG3 CH2 
33-bp homologous to G3CHF 
12-bp homologous to G3CHR 
G3C2R GCTCTCGGGGCTGCCCTTTGGCTTTGGAGATGGTTT 3’; rhesus macaque IgG3 CH2 30-bp homologous to G3C3F 
G3C3F TCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCGCAGG 5’; rhesus macaque IgG3 CH3 30-bp homologous to G3C2R 
IG4CR1 ATGCTGGGCATGGGGGTGTGAACTCAACTCTCTTGT 3’; rhesus macaque IgG4 CH1 12-bp homologous to IG4CF2 
IG4CF2 CATGCCCAGCATGCCCAGCACCTGAACTCCTGG 5’; rhesus macaque IgG4 CH2 12-bp homologous to IG4CR1 
IG4R2 GCTCTCGGGGCTGCCCTTTGGCTTTGGAGATGG 3’; rhesus macaque IgG4 CH2 33-bp homologous to IG4F3 
IG4F3 CCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGC 5’; rhesus macaque IgG4 CH3 33-bp homologous to IG4R2 
IgNotI ATTAGCGGCCGCATAATGGGTGACAATGACATCCACTTTGCCTTTCTCTCCACAGGTGTGCATTCCCAGGTCCAATTGCAGCAGCCT 5’; murine anti-NIP VHb 
Containing NotI site (5’-GCGGCCGC-3’) 
Containing full 33-bp sequence of FVH5FW 
IgXhoI ACTCACTCGAGGGATCCATTACTAGTAGCAGGTGCCGTCCACCTCCGCCATGATCTGCGTGTAGTGGTTGTGCAGA 3’; rhesus macaque IgG CH3c 
Containing XhoI site (5’-CTCGAG-3’) 
Containing partial 65-bp sequence of FCG4R 
Containing full 22-bp sequence of IGC2 
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a
Ending with or before the last single digit/letter with -FW or -F, or ending with NotI, forward direction; ending with –R or XhoI, 
reverse direction; IgC2, reverse direction. 
b
Bold and underline, restriction endonuclease sequences; bold and italic, with or without underline, overlapping (“homologous”) 
region (with underline, identical; without underline, complementary in reverse direction) with the relevant primer(s) indicated in 
“Sequence characteristics” column. 
c
For non-flanking (“internal”) primers, the 5’ or the 3’ end represents that at the 5’or 3’ intron-exon junction, respectively.
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NIP-rhIGHG2, NIP-rhIGHG3, and NIP-rhIGHG4 are 1,390, 1,369, 1,423, and 1,366, 
respectively. These constructs encode four corresponding rhesus macaque IgH subclasses. As 
mentioned above, the final fragment contains two unique BsmI (or NotI) and BamHI (or XhoI) 
RE sites whose sequences were embedded in the two far end flanking primers (i.e. the outermost 
5’ and 3’ primers) and were introduced into the constructs by PCRs. 
SOE-PCRs were carried out by Expand High Fidelity polymerase (Roche Diagnostics 
North America, Indianapolis, IN) or Ex Taq DNA polymerase (Clontech Laboratories Inc., 
Mountain View, CA) in a total of 50 or 100 μl final reaction volume containing 10-200 ng 
plasmid DNA, 10-50 pmol (each) primers, 200-250 µM (each) dNTPs, 1.5-2.5 mM MgCl2, and 
2-2.5 U of DNA Taq polymerase. DNA concentration of samples was calculated using the 
formula C (pmol/μL) = (75 x A260 x d)/(bp x l), in which A260 is the absorbance at 260 nm, d is 
the dilution factor, bp is the length of DNA in basepair, and l is cuvette width in cm. PCR 
conditions were as follows: after initial denaturation at 95°C for 5-10 min to melt strands into 
single strands, cDNAs were amplified for 25-40 cycles, with each cycle consisting of 94°C for 
30 sec-1 min to melt strands, 56°C for 30 sec-1 min to anneal primers, and 72°C for 30 sec-2 min 
and 30 sec to extend strands. To ensure complete extension, a final step at 72°C for 5-10 min 
was applied. The negative controls consisted of the reaction mixture with no template DNAs. 
Adjustment of PCR conditions and parameters, including optimization of time in each 
step and of the annealing temperature (from 52-60
0
C, with 0.5
0
C or 1
0
C increment, to promote 
annealing), as well as additional cloning steps in pCR2.1-TOPO TA vector (see below for 
procedures) for some of the gene segments and fragments, were needed to minimize non-specific 
products and to improve the success of SOE-PCR ligation and amplification. The concentrations 
of the two primers in each primer pair were close to each other and ranged from 20-200 nM per 
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reaction (in each reaction, specific primers were used dependent on which PCR was being 
performed, as described above). To allow for better annealing and extension of overlaps in some 
reactions – such as those for generation of IgG3, which were with additional hinge primers – 
PCRs that used equimolar concentrations of DNA fragments were run without primers and low 
annealing temperature during early cycles (i.e. the first 5-10 cycles), followed by a higher 
annealing temperature with fresh PCR mixtures in the remaining 20-30 cycles. Whenever 
possible, fragments and sub-fragments (intermediate fragments) were put into cloning plasmid 
vectors to serve as a source of DNA templates. Flanking primers were sometimes added after 
two to three cycles to reduce competition for the available reagents in the reactions. To 
determine the optimal SOE-PCR reaction conditions and parameters, varying magnesium 
concentrations were also applied in a series of SOE-PCR reactions. The molar ratios of the two 
DNA segment or fragment templates used in annealing SOE-PCRs were generally equal (1:1, 
with total DNA amount was at least 0.7 μg/50 ml PCR); but in some cases, variable ratios such 
as 1:2, 1:3, or 1:5, dependent upon their sizes, were applied in order for the desired fragments to 
be better annealed. 
 
2.2.3. Cloning and sequence analysis of the NIP-rhIGHG cDNA constructs 
To assess the fidelity of PCR reactions and to improve the purity of the fused fragments 
(i.e. to minimize the appearance of non-specific side products), SOE-PCR products were cloned 
into pCR2.1-TOPO cloning vector (Fig. 2.4). As described above, the resultant cDNA hybrids 
were introduced at the 5’ end of V coding gene and the 3’ end of C coding gene region with 
BsmI and BamHI (B-B) restriction sites, respectively, in one subset of the molecules, or with 
NotI and XhoI (N-X) restriction sites, respectively, in another subset. These restriction sites were 
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intentionally incorporated (embedded) in the appropriate primers and were unique, as they were 
not present in any of the examined IgH cDNA genes. These sites will allow for cloning of the 
cDNA into specialized expression vectors (see below). After SOE-PCR annealing and 
amplification, an appropriate volume of SOE-PCR reactions containing the final chimeric IgG 
fusion genes were subjected to electrophoresis on a 1-2% agarose gel (dependent upon the 
fragment sizes) diluted in TBE buffer (Sigma–Aldrich Co., St. Louis, MO) and containing 0.1-
0.2 mg/ml ethidium bromide (Sigma–Aldrich Co., St. Louis, MO). The DNAs were subsequently 
visualized using an ultraviolet transilluminator, and the bands of interest (showing expected size) 
were individually excised and purified using QIAquick Gel Extraction kit (Qiagen Inc., 
Valencia, CA) using a microcentrifuge. Purified NIP-rhIGHG PCR products were then cloned 
within EcoRI sites into pCR 2.1-TOPO TA cloning vector (Invitrogen, Carlsbad, CA), which 
contains an ampicillin resistance gene. For optimal incorporation, different molar ratios 
(vector:insert) were applied, including 1:1, 1:3, 1:5, 1:10, 2:1, 3:1, and 5:1 (higher ratios were for 
difficult cloning). The amount of vector to start with ranged between 10-20 ng and was 
calculated as [(ng vector x kb insert)/kb vector] x (moles insert/moles vector) = ng insert 
(http://www.promega.com/biomath/Default.htm). Resultant plasmids were subsequently 
transformed into Top10 Escherichia coli (E. coli) chemically competent cells using One Shot 
Chemical Transformation kit (Invitrogen, Carlsbad, CA), following the manufacturer's protocols. 
The competent cells were then spread onto LB agar plates containing 50 μg/ml of ampicillin and 
1 μg of X-Gal for screening for suitable colonies. Insert-positive clones were then picked and 
further cultured (expanded) by incubation overnight in LB culture tubes containing 50 μg/ml of 
ampicillin at 37°C in a shaking rotary incubator (200-230 rpm).
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Fig. 2.3. Flowchart diagrams outlining different experimental strategies for generation of 
recombinant NIP-rhIGHG cDNA constructs by SOE-PCRs (not drawn to scale). (A) PCR 
amplification of individual mouse VH (represented as the yellow-line, enlarged box) and rhesus 
macaque IgG CH (represented as red-line, enlarged boxes) fragments  (i.e. CH1, CH2, and CH3) 
encoding corresponding domains of recombinant IgGs to be generated. These fragments are 
represented in the 5’ to 3’ orientation. cDNAs coding for these VH and CH domains were 
amplified from the appropriate plasmid vectors (shown are not the real names of the plasmids), 
retrieved from our plasmid repository. The direction of the primers used to amplify these 
fragments are illustrated as short black horizontal arrows (shown are not the real names of the 
primers). Straight short black lines represent flanking sequences. (B) A representative strategy of 
SOE-PCR joining (see Fig. 1.8 for the principle) of DNA fragments. The fragments were jointed 
by SOE-PCRs using the appropriate primer sets, as indicated. Arrows indicate the direction of 
the primers used to amplify the fragments. (C) An alternative strategy. (D) Additional strategies. 
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Fig. 2.4. Ligation of PCR products into pCR2.1 TOPO TA cloning vector. (A) These fragments 
are used as an example to show the procedure of TOPO cloning for ligation of PCR products (as 
to assess the fidelity of PCRs). The recognition sites for a number of restriction endonucleases 
(the unique multiple cloning site, which is used to clone in DNA fragments of interest) are 
embedded within the lacZ coding sequence. Because the lacZ peptide will be functionally 
disrupted or inactivated by the presence of the DNA insert, the lacZ coding gene sequence is 
used as a selectable marker. (B) Schematic representation of ligation of PCR product ligates into 
TOPO vector in the presence of  Topoisomerase (hence the name of the vector). Some figure 
pieces are reproduced from the internet.
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NIP-rhIGHG insertion, proper orientation, and accuracy of sequences were confirmed by 
RE digestion and DNA sequencing (Fig. 2.5). Briefly, the minipreps DNA Purification System 
kit (Promega Corporation, Madison, WI) was used to purify plasmid DNAs extracted from 
grown clones in LB medium, and the obtained plasmid DNAs were digested with EcoRI (New 
England Biolabs, Beverly, MA). EcoRI-digested plasmids were then electrophoresed on a 1% 
agarose gel to verify the presence of the desired insert based on the size of the inserted 
fragments. Bands containing NIP-rhIGHG constructs with the correct size were extracted using a 
QIAquick gel extraction kit (Qiagen Inc., Valencia, CA) and the recombinant plasmids were 
sequenced to confirm cloning correctness. All DNA sequences were determined using the ABI 
Prism Dye Termination Cycle Sequencing kit and on an ABI model 3100 automated sequencing 
apparatus (PerkinElmer, Wellesley, MA). Sequencing primers were those used for PCR 
amplifications and the forward and reverse M13 primers. 
Further sequencing analysis was also applied to sequences of the resultant constructs. 
MacVector software (Accelrys Inc., San Diego, CA) and the free BioEdit program 
(http://www.mbio.ncsu.edu/bioedit/bioedit.html) were used to identify overlapping regions and 
to edit sequences. Sequences were aligned using the CLUSTAL function of the MEGALIGN, 
part of the LASERGENE software package (DNASTAR Inc., Madison, WI). The prediction of 
potential N-glcosylation sites was conducted by analyzing the full length sequence of the 
obtained molecules using the online tool NetNGlyc 1.0 Server 
(http://www.cbs.dtu.dk/services/NetNGlyc/), which is based on identifying Asn-Xaa-Ser/Thr 
consensus sequences (Julenius et al., 2005). Drawing plasmids was performed using the free 
Plasm plasmid drawing software (http://biofreesoftware.com/plasm). Standardized nomenclature, 
labels, and numbering of IMGT®, the international ImMunoGeneTics information system® 
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(http://www.imgt.org or http://imgt.cines.fr) (Lefranc et al., 2009) were used to identify IgSF 
gene segments, as well as to display and discuss sequencing data based on human reference 
sequences. Two-dimensional representation, or IMGT Colliers de Perles on one layer was 
obtained with the IMGT Collier-de-Perles tool in the IMGT/DomainGapAlign 
(http://www.imgt.org/3Dstructure-DB/cgi/Collier-de-Perles.cgi) (Ehrenmann et al., 2010). 
Allelic polymorphisms and characteristic positions of the C-like domains were described using 
the IMGT unique numbering for C domain [C-DOMAIN of IG and T cell receptors (TR)] 
(Lefranc et al., 2005). 
 
2.2.4. pLNOH2 and P2561/2/3 expression vector systems and the murine IgH-defective 
myeloma J558L cell line 
For expression vectors, we used the pLNOH2 (or pLNOH2γ3) (Norderhaug et al., 1997) 
plasmid vector (kindly provided by Drs. Lars Norderhaug and Inger Sandlie, University of Oslo 
and Ab Design AS, Nesoddtangen, Norway) (Fig. 2.6). This vector is derived from the 
expression vector pcDNA3 (Invitrogen, Carlsbad, CA) and contains essential elements for 
transcription and translational regulation. Specifically, it consists of a CMV promoter (P) 
situated at the 5’ end of a gene cassette containing an Ig leader (L) (signal peptide) region 
sequence of murine Ig genes (to permit secretion of the fusion protein), a murine VH gene 
encoding an Igλ domain with specificity for the hapten NIP inserted between RE sites BsmI and 
BsiWI, followed by an intron. The intron comprises splice acceptor (GU) and splice donor (AG) 
signals for correct processing of mRNA. The vector also harbors a gene restriction cassette, 
located downstream of the murine V gene and inserted between RE sites HindIII and BamHI, 
encoding the CH fragment of human IgG3 sequence (IGHG3), followed by a strong 
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polyadenylation signal and transcription termination sequence in the 3’ end (pA). These C and V 
region genes together encode complete IgG H chains. The vector further contains unique 
restriction sites for easy subcloning of V and C region genes as cassettes, and can be used to 
express an anti-NIP VH gene segment in combination with any CH region genes of different IgG 
subclasses exchanged as HindIII-BamHI fragments (Norderhaug et al., 1997). For selection and 
stable expression of transformant cells, the vector also carries a neomycin resistance gene, which 
is under the control of CMV promoter. The vector also possesses an ampicillin resistance marker 
gene (Amp) (for selection in E. coli), f1 origin of replication (f1), and SV40 origin of replication 
(to allow for transient expression). The use of the vector allows both transient and stable 
expression in mammalian cells. 
To improve stability of expression vectors in transfected cells, we also used a modified 
version of the vector pLSXN (BD Biosciences, San Jose, CA), which contains long terminal 
repeats (LTR) that allow for the gene of interest to integrate into the host cell chromosomes for 
stable expression (Fig. 2.8). Constitutive transcription of cloned genes inserted into this plasmid 
vector is driven by CMV promoter. Promoter and enhancer sequences controlling expression of 
the gene of interest in the multiple cloning site are also inserted in the 5’ viral LTR of this vector. 
pLSXN also contains a neomycin resistance gene, controlled by SV40 early promoter (PSV40e), 
that allows antibiotic transfectant selection in eukaryotic cells. Additionally, pLXSN consists of 
Col E1 origin of replication and E. coli Amp resistance gene for propagation and antibiotic 
selection in bacteria. We amplified by PCR using primers that incorporated desirable RE sites a 
portion of the pcDNA3.1 constructs that contains cDNA of NHP FcγIIIRa (or another gene of 
interest), a CMV promoter, L signal peptide, a bovine growth hormone polyadenylation signal, 
and an f1 origin. This PCR portion was then sequentially transferred to the multiple cloning site 
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Fig. 2.5. Schematic representation of the PCR- and SOE-PCR-amplified IGHG fragments that 
make up of the four recombinant NIP-rhIGHG  (Igγ) cDNA constructs. CH1, the hinge (for 
Igγ3), CH2, and CH3 amplified fragments of each Igγ cDNA construct, as well as the VH 
amplified fragment to be connected to all of these constructs, are shown. Each amplified 
fragment is represented as an enlarged box, as indicated. The VH fragment, which was derived 
from murine myeloma and specific to NIP (5-iodo-4-hydroxy-3-nitrophenyl acetyl), was joined 
by SOE-PCRs to a complete rhesus macaque IgH fragment, which were constructed also by 
SOE-PCRs. Name and relative location (indicated by vertical black bars) of primers used to 
amplify different fragments in these SOE-PCRs are depicted. The final recombinant constructs 
were amplified in SOE-PCRs using the primers flanking the VH 5’ end (FVH5FW) and the CH3 
3’ end (FCG4R, or IGC2 in the case of NIP-rhIGHG4), as indicated. Each primer was designed 
to flank the appropriate gene fragments; the sequences of the primers used are given in Table 2.1. 
The trans-membrane exons at the 3’ end of the mRNA of the Igγ chains are not depicted. The 
Igγ3 hinge is not drawn to scale. Illustrated below the scheme is a bar representing relative 
length distance scale (in bp) in the 5’ to 3’ orientation for the fragments. The intron-exon 
organization of the IGHG genes was inferred from the human and rhesus macaque sequences 
publicly available. The necessary splice sites found at intron boundaries and the sequences of the 
introns  were removed.
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Fig. 2.6. Schematic representation of the structure of a representative recombinant NIP-rhIGHG 
cDNA construct (shown is the NIP-rhIGH3 cDNA construct) and simplification of the 
architecture of the expression plasmid vector pLNOH2, highlighting regions of functional 
significance and relevant features (not drawn to scale). (A) Schematic representation of structure 
of recombinant NIP-rhIGHG3 cDNA construct. A mouse VH fragment with NIP specificity that 
contained a BsmI restriction site at the 5’ end was joined by SOE-PCRs to rhesus macaque Igγ3 
CH fragment constructed also by SOE-PCRs and contained a BamHI restriction site at the 3’ 
end. Only restriction sites at the ends of the constructs are depicted. The trans-membrane exons 
at the 3’ end of mRNA of IgH chains are not illustrated. The hybrid chain was subcloned into the 
expression plasmid vector pLNOH2 onto BsmI and BamHI sites. The hinge is not drawn to scale. 
(B) Simplification of the map of specialized pLNOH2 expression vector, highlighting regions of 
relevant features (not drawn to scale). This double-stranded closed-circular DNA molecule 
vector is derived from vector pcDNA3 (Invitrogen, Carlsbad, CA) (Norderhaug et al., 1997). 
Expression is driven by a cytomegalovirus promoter (CMV) and leader (L) (signal peptide) 
sequence (L permits secretion of the expressed protein). The vector contains, adjacent to L 
sequence, an anti-NIP murine VH gene cloned in BsmI and BsiWI restriction sites, followed by a 
human genomic Igγ3 CH gene cassette, which can be replaced by those of different subclasses of 
rhesus macaques onto the HindIII and BamHI sites, as indicated. CH1, CH2, and CH3 refer to 
the corresponding domains in Igγ3 CH genes. Polyadenylation signal (pA; recognition sequence 
for polyadenylation) of the vector is inserted downstream of the Igγ CH coding sequence to 
ensure proper and efficient processing of mRNA transcript in eukaryotic cells. The vector 
backbone also contains an f1 ori (f1) for single-stranded DNA production (plasmid origin of 
replication), as well as an SV40 promoter (SV40ori) for plasmid replication in mammalian cells. 
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Plasmid DNA replication occurs in one direction, as illustrated by the f1 ori arrow. Located 
downstream of SV40ori region in the vector is a gene cassette for neomycin resistance (Neo), 
which is controlled by SV40 promoter and allows for G418 antibiotic selection of stable 
expression by transfected eukaryotic cells. Structurally similar to gentamycin and generally toxic 
to eukaryotic and prokaryotic cells, the aminoglycoside antibiotic G418 is useful for selection of 
cells stably transfected with Neo gene (presence of insert DNA will disrupt functional activities 
and allow for selection). The pLNOH2 vector also comprises an ampicillin resistance gene 
(Amp) for propagation and antibiotic selection in bacteria (E. coli). The curve arrows on the 
genes illustrate the direction of transcription. VH gene is oriented so that its direction of 
transcription is opposite to that of the Amp gene. BsmI and BamHI sites, located downstream of 
CMV promoter/L sequence and Igγ CH cassette, respectively, are unique and can be used for 
directional insertion of constructs of interest as BsmI-BamHI restriction fragments. The BsmI-
BamHI restriction fragments of NIP-rhIGHG inserts are ~1.37 kb-1.42 kb in size, varying 
dependent on IgH subclasses. The vector sequence totals ~8.6kb in length and all sites illustrated 
are unique (occur only once in within the plasmid sequence). The orientation and sequence of 
DNA inserts in the recombinant plasmids were confirmed by RE digestions and/or nucleotide 
sequencing. This map was constructed using the plasmid drawing software Plasm 
(http://biofreesoftware.com/plasm) and based on information described in Brekke and 
Thommesen, 2003, and Norderhaug et al., 1997.
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of pLXSN (BD Biosciences, San Jose, CA) (Rogers et al., 2006), generating the P2561/2/3 
expression vectors. These recombinant plasmid vectors facilitate selection of transformants on 
culture media containing ampicillin, and enable stable integration into nuclear chromosomal 
cellular DNA. 
For production of intact recombinant IgGs, we employed a well-characterized and 
genetically stable mammalian host cell line, the BALB/c murine IgH-loss-variant myeloma (i.e. 
Ab-producing cells) J558L cells (Oi et al., 1983; kindly provided by Dr. Sherie L. Morrison, 
University of California, Los Angeles, Los Angeles, CA). Although being a murine 
plasmacytoma, these cells do not produce intact mouse Ig Abs as they express no endogenous 
IgH chain [due to a spontaneous loss of IgH chain from their parental myeloma cell line J558 
(Morrison, 1985)]. However, these cells continue to constitutively synthesize and secret an IgL 
λ1 chain specific for NIP (Oi et a., 1983), which can form complete Ig molecules with NIP 
affinity when combined with anti-NIP (i.e. containing anti-NIP VH) IgH chains. The cells can 
also recombine two transfected DNA molecules in an appropriate manner (in about 30% of cells 
that received and integrated intact copies of both DNA molecules) (Fell et al., 1989). Thus, once 
transfected with an IgH chain expression vector, such as that encoded in pLNOH2 plasmid, the 
cell machinery will synthesize and assemble IgL and IgH chains (chain-assembly), ultimately 
secreting endogenously intact Ig molecules. Additionally, murine IgH-chain defective myeloma 
cells are capable of producing greater amounts (and with higher protein concentration) of ectopic 
fusion protein compared to other cell lines, including CHO or HEK293 cells (Howard et al., 
2002). The cells were maintained in Iscove’s modified Dulbecco’s medium (IMDM) 
supplemented with 10% fetal bovine serum (FBS), penicillin G sodium 100 IU/ml, and 
streptomycin sulfate 100 μg/ml under standard conditions in 25-ml or 75-ml sterile filter screw-
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Fig. 2.7. Schematic representation of generation of recombinant expression plasmid vector 
pLNOH2-IgH (not drawn to scale). NIP-rhIGHG constructs were PCR-amplified from 
appropriate TOPO vectors using forward primer FVH5FW (containing BsmI restriction site in its 
5’ end) and reverse primer FCG4R (containing BamHI restriction site in its 5’ end), as indicated. 
The resultant PCR products were then ligated into pLNOH2 vector previously digested with both 
BsmI and BamHI REs. The recombinant constructs are therefore encoded within BsmI-BamHI 
sites of the resulting recombinant expression vector.
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Fig. 2.8. Simplification of the architecture of the expression plasmid vector P2561/2/3, 
highlighting regions of functional and relevant features (not drawn to scale). The vector contains 
a unique multiple cloning site for cDNA insertion and a variety of promoters, including strong 
retroviral promoters, to facilitate expression of inserted cDNA constructs. This double-stranded 
closed-circular DNA molecule vector was made up by ligating NIP-rhIGHG-containing HpaI-
SalI restriction fragment (~1.1 kb in size) of recombinant expression pcDNA3.1(+) vector into 
retroviral vector pLXSN to HpaI and XhoI restriction sites (~5.9 kb in size, after digestion). RE 
HpaI, which cuts between nucleotide location 163-164 or 1,477-1,478 in pcDNA3.1(+) or 
pLXSN vector, respectively, is a blunt-end ligation. RE SalI, which cuts between nucleotide 
location 1,272-1,273 in pcDNA3.1(+) vector, and RE XhoI, which cuts between nucleotide 
location 1,484-1,485 in pLXSN vector, have their overhangs matched (ligation would destroy 
these cut sites). Expression is driven by a cytomegalovirus promoter (CMV)/leader (L) sequence, 
which are derived from pcDNA3.1(+) vector (L signal peptide allows secretion of protein). In 
addition to recombinant NIP-rhIGHG constructs, the HpaI-SalI-digested restriction fragments 
that were cut out from the recombinant pcDNA3.1(+) vectors also comprise of the 
pcDNA3.1(+)-derived polyadenylation signal (pA; recognition sequence for polyadenylation), 
located downstream of Igγ CH coding sequence to direct proper and efficient processing of 
mRNA transcript in eukaryotic cells, as well as of f1 ori (f1; plasmid origin of replication),which 
is for single-stranded DNA replication. Plasmid DNA replication occurs in one direction, as 
illustrated by the f1 ori arrow. The P2561/2/3 vector maintains from pLXSN retroviral vector 
SV40 early promoter (SV40ori) for plasmid replication in mammalian cells, the gene cassette for 
neomycin resistance (Neo), located downstream of and controlled by SV40ori promoter, which 
allows for G418 antibiotic selection of stable expression by transfected eukaryotic cells, as well 
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as ampicillin resistance gene (Amp) for propagation and antibiotic selection in bacteria (E. coli). 
Therefore, only bacteria containing the vector are capable of growing in the presence of 
ampicillin, and cell clones selected by Neo resistance indicate those cells in which an 
endogenous gene was disrupted due to the proviral insertion. pLXSN vector also contains, in the 
5’ viral long terminal repeat (LTR) sequence, a viral promoter and enhancer sequences that 
direct expression of the genes of interest inserted in its multiple cloning site. Thus, P2561/2/3 
vector permits expression of DNA constructs inserted into the multiple cloning site, which is 
sandwiched between the 5′ and 3′ LTR sequences, under the controls of a variety of promoters 
(i.e. retroviral LTR, CMV, or SV40ori). The curve arrows on the genes illustrate the direction of 
transcription. VH gene is oriented so that its direction of transcription is opposite to that of Amp 
gene. As with expression vector pLNOH2 regarding BsmI and BamHI sites, NotI and XhoI sites 
in P2561/2/3 vector, which are located downstream of CMV promoter and Igγ CH cassette, 
respectively, are unique; these sites separate CMV promoter from Neo gene sequence and can be 
used for directional insertion of recombinant constructs of interest as NotI-XhoI restriction 
fragments (none of these constructs has NotI or XhoI site). NotI-XhoI restriction fragments of 
NIP-rhIGHG inserts are ~1.37 kb-1.42 kb in size, varying dependent on IgH subclasses. 
P2561/2/3 vector sequence totals ~8.4 kb (~7.0 kb if without insertion of a recombinant 
construct) in length and all sites indicated are unique (occur only once in within plasmid 
sequence). pLXSN vector (~5.9 kb in size), through its retroviral 5’ LTR and 3’ LTR sequences, 
between which the gene of interest are cloned, facilitates integration of the insert into 
chromosomes for stable expression and, therefore, making it easy for isolation and providing 
higher yield than if using expression vectors pLNOH2 or pcDNA3.1(+) alone (both of which 
have almost the same yield). The orientation and sequence of DNA inserts in recombinant 
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plasmids were confirmed by RE digestions and DNA sequencing. This map was constructed 
using the plasmid drawing software Plasm (http://biofreesoftware.com/plasm) and based on 
information described in Rogers et al., 2006, and on Clontech website 
(http://www.synthesisgene.com/vector/pLXSN.pdf). Some figure pieces are reproduced from the 
internet.
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caps flasks, and grown at 37°C with 5% CO2 atmosphere. 
 
2.2.5. Generation of expression vectors for NIP-rhIGHG chimeric constructs 
To construct NIP-rhIGHG IgH expression vectors, we excised and replaced VH and 
human IgG3 CH genes in pLNOH2γ3 plasmid with cDNA containing anti-NIP VH of 
pLNOH2γ3 fused to the entire Chinese rhesus macaque IGHGs (IgG CH) as a single fragment. 
pLNOH2 was sequentially digested with BsmI and BamHI or NotI and XhoI RE pair (New 
England BioLabs, Ipswich, MA) to remove murine VH and human IGHG3 genes from the parent 
vector (Fig. 2.7 and 2.9). A verified TOPO clone containing cDNA constructs encoding 
sequence of recombinant NIP-rhIGHG was similarly excised (i.e. under sequential digestion with 
the same two REs) to release the constructs. Resultant ~1.5-kb BsmI-BamHI-digested gene 
fragments obtained from TOPO clones were purified and subcloned into pLNOH2 to the unique 
BsmI and BamHI RE sites, downstream of CMV promoter and in proper orientation, to create 
constructs pLNOH2-rhIGHG1, pLNOH2-rhIGHG2, pLNOH2-rhIGHG3, and pLNOH2-
rhIGHG4. Only pLNOH2 plasmids with correct DNA sequences, which are the original anti-NIP 
VH fused with each of the four rhesus macaque IGHG subclasses, were used for transferring of 
expression vector and mammalian cell transfection. 
To improve the stability of expression vectors in transfected cells, the above mentioned 
P2561/2/3 expression vectors were used. Firstly, the original NIP-rhIGHG constructs were PCR-
amplified from verified pCR2.1-TOPO vector clones (that carry the original engineered NIP-
rhIgG constructs) using forward IgNotI and reverse IgXhoI primers (Table 2.1). These 
amplifications added NotI and XhoI RE sites into the 5’ end and the 3’ end, respectively, of 
original NIP-rhIGHG cDNA constructs. Next, the modified NotI-XhoI-containing NIP-rhIGHG
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Fig. 2.9. Schematic representation of generation of recombinant expression plasmid vectors 
pcDNA3.1-IgH and P2561/2/3-IgH  (not drawn to scale). The NIP-rhIGHG constructs were 
PCR-amplified from appropriate TOPO vectors using forward primer IgNotI (containing NotI 
restriction site in its 5’ end; Table 2.1) and the reverse primer IgXhoI (containing XhoI restriction 
site in its 5’ end; Table 2.1), as indicated. Resultant PCR products were then ligated into 
pcDNA3.1(+) or P2561/2/3 vectors previously digested with both NotI and XhoI REs. 
Recombinant constructs are therefore encoded within NotI-XhoI sites of resulting recombinant 
expression vectors.
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cDNA constructs were ligated into ampicillin-resistant pCR2.1 TOPO TA cloning vector 
(Invitrogen, Carlsbad, CA), within EcoRI sites, following the procedure as described previously. 
Then the ~1.5 kb fragments (with confirmed correct sequence) were released from pCR 2.1 
TOPO clones (that carry the modified engineered NIP-rhIGHGs) by sequential digestion with 
NotI and XhoI REs (New England BioLabs, Ipswich, MA), and cleaned up on a 1% agarose gel. 
These NotI-XhoI-containing fragments were subsequently subcloned into expression vectors 
P2561/2/3 using the unique NotI and XhoI RE sites, downstream CMV promoter and in proper 
orientation, to yield plasmid constructs P2561/2/3-rhIGHG1, P2561/2/3-rhIGHG2, P2561/2/3-
rhIGHG3, and P2561/2/3-rhIGHG4. Thus, the final IgG gene cassettes contained at their 5’ end a 
NotI site (between CMV promoter and Ig leader) and at their 3’ end a XhoI site (between Ig CH 
region stop codon and poly(A) signal sequence). 
In addition to using P2561/2/3 vectors, the ~1.5-kb NotI-XhoI-digested fragments were 
also subcloned – to the unique NotI and XhoI RE sites – onto pcDNA3.1 expression vector by 
similar procedures, yielding constructs pcDNA3-rhIGHG1, pcDNA3-rhIGHG2, pcDNA3-
rhIGHG3, and pcDNA3-rhIGHG4. 
Thus, two subsets of recombinant pCR2.1-TOPO cloning vectors were digested with a 
pair of REs – BsmI and BamHI or NotI and XhoI – as appropriately (Fig. 2.7 and 2.9). Excised 
restriction cDNA hybrid constructs were accordingly engineered into plasmids pLNOH2, 
pcDNA3.1, and P2561/2/3 digested with corresponding pair of REs to make final recombinant 
expression vectors. Insertion and orientation were analyzed by PCR and RE digestion, and 
subsequently confirmed by DNA sequencing in both forward and reverse directions. 
All ligation reactions were performed overnight at 14°C in the presence of T4 DNA 
ligase (Roche Diagnostics North America, Indianapolis, IN). Resultant NIP-rhIGHG-containing 
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plasmid DNAs were then transformed into and amplified in Top10 E. coli competent cells 
selected on ampicillin (Invitrogen, Carlsbad, CA) by heat shock, as previously described (except 
that no X-Gal was included in LB plates). Colonies were first screened for the presence of 
insertion by PCR directly on raw extracts from clones. Subsequently, miniprep DNAs derived 
from the PCR-screened positive colonies, which were purified by plasmid mini-preparations 
(Qiagen Inc., Valencia, CA), were verified for insertion and proper orientation by RE digestion 
using BsmI and BamHI REs, and by DNA sequencing. After verification, good clones were 
expanded and prepared with an EndoFree plasmid maxi kit (Qiagen Inc., Valencia, CA). The 
maxiprep yields from these expression vectors varied among 1.5-2.5 μg/ml (with the use of an 
initial culture volume of 5 ml). 
 
2.2.6. Production of transient and stable J558L transfectoma cell lines expressing 
recombinant NIP-rhIGHG chimeras 
To determine whether pLNOH2, pcDNA3.1, and P2561/2/3 vectors that contained cDNA 
constructs encoding NIP-rhIGHG IgH subclass chimeras and containing CMV promoter, murine 
Ig leader, and poly-A signal sequences could express complete IgGs, we transfected each of 
them into J558L cells. Transfection was performed by electroporation using closed-circle DNA 
plasmids and G418-resistant clones would grow out. Transfectoma cell lines were produced on 
small-scale expression for specificity analysis purpose. Only plasmids with correct DNA 
sequences were used for transfection. Before transfection, production of murine IgL λ chain by 
J558L cells was confirmed by ELISA. 
Briefly, after antibiotic-resistant bacterium cells retaining the constructs were selected, 
NIP-rhIGHG-containing plasmid vectors were purified and prepared in large quantities using 
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using EndoFree Plasmid Maxi kits (Qiagen Inc., Valencia, CA). The quantity and quality of 
DNA were assessed by DNA gel electrophoresis and by optical density at 260/280 nm. Twenty 
micrograms of each supercoiled plasmid expression vector DNAs, including those of pLNOH2, 
which served as positive controls (known to react with rhesus macaque IgGs), were pulsed into 5 
x 10
6
 to 1 x 10
7
 J558L cells resuspended in 200-300 μl ice-cold PBS (without Ca2++ and Mg2++) 
placed in 1 cm x 0.4 cm x 4.5 cm plastic microcuvettes that had been equipped with aluminum 
electrodes. Two to three pulses at 1 second intervals with 300 V were applied using the gene 
pulser Electroporator II (Invitrogen, Carlsbad, CA), setting at 1000 μF (at a capacitance setting 
of 25 μF) and infinite resistance (giving a ~30-40 msec pulse). Following 10 min of incubation 
on ice, the cells were suspended in pre-warmed 10-20 ml of complete IMDM [i.e. Iscove’s 
modified Dulbecco’s medium containing 2 mM L-glutamine, 100 IU/ml penicillin G sodium, 
100 g/ml streptomycin sulfate, 5 mM HEPES (Sigma–Aldrich Co., St. Louis, MO), and 5-10% 
fetal bovine serum (FBS)]. The cells were allowed to recover by incubation for 24-48 hrs at 37
0
C 
in a 5% CO2 atmosphere. 
At 72 h post-transfection, stable transfectants were selected by resistance under the final 
concentration of 0.8-1.0 mg/ml (400-2,000 μg/ml) geneticin (antibiotic G418; Invitrogen, 
Carlsbad, CA) in complete IMDM medium and were allowed to grow to saturation for four 
weeks or until a concentration of 3-4 x 10
6
 cells/ml was achieved. During incubation, cell 
supernatants were harvested and replaced at 5, 10, 14, 21, and 28 days post-transfection. 
Supernatants were also obtained from the cells that were allowed to grow to saturation for up to 
six weeks. Cell supernatants were centrifuged (20,000 g for 30 min) to remove cellular debris 
before using in subsequent assays. Because usually production of Abs gradually decline due to 
transient nature of transfection, cell cultures were terminated after six weeks. 
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2.2.7. Detection of Igλ and complete (assembled) recombinant NIP-rhIGHG chimeric 
antibodies 
Ab production and binding activity to specific antigen of anti-NIP murine Igλ chain and 
complete recombinant IgG (NIP-rhIgGs) in transfected J558L cell supernatants were determined 
by capture enzyme linked immunosorbent assay (ELISA). Secreted IgGs were detected by either 
immobilized affinity purified goat anti-monkey IgG(H+L)-specific Abs (KPL, Baltimore, MD; 
Cat. #071-11-021; for detection of IgH γ), or an immobilized goat anti-mouse Ig λ Abs (Southern 
Biotech, Birmingham, AL; Cat. #1060-01; IgL-specific Ab, for detection of IgL λ), or 
immobilized NIP-BSA (KPL, Baltimore, MD; NIP-specific IgGs, containing both anti-NIP VL 
and VH regions; for detection of whole IgG Ab). For goat anti-mouse Igλ ELISAs, bound Igλ 
was detected by HRP-conjugated secondary Ab goat anti-mouse λ (Invitrogen, Carlsbad, CA). 
For anti-IgH γ-specific or anti-whole chimeric IgG Abs, bound Abs were detected by horse 
radish peroxidase (HRP)-conjugated anti-monkey IgGs (KPL, Baltimore, MD; Cat. #074-11-
021). All Ab reagents were diluted in blocking buffer. 
Briefly, 96-well high-binding polyvinyl microtiter ELISA plates were coated with 50 μl 
goat anti-mouse Ig λ Ab (Invitrogen, Carlsbad, CA) at 4 or 8 μg/ml or with NIP-BSA (KPL, 
Baltimore, MD) at 8 or 15 μg/ml in coating buffer (KPL, Baltimore, MD). Following incubation 
at 4°C overnight, plates were washed with PBS containing 0.05% Tween-20 and unoccupied 
wells were blocked with 5% FCS (or BSA) diluted in PBS at 37°C for 30 min. After washing the 
plates, undiluted cell culture supernatants of G418 resistant transfectants and the appropriate 
controls [positive control: purified murine myeloma IgG3 λ (Sigma–Aldrich Co., St. Louis, MO; 
Cat. # M9019; negative controls: culture media plus 5% FCS] were added to pre-coated plates 
(100 μl/well) for triplicate wells. For Igλ assays, culture supernatant from untransfected J558L 
112 
 
 
cells (test samples), purified mouse myeloma IgG1 with a λ-chain (Sigma–Aldrich Co., St. 
Louis, MO) (positive control), or 5% FCS in either culture media or PBS [or 0.05% (vol/vol) of 
PBS-Tween 20] (negative control), was added (100 μl/well), and incubated at 37°C for 1 h. For 
IgH/IgG assays, supernatants from transfected J558L cells (test samples), from unstranfected 
cells (negative controls), or from cells transfected with pLNOH2 (positive controls), were added 
(100 μl/well), and incubated overnight at 4°C. Following washing four times with PBS 
containing 0.05% Tween 20 to remove unbound Ab, the bound Abs were detected by adding 
(100 μl/well) 1/1,000-1/10,000 diluted, appropriate HRP-labeled secondary Abs [HRP-
conjugated goat anti-mouse Igλ (Invitrogen, Carlsbad, CA) for detection of IgL λ and IgG, and 
HRP-conjugated anti-monkey IgH γ (KPL, Baltimore, MD) for detection of IgH and IgG]. Plates 
were incubated for 1 h at 37°C, washed four times, and the bound peroxidase was revealed by 
adding OPD and ABTS/H2O2 (Sigma–Aldrich Co., St. Louis, MO) for color development, 
followed by addition of stop solution. Absorbance was measured at 405 or 492 nm after 15-30 
min using an automated Benchmark microplate reader (Bio-Rad, Hercules, CA). Tests were done 
in triplicate wells and triplicates were averaged. 
 
2.3. Results 
2.3.1. Four NIP-rhIGHG cDNA hybrid constructs were successfully generated by SOE-PCRs 
and were properly incorporated into pCR2.1-TOPO cloning vector 
cDNA segments encoding anti-NIP murine VH and rhesus macaque individual CH 
domains CH1, CH2, and CH3 (the hinge is embedded in CH1 and CH2 domains, as previously 
described) of each of four rhesus macaque IgG subclasses were successfully amplified by PCRs 
from the appropriate plasmid vectors (data not shown). Complete IgH cDNA hybrid encoding
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Fig. 2.10. Gel electrophoresis separation of DNA products resulting from SOE-PCR annealing 
and amplification or digestion of clones of recombinant gene constructs of NIP-rhIGHG1 (A), 
NIP-rhIGHG2 (B), NIP-rhIGHG3 (C), and NIP-rhIGHG4 (D) that were ligated into cloning and 
expression vectors. RE digestions were used to confirm that the recombinant constructs had each 
been inserted into the correct region of vectors and in the correct orientation (which were 
subsequently confirmed by DNA sequencing). SOE-PCR-generated products or fragments 
obtained from RE-digested DNA plasmids were separated on 1-2% agarose gels, adjacent to 
DNA molecular weight standards. The gels were stained with ethidium bromide and were 
visualized and photographed under UV light. Each quadrant in this figure contains a 
representative gel for, from left to right, annealing and amplification of subclass recombinant 
gene construct using the two flanking primers at the 5’ end of VH and the 3’ end of CH3 by a 
single SOE-PCR, RE with single enzyme EcoRI of pCR2.1 TOPO TA transformed clones, and 
restriction digestion with double enzymes BsmI and BamHI of pLNOH2 transformed clones. 
Arrows indicate where DNA fragments are expected to be shown (correct-sized bands). In each 
gel, both lanes shown correspond to the same DNA product, except for the middle gels in (A) 
and (B), which have only one lane shown. For lanes with two bands, the above released band 
corresponds to the digested vector and the below released band corresponds to the inserted DNA 
fragment. The DNA molecular weight standards are represented by lanes with multiple bands. 
As being shown, in each quadrant, the size (in kilobase-pairs, kb) of DNA fragments after RE 
digestions are the same as those of the SOE-PCR products, which are 1.39 (A), 1.37 (B), 1.42 
(C), and 1.37 (D). The size (kb) of plasmid vectors after digestions are 3.9 (pCR2.1 TOPO 
cloning vector) and 7.2 (pLNOH2 expression vector). Only representative clones containing 
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bands of expected sizes are shown. Lanes showing no bands correspond to undetectable DNA 
products.
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each IgG subclass was created by several sequential SOE-PCRs. Agarose gel analysis of these 
SOE-PCR products (Fig. 2.10) showed DNA bands of approximately 1.39, 1.37, 1.42, and 1.37 
kb, representing the four corresponding recombinant IgH hybrids, IgHγ1, IgHγ2, IgHγ3, and 
IgHγ4, respectively. When performed with the annealing temperature of 560C or 580C and a 
magnesium concentration of 2.5 mM, SOE-PCRs using the two outermost flanking primers were 
generally found to yield minimal non-specific (due to sequence differences) products while 
producing desired amplification fragments. 
For cloning and sequencing, resultant hybrid cDNA genes were subsequently ligated into 
pCR2.1-TOPO TA cloning vector. These ligations resulted in two subsets of recombinant 
cloning vectors: one containing cDNAs carrying BsmI-BamHI restriction sites and the another 
carrying NotI-XhoI restriction sites. Insertion and orientation were checked by PCR and RE 
digestion. Digestion of resultant recombinant cloning vectors with EcoRI (Fig. 2.10) or BsmI and 
BamHI pair (data not shown) for the BsmI-BamHI subset, as well as with EcoRI or NotI and XhoI 
pair (Fig. 2.11) for the NotI-XhoI subset, yielded bands of similar sizes as those of SOE-PCR 
products of corresponding cDNA hybrids. These results verified the correct size and proper 
orientation of the hybrids incorporated in pCR2.1 TOPO TA clones. 
Correct sequence and orientation of the hybrids were also confirmed by DNA sequencing 
in both forward and reverse directions across the inserted points. Alignment of deduced amino 
acid sequences of IgH γ CH1, CH2, and CH3 domains belonging to four IgG isotypes (IgG1, 
IgG2, IgG3, and IgG4) gene fragments from human (Homsap) and rhesus macaque (Macmul) is 
shown in Fig. 2.12. Each rhesus macaque CH domains contains a similar number of amino acids 
as that found in human counterparts, which is 98, 109-110, and 107, in CH1, CH2, and CH3 
domains, respectively. Majority of differences were located in the hinge region for all compared
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Fig. 2.11. Gel electrophoresis separation of DNA fragments resulting from digestions of clones 
of recombinant gene constructs of NIP-rhIGHG1, NIP-rhIGHG2, NIP-rhIGHG3, and NIP-
rhIGHG4 that were ligated into cloning and expression vectors. RE digestions were used to 
confirm that recombinant gene constructs had each been inserted into the correct region of 
vectors and in the correct orientation (which were subsequently confirmed by sequencing). 
Fragments obtained from RE-digested DNA plasmids were separated on 1-2% agarose gels, 
adjacent to DNA molecular weight standards. The gels were stained with ethidium bromide and 
were visualized and photographed under UV light. Shown in this figure are a representative gel 
for restriction digestion with double enzymes BsmI and BamHI of pLNOH2 transformed clones 
(A), with single enzyme EcoRI of pCR2.1 TOPO TA transformed clones (B), with double 
enzymes NotI and XhoI of pCR2.1 TOPO TA transformed clones (C), and with double enzymes 
NotI and XhoI of P2561/2/3 transformed clones (D). As being shown, each lane displays two 
bands, of which the above released band corresponds to the digested vector and the below 
released band corresponds to inserted DNA fragment. Number of lanes corresponding to each 
construct varies, as indicated by the horizontal lines. The vertical arrows with short notations 
show lanes corresponding to the indicated constructs. The DNA molecular weight standards are 
represented by lanes with multiple bands. In each quadrant, the size (in kilobase-pairs, kb) of the 
DNA fragments after RE digestions are 1.39, 1.37, 1.42, and 1.37 for NIP-rhIGHG1, NIP-
rhIGHG2, NIP-rhIGHG3, and NIP-rhIGHG4 construct, respectively. The size (kb) of the 
plasmid vectors after digestions are 3.9 (pCR2.1-TOPO), 7.2 (pLNOH2), and 7.0 (P2561/2/3). 
Only representative clones containing bands of the expected sizes are shown. Lanes showing 
only one band (with size similar to that of the relevant vector) correspond to clones without 
successful DNA ligation.
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sequences (Table. 2.2). Two-dimensional structure and secondary structure according to IMGT 
were also displayed (Fig. 2.13). As discussed previously, these IMGT Collier de Perles graphical 
two-dimensional representations provide useful information for relating structure to potential 
function (Bertrand et al., 2004). The sequence of anti-NIP V regions of the resultant rhesus 
macaque IgHs was identical to each other and to the original sequence (data not shown). 
Taken together, these data indicate that all four chimeric NIP-rhIGHG cDNA gene 
constructs were accurately and successfully created by SOE-PCRs and were properly 
incorporated into pCR2.1 TOPO TA cloning vectors. 
 
2.3.2. Four NIP-rhIGHG cDNA hybrid constructs were successfully engineered into 
pLNOH2, pcDNA3.1(+), and P2561/2/3 expression vectors 
As shown in Fig. 2.11, pLNOH2 plasmids digested by BsmI and BamHI gave rise to 
individual bands of approximately 1.39, 1.37, 1.42, and 1.37 kb, which were the same size as that 
of corresponding SOE-PCR products. Analysis of the restriction digests with NotI and XhoI (Fig. 
2.11) confirmed that the cDNA hybrids were successfully engineered into pLNOH2. Similar 
restriction digests with BsmI and BamHI pair or with NotI and XhoI RE pair indicated that the 
hybrids were recombined into P2561/2/3 (Fig. 2.11) and pcDNA3.1 (data not shown) vectors. 
The correct insertion and proper orientation were also confirmed by sequencing cDNA hybrids 
(data not shown). DNA sequencing data of NIP-rhIGHG hybrid genes were consistent with DNA 
sequences of VH (data not shown) and rhIGHGs genes listed in Genbank (Fig. 2.12). 
Taken together, these data demonstrate that all four chimeric NIP-rhIGHG cDNA gene 
constructs were accurately and successfully engineered into pLNOH2, pcDNA3.1, and 
P2561/2/3 expression vectors.
120 
 
 
121 
 
 
Fig. 2.12. Alignment of deduced amino acid sequences of IgH CH1, CH2, and CH3 domains of 
four IgG isotypes (IgG1, IgG2, IgG3, and IgG4) from human (Homsap) and rhesus macaques 
(Macmul). The top upper line illustrates the domain beta strands, as indicated by the letters and 
numbering positions, with a horizontal arrow; the double letters represent the turns (AB, DE, and 
EF) and the loops (BC and FG) between the sandwich fold beta strands, or the transversal strand 
(CD) (Lefranc et al., 2005). The second and third upper lines indicate the C-DOMAIN IMGT 
unique numbering. Conserved Cys residues (i.e. positions 23 and 104) are colored in magenta; 
conserved Trp (position 41) and hydrophobic residues (positions 89 and 121) are illustrated in 
blue. Residues of the beta strand loops (BC and FG) are shown in dark red. Two sequences for 
each individual domain of rhesus macaques were included for each IgH domain and are bordered 
in single-line enlarged boxes, as indicated. In each box, the above sequence (black “Macmul” 
text) indicates the published sequences and the below sequence (colorful “Macmul” text) 
indicates the sequences generated in the present study. The GenBank access codes for the 
published sequences included are AAQ57550.1 (IGHG1), AAQ57562.1 (IGHG2), AAQ57556.1 
(IGHG3), and AAQ57568.1 (IGHG4) (Scinicariello et al., 2004). Between parentheses is the first 
amino acid that results from the splicing of each preceding exon. Underlined Cs indicate Cys 
residues that have the potential to form intra-chain disulfide bonds. Potential N-linked 
glycosylation sites (N-x-S/T; x denotes any amino acid) are underlined. Dot-line small-sized 
boxes represent residual differences between rhesus macaques and humans with regard to amino 
acids that are known to be functionally important, including those of potential N-linked 
glycosylation sites (n=2), or with regard to Cys (which is known to have the potential to form 
intra-chain disulfide bonds) (n=1). The last nine amino acids in the non-human primate species 
are not present in the figure, and slashes indicate the positions where our sequences are ended. 
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Dots illustrate the IMGT gaps (missing amino acids, according to the IMGT unique numbering) 
inserted to maximize alignment. This display is according to the IMGT unique numbering for C-
DOMAIN and C-LIKE DOMAIN and is based on the IMGT protein display (Lefranc et al., 
2005).
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Table 2.2. Deduced amino acid sequences of the hinge of IgH CH1, CH2, and CH3 domains of four IgG isotypes (IgG1, IgG2, IgG3, 
and IgG4) from human (Homsap) and rhesus macaque (Macmul)
a
. 
 
aTwo sequences for each hinge of rhesus macaques were included for each IgH isotype: the above sequence (black “Macmul” text) 
indicates the published sequences (Scinicariello et al., 2004) and the below sequence (colorful “Macmul” text) indicates the sequences 
generated in the present study. The hinge is composed of three distinct regions: the upper hinge (the fragment in front of the italic, 
underlined text), the core hinge (the italic, underlined text fragment), followed by the lower hinge/CH2 terminus [although the “lower 
hinge” is encoded by the C-terminus of the CH2 exon, it is considered to be part of the hinge due to the intermolecular interactions 
(Burton and Woof, 1992)]. Human IgG3 hinge has four sequence repetitions, with three times the [(E)PSKCDTPPPCPRCP] sequence 
is repeated. Between parentheses is the first amino acid that results from the splicing of each preceding exon. Underlined C, Cys 
involved in the formation of intrachain disulfide bridges. The GenBank access codes for the published sequences included are 
AAQ57550.1 (IGHG1), AAQ57562.1 (IGHG2), AAQ57556.1 (IGHG3), and AAQ57568.1 (IGHG4) (Scinicariello et al., 2004).
 IGHG1 IGHG2 IGHG3 IGHG4 
Homsap (E)PKSCDKTHTCPPCP(A)PELLGGP
e  (E)RKCCVECPPCP(A)PPVAGP [H1]  (E)LKTPLGDTTHTCPRCP(A)PELLGGP (E)SKYGPPCPSCP(A)PEFLGGP 
   [H2]  (E)PSKCDTPPPCPRCP  
   [H3]  (E)PSKCDTPPPCPRCP  
   [H4]  (E)PSKCDTPPPCPRCP  
Macmul (E)IKTCGGGSKPPTCPPCP(A)PELLGGP (G)LPCRSTCPPCP(A)ELLGGP            (E)FTPPCGDTTPPCPPCP(A)PELLGGP  (E)FTPPCPPCP(A)PELLGGP  
Macmul (E)IKTCGGGSKPPTCPPCP(A)PELLGGP (G)LPCRSTCPPCP(A)ELLGGP            (E)FTPPCGDTTPPCPPCP(A)PELLGGP  (E)FTPPCPPCP(A)PELLGGP  
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2.3.3. Four chimeric NIP-rhIGHG IgH chains with NIP-specificity of the original murine VH 
were successfully expressed by J558L cells 
ELISA plates were coated with purified anti-monkey IgG, which recognizes different Ab 
epitopes of the whole IgG(H+L) or IgH. Therefore, affinity purified anti-monkey IgG(H+L) 
recognized recombinant IgH or IgG subclasses, which were bound to and were detectable by 
HRP-conjugated anti-monkey IgG [due to the bivalent nature of IgGs (two IgH chains in a single 
IgG)]. As shown in Fig. 2.16, the average OD reading at 405 nm in supernatants collected from 
cells transfected with chimeric IgH fusions was much higher than that of negative controls using 
the whole IgG- or IgH-specific conjugate, indicating that chimeric IgGs are bound by anti-
monkey IgG Abs. These OD values were similar to or in several cases even higher than those of 
positive controls (Fig. 2.16). We found no expressed IgH nor IgG in IMDM medium 
transfectoma supernatants, which served as negative controls as well. Supernatants of pLNOH2 
(served as a positive control) reacted with immobilized purified anti-monkey IgG, while the 
medium control (IMDM) or supernatant of untransfected J558L cells was non-reactive with the 
purified Ab (Fig. 2.16). These results confirm the chimeric IgH identity through its anti-monkey 
IgH-specific reactivity upon transfection and selection in J558L cells. 
 
2.3.4. Four NIP-rhIGHG intact IgG subclass Abs that retained binding specificity of the 
original V regions were successfully produced by J558L cells 
To verify that secreted recombinant rhesus macaque IgH chains were assembled with 
NIP-specific murine IgL λ chains, we carried out another set of sandwich ELISAs where NIP-
BSA was immobilized on plates and bound IgGs were detected by HRP-conjugated anti-monkey 
IgG Abs. Before transfection, production of murine IgL λ from J558L cells was confirmed by
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Fig. 2.13. Two-dimentional representation, or IMGT Colliers de Perles, of rhesus macaque 
(Macmul) CH domain sequences of each of the four IGHG subclass molecules. Shown are 
Colliers de Perles representation on one layer obtained with the IMGT/Collier-de-Perles tool in 
the IMGT/DomainGapAlign (http://www.imgt.org/3Dstructure-DB/cgi/Collier-de-Perles.cgi) 
(Ehrenmann et al., 2010). Colliers de Perles is the two-dimentional graphical representations of 
IG and TR V, C domains, highlighting conserved amino acids. The C-DOMAIN IMGT Colliers 
de Perles is based on the IMGT unique numbering for C- and C-LIKE DOMAIN and allows 
sequence comparison of Ig superfamily (IgSF) domains in different species (one layer Colliers 
de Perles), as well as localization of amino acids involved in FcR binding, in C1q binding, and in 
N-glycosylation sites (two layer Colliers de Perles) (Lefranc et al., 2005). The conserved Cys 
(position 23), and Cys (position 104), are indicated. Blue circles or squares represent core 
positions at which hydrophobic amino acids (I, V, L, F, C, M, A) and W are found in more than 
50% of analyzed IgSF sequences. All Pro residues are shown in yellow. Squares illustrate 
homology with the corresponding positions in the V-DOMAINs (positions 26, 39, 104, and 118) 
or delimitation of the characteristic transversal CD strand of the C-LIKE-DOMAINs (positions 
45 and 77). The BC loop, CD transversal strand, and FG loop are limited by amino acids 
displayed in squares. Hatched circles indicate missing positions according to the IMGT unique 
numbering for C-DOMAIN and C-LIKE-DOMAIN (Lefranc et al., 2005). Arrows indicate the 
beta strand direction.
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Fig. 2.14. Prediction of potential N-glcosylation sites for CH3 domains of human (above) and 
rhesus macaque (below) IgG4 sequences, conducted by the use of the online tool NetNGlyc 1.0 
Server (http://www.cbs.dtu.dk/services/NetNGlyc/), which is based on identifying Asn-Xaa-
Ser/Thr consensus sequences (Julenius et al., 2005). Unlike in humans (above), in rhesus 
macaques (below), IgG4 has one additional computationally-predicted N-glycolsylation site at 
CH3.
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Fig. 2.15. Expression by J558L cells of NIP-specific mouse Igλ associated with secreted 
recombinant IgHs as detected by sandwich ELISA for its binding to purified anti-mouse IgL λ 
Abs produced in goat (NIP anti-λ ELISA). For detecting an antigen or Ab, sandwich ELISA is a 
sensitive and specific technique that uses two Abs, both of which are specific to the antigen or 
the Ab of interest and bind it at non-overlapping epitopes. Undiluted supernatants collected at 
different time points from J558L cells transfected with recombinant pLNOH2 expression vector 
containing NIP-rhIGHG1, NIP-rhIGHG2, NIP-rhIGHG3, or NIP-rhIGHG4 chimeric construct, 
from unstransfected cells (represents a negative control), or from cells transfected with the 
original pLNOH2 vector, which encodes human IgH and is specific for NIP, were incubated on 
ELISA plates coated with goat anti-mouse λ (Southern Biotech, Birmingham, AL; Cat. #1060-
01). IgL λ was detected by HRP-conjugated secondary Ab goat anti-mouse λ (Southern Biotech, 
Birmingham, AL; Cat. #1060-05). Absorbance was measured at 405 nm using an automated 
microplate reader. Purified mouse IgG3 λ (Sigma–Aldrich Co., St. Louis, MO; Cat. # M9019) 
was added as a positive control. IMDM, the cell culture medium, and PBS, were also included to 
serve as additional negative and blank controls. Day numbers indicate numbers of days after 
transfection when supernatants were harvested for testing. Values are means of duplicate wells. 
The assays were performed twice and yielded similar results. *Data shown for IMDM/PBS, 
Untransfected, and pLNOH2 were from the NIP-rhIGHG3 experiments, which were used as 
representative; IMDM/PBS, Untransfected, and pLNOH2 values obtained from the NIP-
rhIGHG1, NIP-rhIGHG2, and NIP-rhIGHG4 experiments were similar. PosCTRL**, purified 
mouse IgG3 λ (Sigma–Aldrich Co., St. Louis, MO; Cat. # M9019). 
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ELISA (data not shown). 
As shown in Fig. 2.17, supernatants collected from cells transfected with recombinant 
IgH hybrids that were captured with NIP-BSA were readily detectable with HRP-conjugated 
anti-monkey IgGs. Supernatant from cells transfected with pLNO2 vector (human IgG3), which 
represented a positive control, also bound NIP-BSA. No binding was observed for supernatants 
from untransfected cells. These data indicate that intact IgG subclass Abs were assembled, as 
secreted recombinant Ab molecules featured both the VL/VH IgL NIP-specificity and the anti-
monkey IgH-specific reactivity. 
For all gene hybrids, Ab secretion level was with a peak on day 10 after transfection (Fig. 
2.16, 2.17, and 2.18). Furthermore, protein production proceeded as early as at day 5 (Fig. 2.16 
and 2.17). Six weeks after transfection, ELISA assays showed that the transfectomas producing 
good quantities of IgGs were still active (i.e. secreting Abs) (data not shown). Expression levels 
varied dependent on subclasses and the yield was generally highest for IgG2, followed by IgG3 
then IgG4, and lowest for IgG1 (Fig. 2.18). During the examining period of time (up to six 
weeks post-transfection), production of murine λ IgL by J558L cells was confirmed by ELISA 
(Fig. 2.15). In these assays, ELISA plates were coated with goat anti-mouse λ [purified anti-
mouse λ Abs produced in goat (NIP-specific anti-VL/VH λ Abs)] and bound IgL λ was detected 
by HRP-conjugated secondary Ab goat anti-mouse λ. 
Taken together, production of recombinant IgGs recognized by both anti-NIP (i.e. Fab) 
and anti-monkey (i.e. Fc/IgH) Abs suggest that upon transfection with chimeric NIP-rhIGHG 
vectors, the IgH-deficient myeloma J558L cells produce complete H2L2 complete IgG molecules, 
resulting from pairing of transfected recombinant IgH with IgL λ endogenously expressed by the 
cells. Secreted Abs were with the pre-defined specificity (intact binding capability) against NIP.
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Fig. 2.16. Production of recombinant NIP-rhIGHG IgH chains of different IgG subclasses as 
determined by sandwich ELISA for their binding to an affinity purified anti-monkey IgG 
produced in goat (monkey-specific anti-gamma ELISA). For detecting an antigen or Ab, 
sandwich ELISA is a sensitive and specific technique that uses two Abs, both of which are 
specific to the antigen or the Ab of interest and bind it at non-overlapping epitopes. Undiluted 
supernatants collected at different time points from J558L cells transfected with a recombinant 
pLNOH2 expression vector containing the NIP-rhIGHG1 (A), NIP-rhIGHG2 (B), NIP-rhIGHG3 
(C), or NIP-rhIGHG4 (D) chimeric construct, from unstransfected cells (represents a negative 
control), or from cells transfected with the original pLNOH2 vector, which encodes human IgH 
chain and is specific for NIP [represents a positive control (known to react with rhesus macaque 
IgG)], were incubated on ELISA plates coated with affinity purified goat anti-monkey IgG(H+L) 
(KPL, Baltimore, MD; Cat. #071-11-021) as the capture Ab. Bound Abs were detected by HRP-
conjugated secondary Abs goat anti-monkey IgG (whole IgG- or IgH-specific) (KPL, Baltimore, 
MD; Cat. #074-11-021) for rhesus macaques. Due to rhesus macaque IgG bivalency, if they bind 
to immobilized purified goat anti-monkey IgG, they will also bind to HRP-conjugated goat anti-
monkey secondary Abs. Absorbance was measured at 405 nm using an automated microplate 
reader. IMDM, the cell culture medium, was also included to serve as an additional negative 
control. Day numbers indicate numbers of days after transfection when supernatants were 
harvested for testing. Values are means of duplicate wells. The assays were performed twice and 
yielded similar results.
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Fig. 2.17. Production of complete recombinant NIP-rhIGHG Abs of different IgG subclasses as 
determined by capture (indirect) ELISA for their binding to NIP-BSA (NIP coupled to BSA) 
antigen (NIP-specific anti-gamma ELISA). Expression of rhesus macaque IgH and its ability to 
pair with NIP-specific mouse IgL λ were tested using capture ELISAs. Undiluted supernatants 
collected at different time points from J558L cells transfected with a recombinant pLNOH2 
expression vector containing NIP-rhIGHG1 (A), NIP-rhIGHG2 (B), NIP-rhIGHG3 (C), or NIP-
rhIGHG4 (D) chimeric construct, from unstransfected cells (represents a negative control), or 
from cells transfected with the original pLNOH2 vector, which encodes human IgH chain and is 
specific for NIP (known to react with rhesus macaque IgG and represents a positive control), 
were incubated on ELISA plates coated with NIP-BSA (Biosearch Technologies, Birmingham, 
AL; Cat. #N-5040-10; 8-15 μg/ml). Bound Abs were detected by HRP-conjugated secondary 
Abs goat anti-monkey IgG (whole IgG- or IgH-specific) (KPL, Baltimore, MD; Cat. #074-11-
021) for rhesus macaques. Absorbance was measured at 405 nm using an automated microplate 
reader. IMDM, the cell culture medium, was also included to serve as an additional negative 
control. Day numbers indicate numbers of days after transfection when supernatants were 
harvested for testing. Values are means of duplicate wells. The assays were performed twice and 
yielded similar results.
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Thus, four chimeric NIP-rhIGHG intact IgGs that retained binding specificity of the original 
anti-NIP V regions were successfully produced. 
 
2.4. Discussion 
One of the major reasons for lack of IgG functional in vitro studies for the rhesus 
macaque model is the unavailability of specific serological reagents, whereas human Abs poorly 
or rarely interact with rhesus macaque effector leukocytes. To circumvent this pitfall, we have 
engineered recombinant Abs representing each of the four IgG subclasses of rhesus macaques. 
Previously, our laboratory has utilized molecular cloning techniques to identify and characterize 
IgG genes in rhesus macaques. From these studies, four IgG subclasses are discovered and are 
found to be variable most in the hinge region, although isotypic variation in amino acid 
sequences is also identified in CH1, CH2, and CH3 domains (Scinicariello et al., 2004). In 
addition to isotypic variation, intra-species allelic polymorphism also appears among individual 
animals. Of particular note from these findings is the addition in rhesus macaque IgG4 CH3 
domain of a potential N-glycosylation site, from which possible related structural and/or 
functional changes remain to be elucidated. These characterized IGHG genes in rhesus macaques 
have provided the knowledge to generate their recombinant Abs. 
In this study, we describe the procedures for engineering four chimeric recombinant 
murine-rhesus macaque IgGs. Here the ~1.4-1.5 kb BsmI-BamHI- and NotI-XhoI-containing IgH 
chain cDNA cassettes (which contained a murine VH region specific for the hapten NIP) of each 
of the four rhesus macaque IgG CH subclasses, were constructed by SOE-PCRs and 
subsequently cloned into pLNOH2 and P2561/2/3 expression vectors, respectively. Resultant 
IgH expression vectors were then transfected by electroporation into a murine myeloma cell line, 
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Fig. 2.18. Different yields in production of recombinant NIP-rhIGHG Abs of different IgG 
subclasses as determined by ELISA for their binding to NIP-BSA antigen [(A); NIP-specific 
anti-gamma ELISA] or to an affinity purified anti-monkey IgG produced in goat [(B); monkey-
specific anti-gamma ELISA]. Undiluted supernatants collected at day 10 post-transfection from 
J558L cells transfected with recombinant pLNOH2 expression vector containing the NIP-
rhIGHG1, NIP-rhIGHG2, NIP-rhIGHG3, or NIP-rhIGHG4 chimeric construct, from 
unstransfected cells (represents a negative control), or from cells transfected with the original 
pLNOH2 vector, which encodes human IgH chain and is specific for NIP (known to react with 
rhesus macaque IgG and represents a positive control), were incubated on ELISA plates coated 
with NIP-BSA (Biosearch Technologies, Birmingham, AL; Cat. #N-5040-10; 8-15 μg/ml) (A) or 
with with purified goat anti-monkey IgG (KPL, Baltimore, MD; Cat. #071-11-021) (B). Bound 
Abs were detected by HRP-conjugated secondary Abs goat anti-monkey IgG (whole IgG- or 
IgH-specific) (KPL, Baltimore, MD; Cat. #074-11-021) for rhesus macaque. Absorbance was 
measured at 405 nm (the X-axis) using an automated microplate reader. IMDM, the cell culture 
medium, was also included to serve as an additional negative control. Values are means of 
duplicate wells. The assays were performed twice and yielded similar results. *Data shown for 
IMDM and Untransfected were from the NIP-rhIGHG3 experiments, which were used as 
representative; IMDM and Untransfected values obtained from the NIP-rhIGHG1, NIP-
rhIGHG2, and NIP-rhIGHG4 experiments were similar).
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J558L, which express the NIP-specific IgL chain. Surviving cells were selected by G418 
antibiotics and IgG production was determined by ELISA. Successful production and identity of 
intact recombinant IgGs were confirmed by their capability of binding the hapten NIP and being 
bound by purified goat anti-monkey Abs. All resultant recombinant molecules were confirmed 
for sequence accuracy. 
The recombinant DNA method is a powerful tool for construction of Ab genes and 
production of genetically engineered Abs with novel or modified structural and/or functional 
properties for applications in both basic and applied research. With more and more Ig gene 
sequences and specifically constructed vectors for subsequent cloning and expression become 
available, the process of producing recombinant Igs can nowadays be faster and more flexible. 
cDNA-based vector systems have been also used to express chimeric murine (V)-human (C) Abs 
under CMV promoter direction (McLean et al., 2000; Preston et al., 1998; Norderhaug et al., 
1997). Also, in vitro Ab expression requires cloning of Ig (V and C) gene fragments into 
eukaryotic cell expression plasmids containing specifically constructed functional sequences, 
including those encoding an Ig promoter (for transcription control), an Ig intron leader (allowing 
for secretion of fusion protein), a poly(A) signal (for transcription termination), an origin of 
replication, and antibiotic resistance markers (for clone selection) (Tiller et al., 2008; Wrammert 
et al., 2008). Several such Ig expression vectors have been developed (Tiller et al., 2008; 
McLean et al., 2000; Persic et al., 1997). However, Ig expression vectors lacking intron 
sequences have generally yielded a low level of secreted Abs (Gillies et al., 1989; Neuberger and 
Williams, 1988). In this study, we took advantages of these techniques to successfully create and 
produce four complete recombinant chimeric cDNA gene constructs consisting of rhesus 
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macaque IgG CH region genes in combination with the murine VH region genes whose protein 
product direct against the NIP hapten. 
Amplification of rhesus macaques IgG CH gene segments was carried out with 
degenerate primers designed from known conserved regions of IgG CH sequences in humans 
and optimized for sufficient (re)amplification SOE-PCRs. Also, these primers were designed so 
that they would not only amplify Ig gene fragments, but also appropriately add unique, desirable 
RE sites that overlapped with adjunct fragments or with the cloning and expression vectors – yet 
absent in IgG gene constructs (Persic et al., 1997) – for easy exchange of Ig gene cassettes and 
allowing for straightforward subsequent cloning of DNA constructs. These primers have allowed 
murine V region genes to be fused in frame to rhesus macaque C regions genes to create a single, 
complete IgH chain fragment for cloning and ligation. Additionally, the primers employed were 
also appropriately provided with sequence extensions for overlap reactions or were embedded 
with necessary Ig functional element sequences for transcription, transport, and translation. 
The creation of recombinant IgH gene fragment in this study relied on the method for 
splicing two pieces of DNA, SOE-PCR (Yolov and Shabarova, 1990; Yon and Fried, 1989). As 
previously described, this technique is a powerful tool for fusing two short DNA fragments 
whose total length is not greater than 3-4 kb (Kuwayama 2002; Pont-Kingdon, 1997), which is 
ideal for creating IgH gene region. Using sequential SOE-PCRs, we have successfully assembled 
individual DNA fragments with overlapping sequences to generate four recombinant cDNA 
fusion constructs, each encoding a rhesus macaque IgG CH subclass. Constructed plasmids were 
examined by restriction analysis and confirmed by DNA sequence analysis for their sequence 
accuracy and insert orientation. As described in the Materials and Methods section, since the two 
DNA template fragments were introduced at their adjacent end an overlapping sequence, each of 
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them can act as a giant “primer” on the other one. These reactions resulted in the fused DNA 
species to be created in the mixture of early SOE-PCR products. Due to the low concentration of 
the complementary DNA fragments and their shorter sequence (thus, lower melting 
temperature), appearance of the fused DNA species at this stage of SOE-PCR reactions (i.e. 
amplification, not reamplification) would be most successful at a relatively low annealing 
temperature. Indeed, when performed with the annealing temperature of 56
0
C or 58
0
C and a 
magnesium concentration of 2.5 mM, SOE-PCRs that used the two outermost flanking primers 
were generally found to yield minimal nonspecific products while producing desired 
amplification fragments. This melting temperature range should be considered when designing 
degenerate primers. 
In some particular instances, however, such as with IgG3 with which additional primers 
were used, creating a complete recombinant cDNA fragments using these approaches was not 
straightforward: many non-specific DNA species were yielded while little or no desired DNA 
product was produced. In such cases, redesigning internal primers by increasing their overlap 
length (of up to 47-99 nt long; Shevchuk et al., 2004) could improve the (re)amplification 
success rate. This observation is consistent with previous findings (Shevchuk et al., 2004). 
Alternatively, modification of SOE-PCR strategy by adding the flanking primer pairs after 
running of several reactions (i.e. these early runs are with no primers to allow for fusion DNA 
species to pair) could be applied (Shevchuk et al., 2004). Also, in general, we observed that the 
use of equimolar concentrations of DNA template fragments tended to reduce the presence of 
non-specific products. We also note that use of Clontech DNA polymerase generally improves 
the success of amplification compared to using the Taq-based polymerases. Cloning of amplified 
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SOE-PCR products of IgG CH  cDNA fragments into plasmid vectors was also necessary, given 
the slight sequence differences between the IgG subclasses. 
In this study, we used an established pLNOH2 expression plasmid vector that not only 
contains all the essential elements necessary for transcription – including the appropriate intronic 
sequences and the needed splicing signals at the intron boundaries – but also consists of unique 
restriction sites for easy subcloning or straightforward substitution of IgG CH region genes 
(Norderhaug et al., 1997). We have also demonstrated the expression and assembly of full-length 
IgH and IgL to form complete rIgs by a specialized mammalian cell line. The IgH was cloned 
and expressed using a eukaryotic plasmid expression vector. Successful recognition of rIgs by 
whole IgG-specific or IgH-specific conjugate indicate that IgH chains were correctly assembled 
with the IgL chains that were endogenously secreted by J558L cells (these cells express no 
endogenous IgH, hence no intact Abs are secreted). These data proved that IgL and IgH chains 
were produced and were able to covalently associate to make intact (H2L2) IgG molecules. These 
results also indicate that all expressed proteins, throughout the incubation period, were correctly 
folded. Additional experiments, however, are needed to examine if the Abs were glycosylated 
correctly. 
Previous work in our laboratory has used cDNA-based expression systems to produce 
functional recombinant Abs and FcRs (Rogers et al., 2008 and 2006). An early Ig expression 
system was applied to express recombinant Abs composing of NIP-binding V regions and 
macaque IgA CH region genes; the resultant recombinant Abs were able to bind NIP (Rogers et 
al., 2008). In this study, we improved the use of this early Ig expression system by employing 
unique RE sites and made the P2561/2/3 Ig expression system. This system can be used to create 
recombinant Abs possessing rhesus macaque or other NHP polymorphic Ig CH genes for 
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functional characterization of recently recognized high levels of intraspecies variability. Also, 
because our functional Ig gene constructs were transfected into a murine myeloma (i.e. Ab-
producing cells) that endogenously express IgL λ chains, the steps involved in cloning of IgL 
chains could be bypassed, thus avoiding some SOE-PCR and subsequent cloning procedures, 
which are often obstacles in recombinant Ab production. Furthermore, successful production of 
complete chimeric IgG subclasses reactive with purified anti-monkey IgG directed whole IgG or 
IgH and capable of specifically binding to the NIP-BSA hapten, as described in this study, 
confirms that murine IgL λ chain (V and C regions) was successfully engineered into rhesus 
macaque IgH chains while still retained specificity of the original V regions. Since the hapten 
NIP is directed by murine IgL λ chain but not by rhesus macaque IgH regions, the use of this 
specificity would avoid potential detection problems associated with intra- and/or inter-species 
sequence variability within IgH CH domains. Thus, this system would be a useful tool for 
engineering complete recombinant IgG Abs with pre-defined specificity and desired CH regions. 
In conclusions, the Ig cloning and expression systems, and the genetically engineered 
recombinant IgG chimeras created in this study, represent both the foundations and the tools for 
further studies of IgG effector functions, such as activating pathogen-clearance cell-killing 
effector mechanisms through binding corresponding FcγRs, and IgG preferential serum usage 
during various immune responses in the rhesus macaque model. These materials can also be 
utilized for basic studies of Ab structure-function relationship. These potential studies will be 
discussed in more details later in this dissertation. 
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CHAPTER 3                                                                                                                       
RHESUS MACAQUE IGG FC RECEPTORS:                                            
CHARACTERIZATION AND ALLELIC POLYMORPHISMS OF ENCODING GENES 
AND GENERATION OF RECOMBINANT cDNA EXPRESSION VECTORS 
 
(PARTIAL CONTENT OF THIS CHAPTER WAS PUBLISHED AS: 
NGUYEN ET AL., IMMUNOGENETICS 2011;63:351–62) 
 
3.1. Summary 
Macaque models are invaluable for AIDS research. Initial development of HIV-1 
vaccines relies heavily on SIV-infected rhesus macaques. Neutralizing Abs, a major component 
of anti-HIV protective responses, ultimately interact with FcRs on phagocytic and NK cells to 
eliminate the pathogen. Despite the major role that FcRs play in protective responses, limited 
information is available on these molecules in rhesus macaques. In this study, rhesus macaque 
CD64 (FcγRI) and CD32 (FcγRII) homologues were genetically characterized. Presence of 
CD64, CD32, and CD16 (FcγRIII) allelic polymorphisms were also determined in a group of 
nine animals. Results from this study show that the predicted structures of rhesus macaque CD64 
and CD32 are highly similar to their human counterparts. Rhesus macaque and human CD64 and 
CD32 extracellular domains are 94–95% and 88–90% homologous, respectively. Although all 
Cys residues are conserved between the two species, rhesus macaque CD32 exhibits two 
additional N-linked glycosylation sites, whereas CD64 lacks three of them, when compared to 
humans. Three CD64, five CD32, and three CD16 distinct allelic sequences were indentified in 
the nine animals examined, indicating a relatively high level of polymorphism in rhesus macaque 
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FcγRs. Recombinant FcγR gene cDNA constructs were successfully generated and engineered 
into cloning and expression vectors using novel refined plasmid systems. These constructs can be 
cloned into HeLa cells for production of recombinant FcγRs, which will be a useful tool for 
functional studies, including those related to IgG/FcγR interactions and initiation of cellular 
immune responses. Collectively, these results validate rhesus macaques as models for vaccine 
development and Ab responses, while at the same time, underscoring the need to take into 
account the high degree of genetic heterogeneity present in this species when designing 
experimental protocols. 
 
3.2. Materials and methods 
3.2.1. Blood samples, total RNA isolation, reverse transcription, and cDNA synthesis of FcγR 
genes 
Fig. 3.1. shows the major steps involved in identifying and cloning rhesus macaque FcγR 
genes, and in generation of their recombinant cloning and expression plasmid vectors. 
Heparinized blood samples were collected from nine healthy rhesus macaque (Macaca mulatta) 
of different ages housed at the Language Research Center of Georgia State University, Atlanta, 
GA. Animal blood collection was done according to local and federal guidelines. Total RNA was 
extracted from whole blood using QiaAmp RNA Blood Mini kit (Qiagen Inc., Valencia, CA). 
Total RNA (~1–3 μg) was then reverse transcribed into single-stranded cDNA using either oligo 
(dT)15 or random primers, followed by primer extension with the AMV reverse transcriptase 
(Roche Diagnostics North America, Indianapolis, IN), in a total reaction volume of 15–30 μl. 
Next, the resulting first-strand cDNA products were serially diluted and PCR-amplified with 
Expand High Fidelity polymerase (Roche Diagnostics North America, Indianapolis, IN) using  
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Fig. 3.1. Flowchart representation illustrating major steps involved in identifying and cloning 
rhesus macaque FcγR genes, as well as in generation of recombinant FcγR cloning and 
expression plasmid vectors. Individual cDNA gene fragments were first isolated and amplified 
from total RNA extracted from whole blood cells by RT-PCR and PCR using primers that were 
designed based on known conserved regions of corresponding human FcγR gene sequences. 
Resulting cDNA genes were cloned into pCR2.1 TOPO TA cloning vector containing a 
selectable marker sequence, which was used for selection of transformed clones that picked up 
constructs and replicated in competent bacterium cells cultured in medium containing X-gals and 
ampicillin antibiotic. All constructs were verified by DNA sequencing before further steps. For 
generating recombinant molecules, cDNA constructs were firstly amplified from cloning vectors 
by PCR using primers that incorporated appropriate restriction sites (that were used to ligate a 
desired contruct into an expression vector, where it fits exactly between the two restriction sites). 
To make a large quantity of the constructs, resulting recombinant expression vector was then 
transformed back into competent bacterium cells so that they were multiplicated by these cells 
following their division and replication. An appropriate amount of recombinant DNAs were 
made available and ready for mammalian cellular transfection. Some figure pieces are 
reproduced from Smith and Clatworthy, 2010, and from the internet.
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Fig. 3.2. Schematic representation of FcγRIIIa genomic and cDNA structure and of gene 
fragments encoding the extra cellular domains of FcγRI and FcγRII molecules, as well as 
strategy for creating recombinant cDNA fragments. (A) Schematic representation of FcγRIIIa 
genomic and cDNA structure (not drawn to scale). S, signal sequence (encoded in 2 exons); EC, 
extracellular Ig-like domains; TM/CYT, transmembrane/cytoplasmic domains. The intron-exon 
organization of the FcγR genes was inferred from the human and rhesus macaque sequences 
publicly available. The necessary splice sites found at intron boundaries and the sequences of the 
introns  were removed. (B) Diagrammatic representation of gene fragments encoding the extra 
cellular domains of FcγRI and FcγRII molecules and strategy for creating recombinant cDNA 
fragments. Name, direction (horizontal black arrows), and relative positioning/location (colorful 
numbers) of primers as well as corresponding amplified PCR products are depicted. The final 
recombinant constructs were amplified in SOE-PCRs using the outermost flanking primers. The 
sequences of primers used are given in Table 3.1.
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appropriate oligonucleotide primer pairs (see below) in a total of 50 or 100 μl reaction volume. 
PCR conditions were as follows: after initial denaturation at 95°C for 10 min, the cDNAs were 
amplified for 40 cycles, with each cycle consisting of 94°C for 1 min, 56°C for 1 min, and 72°C 
for 2 min and 30 s. To ensure complete extension, a final step at 72°C for 10 min was applied. At 
least two independent RT-PCR reactions using the same total RNA were performed, and from 10 
to 15 independent cDNA clones per individual macaque and from each of two separate PCR 
reactions were analyzed. These steps were performed to rule out that the putative allelic 
polymorphisms were due to a PCR amplification artifact. 
 
3.2.2. Design of primers 
Primers for amplification of macaque FcγRI (CD64) and FcγRII (CD32) genes were 
designed from the corresponding human sequences (assuming conserved homology between 
primates) (Fig.3.2). The terminal sense and antisense FcγRII/FcγRI primers are located within 
the start of the leader region (exon 1) and within the end of the cytoplamic region (FcγRII exon 5 
and FcγRI exon 6), respectively, of the cDNAs shared by multiple human FcγRIIa/FcγRIa 
sequences (Table 3.1). Internal primers for each of these two receptors were situated within exon 
4, which encodes the [D2] domain of CD32, or exon 5, which encodes the [D3] domain of 
CD64. Using these primer sets, the PCR amplification product should span most of the FcγRII or 
FcγRI-targeted cDNAs (covering from exon 1 to the most 3′ exon). Specifically, the CD32.1 and 
CD32.2 primer pair was used to generate a 566-bp product spanning the first part of FcγRII, 
beginning from the leader region. CD32.3 and CD32.8 primer pair would amplify a 502-bp 
fragment that had a 191-bp overlapping sequence with the fragment produced by CD32.1 and 
CD32.2, and that spanned the second part of FcγRII, including the CO-TM-CYT region. 
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Similarly, two FcγRI fragments that had a 194-bp overlapping sequence were amplified by the 
use of CD64.1 and CD64.4 (yielding an 800-bp fragment) and CD64.9 and CD64.10 (generating 
a 424-bp fragment) primer pairs. For FcγRIII, primers included FCG3aF (located within the start 
of the leader region) and FCG3aR (located within the end of the cytoplamic region). All primers 
were designed to generate FcγRIIa, FcγRIa, and FcγRIIIa homologue products, and were used 
for each individual animal of the nine macaques examined. 
 
3.2.3. Cloning and sequencing of amplified FcγR cDNAs 
Appropriate volume of PCR reactions were run on a 2% agarose gel and the bands of 
interest (showing expected size) were excised and purified using QIAquick Gel Extraction kit 
(Qiagen Inc., Valencia, CA) using a microcentrifuge. The purified PCR products were then 
cloned into the pCR2.1 TOPO TA cloning vector (Invitrogen, Carlsbad, CA) for sequencing 
analysis purpose. The plasmids were transformed into Top10 E. Coli chemically competent cells 
using TOPO TA Cloning and One Shot Chemical Transformation following the manufacturer's 
protocols (Invitrogen, Carlsbad, CA). Subsequently, 10–15 inserted, positive colonies from each 
sample were picked and incubated overnight in LB culture tubes at 37°C in a shaking rotary 
incubator (200–230 rpm). The minipreps DNA Purification System kit (Promega Corporation, 
Madison, WI) was used to purify plasmid DNA, and the plasmid DNA was then screened on a 
1% agarose gel after digestion with EcoRI to confirm the inserted fragment size. All DNA 
sequences were determined using the ABI Prism Dye Termination Cycle Sequencing kit and on 
an ABI model 3100 automated sequencing apparatus (PerkinElmer, Wellesley, MA). Sequencing 
primers were those used for PCR amplifications and the forward and reverse M13 primers. 
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Table 3.1. Primers used for amplification of rhesus macaque FcγRa cDNAs. 
   Primer Name                    Sequence (5’-3’)                     Product size (bp)        Position                     Location                    Accession numberc 
   FCG3aF (fw)b        ATGTGGCAGCTGCTCCTCCCA              765                (-51)-(-31)             L-encoded region                DQ423379.1 
   FCG3aR (rv)           TCATTTGTCTTGAGGGTCCTT                                      (714)-(694)            CYT-encoded region          DQ423379.1 
   CD32.1 (fw)       TTTTGCTGCTGCTGGCTTCTGC             556                (-32)-(-11)             L-encoded region                BC020823.1 
   CD32.2 (rv)        ATGCTGGGCACTTGGACAGTGATG                            (527)-(504)            [D2]-encoded exon 4          BC020823.1 
   CD32.3 (fw)       AAGGACAAGCCTCTGATCAAGGTC    502               (337)-(360)            [D2]-encoded exon 4     XM_001118066.2 
   CD32.8 (rv)        TGACATGGTCGTTGGGAGGAAG                                 (838)-(817)            CYT-encoded region          BC020823.1 
   CD64.1 (fw)       GACAGCTCTGCTCCTTTGGGTTC         800                  (-40)-(-18)             L-encoded region               NM_000566.3 
   CD64.4 (rv)        AGGACATTTCCGTCTTCTGTGG                                   (758)-(737)            [D3]-encoded exon 5         NM_000566.3 
   CD64.9 (fw)       AATCTGGTCACCCTGAGCTGTG           424               (565)-(586)            [D3]-encoded exon 5         NM_000566.3 
   CD64.10 (rv)      AATGTCTGTCTTCTTGAAGGCTGG                              (988)-(965)            CYT-encoded region         NM_000566.3 
 
a
Abbreviation and full gene designations are the following: FcγRI: IgG Fc high affinity I receptor (CD64); FcγRII: IgG Fc low affinity 
II receptor (CD32); FcγRIII (or FCG3a): IgG Fc low affinity III receptor (CD16). 
b
fw, forward direction; rv, reverse direction. 
c
GenBank accession number for the reference sequences used for designing primers.
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3.2.4. Construction of rhesus macaque FcγR cloning vector 
The complete CD64 and CD32
 
 extracellular domain cDNA gene fragments were 
generated by SOE-PCR ligating two separate fragments containing overlapping short sequences, 
which were produced by PCRs using the appropriate primer pairs (CD64.1 and CD64.10, and 
CD32.1 and CD32.8; Fig. 3.2 and Table 3.1). The CD16 cDNA fragment was directly amplified 
from relevant sequencing-verified plasmids. To facilitate transfer of these FcγR cDNA fragments 
from TOPO TA cloning vector into expression vectors, HindIII and BamHI restriction sites were 
introduced to their 5' and 3' ends, respectively, by PCRs
 
using forward FCG3FHind and
 
reverse 
FCG3RBam primers (Table 3.2 and Fig. 3.3) on the appropriate cloning vector previously 
generated. Also, additional FcγR cDNA fragments were incorporated with NotI and XhoI 
restriction sites to their 5' and 3' ends, respectively, following a similar strategy with the use of 
FcγR.NotI and FcγR.XhoI primers (Table 3.2 and Fig. 3.4). Resultant FcγR cDNAs (i.e. 
consisting of the two added restriction sites: HindIII and BamHI, or NotI and XhoI) were then 
run on a 1% gel, extracted, and put into pCR2.1 TOPO TA cloning vectors, and were 
subsequently transformed into Top10 E. Coli chemical competent cells for cloning again, 
following previously described procedures. 
 
3.2.5. Construction of rhesus macaque FcγR expression plasmid systems using pcDNA3.1(+) 
(HindIII/BamHI), as well as pcDNA3.1(+) (Not/Xho) and P2561/2/3 (Not/Xho) vectors 
To create expression vectors, the newly RE-added FcγR cDNA gene fragments were 
excised from the pCR2.1-TOPO TA cloning vector clones with correct
 
sequences by sequential 
digestion with
 
HindIII and BamHI and cleaned up on a 1% agarose gel (Fig. 3.3). Plasmids were 
purified using the QIAprep spin miniprep kit (Qiagen Inc., Valencia, CA) and bands containing
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Table 3.2. Primers used for generation of rhesus macaque FcγR recombinant DNA constructs by SOE-PCR amplifications. 
 
a
fw, forward direction; rv, reverse direction. 
b
Bold and underline, restriction endonuclease sequences; bold and italic, with or without underline, overlapping (“homologous”) 
region with the relevant primer indicated in “Sequence characteristics” column. 
c
An (ATG) start codon needed for proper initiation of translation and a stop (TGA) codon necessary for proper termination. 
Primer 
name
a 
Sequence (5’-3’ direction)b Specificity Sequence characteristicsc 
FcγR.FHind 
(fw) 
AGATAAGCTTGATATGTGGCAGCTGCTCCTCCCA 
5’; 
FcγRIIIa 
Containing HindIII site (5’-AAGCTT-3’) 
Containing full 21-bp sequence of FCG3aF 
Containing an ATG start codon 
FcγR.RBam 
(rv) 
TCTAGGATCCTCATTTGTCTTGAGGGTCCTT 
3’; 
FcγRIIIa 
Containing XhoI site (5’-GGATCC-3’) 
Containing full 21-bp sequence of FCG3aR 
Containing a TGA stop codon 
CD32.NotI 
(fw) 
ATTAGCGGCCGCATAATGACTATGGAGACCCAAATGTCTCA
GAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGAC
AGTTTTGCTGCTGCTGGCTTCTGC 
5’; 
FcγRII 
Containing NotI site (5’-GCGGCCGC-3’) 
Containing full 22-bp sequence of CD32.1 
Containing an ATG start codon 
CD32.XhoI 
(rv) 
ACTCGACTCGAGTTATTAGTTATTACTGTTGACATGGTCGTT
GGGAGGAAG 
3’; 
FcγRII 
Containing XhoI site (5’-CTCGAG-3’) 
Containing full 22-bp sequence of CD32.8 
Containing a TGA stop codon 
CD64.NotI 
(fw) 
ATTAGCGGCCGCATAATGTGGTTCTTGACAGCTCTGCTCCTT
TGGGTTC 
5’; 
FcγRI 
Containing NotI site (5’-GCGGCCGC-3’) 
Containing full 23-bp sequence of CD64.1 
Containing an ATG start codon 
CD64.XhoI 
(rv) 
ACTCGACTCGAGTTATTACTACGTGGCCCCCTGGGGCTCCTT
CCGGTGCACCCCTTCCTGCAGCTGTTCTTCTTTTTGTTCCTGA
CATTTCAGCTCTTCTTCTAAATGTCTGTCTTCTTGAAGGCTGG 
3’; 
FcγRI 
Containing XhoI site (5’-CTCGAG-3’) 
Containing full 24-bp sequence of CD64.10 
Containing a TGA stop codon 
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Fig. 3.3. Schematic representation of major steps in generation of recombinant expression 
plasmid vector pcDNA3.1-FcγR-Hind/Bam (not drawn to scale). The FcγR constructs were 
PCR-amplified from the appropriate TOPO vectors using forward primer FcγR.FHind 
(containing HindIII restriction site in its 5’ end) and reverse primer FcγR.RBam (containing 
BamHI restriction site in its 5’ end), as indicated. Resultant PCR products were then incorporated 
into pcDNA3.1 vector previously digested with both HindIII and BamHI REs. Recombinant 
constructs are therefore encoded within the HindIII-BamHI sites of resulting recombinant 
expression vector. 
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FcγR DNAs of the correct size were extracted using a QIAquick gel extraction kit (Qiagen Inc., 
Valencia, CA). The extracted cDNAs were then cloned
 
into the HindIII- and BamHI-digested 
(i.e. within the multiple cloning site) expression vector pcDNA3.1(+), which contain SV40 ori 
and CMV promoter (Invitrogen, Carlsbad, CA). Similar procedures were applied on expression 
vectors pcDNA3.1(+) and P2561/2/3 using NotI and XhoI instead of HindIII and BamHI REs, as 
appropriately (Fig. 3.4). Ligations were performed using T4 DNA ligase (Roche Diagnostics 
North America, Indianapolis, IN) overnight at 14
0
C. Resultant FcγR expression vectors were 
then transformed into Top10 E. Coli chemical competent cells (Invitrogen, Carlsbad, CA) by 
heat shock, as previously described in production of recombinant IgGs. Miniprep DNAs derived 
from the colonies were screened for successful insertion and correct orientation by PCR and RE 
digestions of plasmids using appropriate enzymes, followed by confirmation by DNA 
sequencing in both forward and reverse directions across fusion points with selected FcγR 
primers (and/or pcDNA3.1 T7 and
 
T7 reverse primers). All constructs verified by sequence 
analysis were produced in large quantities of expression vectors using EndoFree Plasmid Maxi 
kits (Qiagen Inc., Valencia, CA), to be used for transfection into HeLa cells by electroporation 
method. 
 
3.2.6. Sequence analysis 
MacVector software (Accelrys Inc., San Diego, CA) and BioEdit program 
(http://www.mbio.ncsu.edu/bioedit/bioedit.html) were used to identify overlapping regions and 
edit sequences. Sequences were aligned with each other within the same receptor group and with 
other known counterparts using the CLUSTAL function of the MEGALIGN, part of the 
LASERGENE software package (DNASTAR Inc., Madison, WI). Construction of the
163 
 
 
                  
164 
 
 
Fig. 3.4. Schematic representation of major steps involved in generation of the recombinant 
expression plasmid vectors pcDNA3.1-FcγR-NotI/XhoI and P2561/2/3-FcγR (not drawn to 
scale). The FcγR constructs were PCR-amplified from the appropriate TOPO vectors using 
forward primer FcγR.NotI (containing NotI restriction site in its 5’ end) and reverse primer 
FcγR.XhoI (containing XhoI restriction site in its 5’ end), as indicated. Resultant PCR products 
were then ligated into pcDNA3.1(+) or P2561/2/3 vectors previously digested with both NotI and 
XhoI REs. The recombinant constructs are therefore encoded within the NotI-XhoI sites of 
resulting recombinant expression vectors.
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phylogenetic tree was also based on the use of the LASERGENE's MEGALIGN part. Prediction 
of potential glycosylation site was performed online using EnsembleGly website 
(http://turing.cs.iastate.edu/EnsembleGly/; Caragea et al., 2007). Standardized nomenclature, 
labels, and numbering of IMGT®, the international ImMunoGeneTics information system® 
(http://www.imgt.org) (Lefranc et al., 2009) were used to display and discuss sequencing data 
based on human reference sequences. Allelic polymorphisms and characteristic positions of the 
C-like domains were described using the IMGT unique numbering for C domain (C-DOMAIN 
of IG and T cell receptors (TR) and C-LIKE-DOMAIN of IgSF other than IG and TR) (Lefranc 
et al., 2005). 
 
3.3. Results 
We identified macaque FcγR at the cDNA level and examined whether allelic 
polymorphisms were present by analyzing PCR-amplified cDNA sequences. These sequences 
were obtained from reverse transcription of whole blood total RNA extracts, followed by PCR 
amplification using primers complementary to human sequences located within the beginning L 
and the ending CO-TM-CYT exons. All PCR amplifications were successful in each of the nine 
animals examined. The introduction of PCR artifacts was minimized by the use of a high-fidelity 
polymerase with proofreading ability, and by carrying out separate PCRs and multiple clone 
selections for each individual animal. The cDNA sequences determined in the present study are 
available as GenBank accession numbers HQ423386- HQ423388 (FcγRIII), HQ423389-
HQ423393 (FcγRII), and HQ423394-HQ423396 (FcγRI).  
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Fig. 3.5. Nucleotide and deduced amino acid sequences of rhesus macaque Fcγ receptor I 
(FcγRI, CD64) (GenBank accession number: HQ423396). Nucleotides are numbered at right and 
amino acids are numbered throughout. The amino acid numbering is in accordance with the 
IMGT unique numbering system for Ig C-like domains (Lefranc et al., 2005). Following the N-
terminal signal sequence (a 13 amino acid part is shown doubly underlined) is the extracellular 
portion of ~270 amino acids in length. The predicted start site of the mature protein is indicated 
by the number “1” below the amino acid A. +1, above the nucleotide sequence, indicates the start 
of the extracellular chain. Underlined Cs indicates cysteines (n=6) that have potential to form 
intra-chain disulfide bonds. Potential N-linked glycosylation sites (n=4; Caragea et al., 2007) (N-
x-S/T) are represented by single-line broken boxes. Boxes with broken double line (n=3) denote 
potential N-linked glycosylation sites recognized in humans only. The underlined sequence 
represents the CO-TM region. The two over-line arrows at the beginning and the end of the 
nucleotide sequence represent the binding regions and directions for the designed CD64.1 
(forward) and CD64.10 (reverse) primers, respectively. The other two over-line arrows in the 
middle of the sequence denote internal primers [CD64.9 (forward) and CD64.4 (reverse), in that 
order]. Arrowheads indicate the allelic positions at which the polymorphic residues (represented 
by amino acids displayed below and in parentheses) identified in this work are present.
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3.3.1. Rhesus macaque FcγRI (CD64) and FcγRII (CD32) cDNA clones exhibit the typical 
mRNA primary structure of their human counterpart 
Using the primer sets which were designed based on human FcγRII gene sequences, we 
identified an almost full-length macaque FcγRII homologue cDNA. The molecule contains 865 
bp, encoding a 288-amino acid protein (Fig. 3.6; shown is a representative sequence). The 
structure of the deduced amino acid sequence was inferred by analogy to published human 
sequences. It was found extensively similar to that described for human FcγRIIa mRNA 
structure, typical of type I membrane IgSF C-like domain proteins. The first 12-amino acid 
stretch, which formed the partial putative N terminal leader (L) region, is followed by a predicted 
mature protein. The mature protein is composed of an extracellular portion of 176 amino acids, 
which, as previously described for the human counterpart receptor, contains two extracellular 
domains, namely [D1] and [D2]. 
As expected, four cysteines (C26, C68, C107, and C151), that have potential to form the 
characteristic C-like intradomain disulfide bonds, are conserved in the extracellular portion (1st-
CYS 23 and 2nd-CYS 104 in the IMGT unique numbering; Lefranc et al., 2005). The conserved 
C-like domain structure suggests that disulfide bonds are formed between C26 and C68 and 
between C107 and C151 in [D1] and [D2], respectively. The conserved C-like extracellular 
portion is followed by a relatively short segment of 32 amino acids (AA) that, by analogy to 
human CD32a, represents the connecting region (CO) of 10 AA and the transmembrane region 
(TM) of 22 AA. The remaining amino acids of the deduced sequence form the partial C-terminal 
cytoplasmic (CYT) region. Three potential N-linked glycosylation sites are conserved between 
humans and macaques, two of which, [D1] N97 and [D2] N95 (IMGT unique numbering; 
Lefranc et al., 2005) are present in the extracellular portion, whereas the third one, [CYT] N10, 
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located in the CYT region, has probably no functional significance (Table 3.3). Macaques carry 
two additional N linked glycosylation sites [D2] N77 and N88 (resulting from amino acid 
changes) compared to humans (Table 3.3 and Fig. 3.6). However, these two positions are 
polymorphic: the first one, [D2] 77, in rhesus macaques, the N glycosylation site being or not 
present, whereas the second one, [D2] 88, is polymorphic in humans, and may have an N-
glycosylated site as shown in the ‘2fcb’ 3D structure (IMGT/3Dstructure-DB; Ehrenmann et al. 
2010). As in humans, two YxxL signatures, separated by 11 amino acids and representing a 
typical immunoreceptor tyrosine-based activation motif (ITAM; YxxLx(7–12)YxxL), are present 
in the CYT region. 
Similar to FcγRII, macaque FcγRI cDNA clones also show a typical human FcγRI 
mRNA organization (Fig. 3.5). The obtained 1,027-bp-encoded 342-amino acid polypeptide 
starts with a putatively partial leader region of 13 residues, followed by the extracellular region 
consisting of three domains [D1], [D2], and [D3] and is 267 amino acids in length, ending with a 
CO region (7AA), a TM region (23 AA) and a partial CYT region. As in humans, six cysteines 
(C26 and C68, C107 and C151, as well as C195 and C243), each pair of which (1st-CYS 23 and 
2nd-CYS 104 in the IMGT unique numbering; Lefranc et al., 2005) forms disulfide bonds of the 
[D1], [D2] and [D3] domain, respectively, are conserved in macaques. However, only four 
potential N-linked glycosylation sites, [D1] N44, [D2] N95, [D3] N6 and N80 (Table 3.3 and 
Fig. 3.5), are present in macaques as compared to the seven present in humans. 
Together, these results show that rhesus macaque FcγRII and FcγRI cDNA clones exhibit 
the typical mRNA primary structure/organization of their corresponding human receptor.
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Fig. 3.6. Nucleotide and deduced amino acid sequences of rhesus macaque Fcγ receptor II 
(FcγRII, CD32) (GenBank accession number: HQ423393). Nucleotides are numbered at right 
and amino acids are numbered throughout. The amino acid numbering is in accordance with the 
IMGT unique numbering system for Ig C-like domains (Lefranc et al., 2005). Following the N-
terminal signal sequence (a 12 amino acid part is shown doubly underlined) is the extracellular 
portion of ~180 amino acids in length. The predicted start site of the mature protein is indicated 
by the number “1” below the amino acid A. +1, above the nucleotide sequence, indicates the start 
of the extracellular chain. Underlined Cs (n=4) indicates cysteines that have the potential to form 
intra-chain disulfide bonds. Potential N linked glycosylation sites (n=5; Caragea et al., 2007) (N-
x-S/T; x denotes any amino acid) are represented by broken boxes, of which those with broken 
double-line (n=2) denote potential N-linked glycosylation sites not recognized in humans. The 
underlined sequence corresponds to the CO-TM region. Closed boxes illustrate the two YxxL 
signatures, separated by 11 amino acids in the intracellular cytoplasmic tail, which represent a 
typical immunoreceptor tyrosine-based activation motif (ITAM; YxxLx(7–12)YxxL) in the 
molecule. The two over-line arrows at the beginning and the end of the nucleotide sequence 
represent the binding regions and directions for the designed CD32.1 (forward) and CD32.8 
(reverse) primers, respectively. The other two over-line arrows in the middle of the sequence 
denote internal primers [CD32.3 (forward) and CD32.2 (reverse), in that order]. Arrowheads 
indicate the allelic positions at which the polymorphic amino acids (represented by amino acids 
displayed below and in parentheses) identified in this work are present. The closed black circle 
indicates a functional polymorphic amino acid in human CD32 (131 H/R), known to define the 
specificity of human CD32 for IgG2. 
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3.3.2. The rhesus macaque CD64 and CD32 extracellular C-like, ligand-binding portion 
shares high homology with that of human CD64 and, to a lesser degree, CD32, respectively 
We compared the FcγRI and FcγRII deduced amino acid sequences obtained from all 
nine macaques examined with the corresponding sequences in humans. The IMGT Collier de 
Perles representation of CD32 and CD64 [D1] and [D2] domains are shown in Fig. 3.7. This 
representation allows to locate amino acids within a topological context by bridging the gap 
between linear amino acid sequences and 3D structures (Kaas et al., 2007). Figures 3.9, 3.10, 
3.11, and 3.12 show that rhesus macaque deduced proteins display totally conserved intron–exon 
boundaries and exhibit high homology in sequence compared to their human counterparts. For 
the extracellular portion alone, amino acid comparisons between these two primate species 
revealed a high level of similarity, which were ~88–90% for CD32 (18–22 changes in the entire 
176-amino-acid extracellular region) and ~94–95% for CD64 (14–16 changes in the entire 267-
amino-acid extracellular region) (percentage ranged depending on the alleles considered in 
comparison). For macaque CD32, these amino acid differences are distributed equally (n=8 to 
11) between [D1] and [D2] domains (Fig. 3.10). However, for CD64, while each of the two first 
domains [D1] and [D2] show relatively equivalent number (n=6 to 8) of amino acid 
differences(compared to humans), its third domain [D3] displays the least change (n=2) (Fig. 
3.9). The TM region in macaque CD32 and CD64 share ~83% (number of amino acid 
differences, n=5) and 93% (n=2) identity with that in humans, respectively. Thus, the number of 
macaque/human amino acid differences in these two receptors is substantially lower in the TM 
region than in the C-like domains.No attempt was made for comparing the L or CYT region 
sequences, as when designing primer sets, we did not aim to confirm the full length of the 
receptors (several residues at L and CYT terminals were not present in the final cloning 
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products). As mentioned above, two additional potentially glycosylated N are observed in 
macaque CD32 (Fig. 3.6). In contrast, two residues of this type are replaced by other amino acids 
in CD64 (Fig. 3.5). Furthermore, replacement of human [D2] T101 (148) in CD64 with A in 
macaques results in breaking of the potential N-linked glycosylation motif of [D2] N99 in the 
receptor. These amino acid changes are present in all animals examined, with the exception of 
the polymorphic amino acid CD32 [D2] 77 (128 in sequence). 
All but one of the human CD32a amino acids known to be crucial for IgG binding 
(Maxwell et al., 1999) are conserved in macaque CD32. These residues include: [D2] K29 and 
P30 (BC loop), S79 and D82 (D strand), and Y113 (FG loop) (113, 114, 130, 133, and 157 in 
sequence, respectively), which presumably directly contact the IgG Fc ligand; [D2] L36, P87 and 
I108 (115, 134, and 155 in sequence), which presumably have the ability to affect conformation 
of the loops; [D2] H80 (131 in sequence) (D strand), the established low-responder polymorphic 
allele (Fig. 3.6). The only exception is at position [D2] 81 (132 in sequence): it is L in humans 
but M in macaques. [D2] M81 is found in all nine macaques examined. It is noteworthy that all 
nine examined macaques display [D2] H80 (131 in sequence) (Fig. 3.10), the well known IgG2 
low-responder polymorphic allele in humans (Warmerdam et al., 1991). Because no human 
CD64a crystal structure has been solved to date (Ellsworth et al., 2010), and thus no specific 
residues crucial for ligand binding have been established, it is not possible to identify potential 
conserved IgG-binding amino acids in the macaque CD64 sequence. However, at least three 
binding interface residues in [D2], W3, W26, and K77 (87, 110, 128 in sequence) found to be 
totally invariant among all human FcγRs (Radaev et al., 2001), are completely conserved in all 
nine macaque CD64 proteins (Fig. 3.9). These amino acids are also conserved in most macaque 
CD32 proteins examined (Fig. 3.10).
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Table 3.3. Correspondence between sequence positions and IMGT unique numbering for potential N-linked glycosylation sites in 
rhesus macaque FcγRsa. 
 
Position
 
 
CD32 domains CD64 domains
 
[D1]
 
[D2]
 
[CYT] [D1]
 
[D2]
 
[D3]
 
In sequences 61 128 135 142 213 42 142 178 223 
In IMGT 97 77 88 95 10 44 95 6 80 
Compared 
to human 
Conserved 
Polymor-
phic 
Polymor-
phic 
Conserved Conserved Conserved Conserved Conserved Conserved 
 
a
Abbreviation and full gene designations are the following: FcγRI: IgG Fc high affinity I receptor (CD64); FcγRII: IgG Fc low affinity 
II receptor (CD32); FcγRIII: IgG Fc low affinity III receptor (CD16).
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Table 3.4. Location and type of allelic polymorphism present in rhesus macaque FcγRsa. 
FcγR 
(total novel 
polymorphism)
c 
[D1] amino acid positions (number of animals)
b 
[D2] amino acid positions (number of animals)
 
6 
(5)
d 
18 
(15.2) 
55 
(90) 
60 
(96) 
75 
(117) 
79 
(121) 
92 
(8) 
93 
(9) 
119 
(40) 
125 
(46) 
126 
(47) 
128 
(77) 
133 
(82) 
140 
(93) 
CD16 (2) ----- ----- ----- ----- 
L/P 
(1) 
----- 
A/T 
(2) 
----- ----- ----- ----- ----- ----- ----- 
CD32 (9) ----- ----- 
M/R 
(4) 
----- ----- 
V/I 
(1) 
----- 
T/P 
(3) 
A/T 
(1) 
K/I 
(5) 
S/A 
(1) 
N/K 
(5) 
N/D 
(4) 
Q/R 
(4) 
CD64 (3) 
V/G 
(1) 
Q/R 
(1) 
----- 
V/A 
(1) 
----- ----- ----- ----- ----- ----- ----- ----- ----- ----- 
 
a
Abbreviation and full gene designations are the following: FcγRI: IgG Fc high affinity I receptor (CD64); FcγRII: IgG Fc low affinity 
II receptor (CD32); FcγRIII: IgG Fc low affinity III receptor (CD16). 
b
Number of individual animals (among of the nine animals examined) whose sequences exhibit polymorphism. 
c
Number of novel allelic polymorphic amino acids that were identified in this work. 
d
Numbers in parentheses indicate the IMGT positions per domain (Lefranc et al., 2005). 
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Together, these data show that the extracellular C-like, ligand-binding portion of rhesus 
macaque CD64 and CD32 shares extensive homology with that of human CD64 and, to a lesser 
degree, CD32, respectively. 
 
3.3.3. A relatively high level of intra-species polymorphism is present in macaque FcγR 
sequences 
Nine (M55R, V79I, T93P, A119T, K125I, S126A, N128K, N133D, and Q142R) or three 
(V6G, Q18R, and V60A) allelic polymorphic residues were identified from all examined 
macaque FcγRII or FcγRI alleles, respectively (Table 3.4). In CD64, all variable residues occur 
in membrane-distal [D1], whereas in CD32, most (seven out of nine) allelic polymorphic sites 
are clustered on a short segment in the membrane-proximal [D2] domain (Table 3.4, Fig. 3.10, 
and Fig. 3.12). Unlike FcγRII and FcγRI, the macaque FcγRIII sequence and a number of its 
allelic polymorphisms have recently been described (Miller et al., 2007; Rogers et al., 2006b). In 
the present study, two previously unreported CD16 allelic variants at the amino acid level were 
identified from the nine macaques examined: most macaques carry [D1] L117 (75 in sequence) 
and [D2] A8 (92 in sequence), whereas one of the animals exhibits [D1] P117 and two animals 
exhibit [D2] T8 in their CD16 domains (Table 3.4, Fig. 3.11, and Fig. 3.12). 
Among the nine macaques examined, five (CD32) and three (CD64 and CD16) distinct 
allelic sequences, differing by at least one amino acid, were recognized (Fig. 3.9 and 3.10, and 
data not shown). 
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Fig. 3.7. IMGT Colliers de Perles of rhesus macaque CD32 (FcγRII) C like [D1] (I), and [D2] 
(II) as well as CD64 (FcγRI) C-like [D1] (III), [D2] (IV) and [D3] (V) domains (on one layer; 
obtained with the IMGT/Collier-de-Perles tool in the IMGT/DomainGapAlign) (Ehrenmann et 
al., 2010). Colliers de Perles is the 2D graphical representations of IG and TR V, C domains, 
highlighting conserved amino acids. The conserved C (position 23), and C (position 104), are 
indicated. Shaded circles or squares represent positions at which hydrophobic amino acids (I, V, 
L, F, C, M, A) and W are found in more than 50% of analyzed IgSF sequences. The BC loop, 
CD transversal strand, and FG loop are limited by amino acids displayed in squares. Hatched 
circles indicate missing positions according to the IMGT unique numbering for C-DOMAIN and 
C-LIKE-DOMAIN (Lefranc et al., 2005). Arrows indicate the beta-strand direction.
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Fig. 3.8. A phylogenetic tree indicating the amino acid sequence similarity among independent 
allelic variants of macaque FcγR molecules identified in this study. Also included are a 
representative human corresponding receptor and a computationally predicted CD32 and CD64-
like sequences (see Figures 3.5 and 3.6 for GenBank accession numbers of these sequences). 
Phylogenetic distances were computed from the CD32 and CD64 amino acid sequences aligned 
in Figures 3.6 and 3.5. For CD16, a representative human (“CD16aHu”; GenBank accession 
number: AK291451.1) and macaque CD16 are included (“CD16Rogers2006”; GenBank 
accession number: ABD83659). The numbers next to the branches indicate the percentage of 
replicate trees. The evolutionary distance bar denotes the number of substitutions per site.
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                       A        AB     B          BC         C     CD       D         E           F         FG            G 
                    (1-15)          (16-26)    (27-38)    (39-45)        (77-84)   (85-96)     (97-104)  (105-117)    (118-128) 
                ———————————————>   ——————————>             ——————>       —————>   —————————>   ——————>               —————————> 
                1         10  15   16      26  27      36  39   45       77   84  85 89    96 97    104 105       117 118    127 
       87654321 | ........|....|123|.........| |........|  |.....|1234567|......|  |...|......| .......| |...........| |.........| 
Human D1      D T TKAVITLQPPWVSVFQ.EETVTLHCEVL HLPG...SSS  TQWFLNGTA.....TQTST... ..PSYRITSASV NDSGEYRC QRGL......SGR SDPIQLEIHR 
Rhe9  D1      - - ----------------.------Q---P R---...---  ---------......-----.. ..---------- K------- ---P......--- ---------- 
Rhe3  D1      - - ---G------------.------Q---P R---...---  ---------......-----.. ..---------A K------- ---P......--- ---------- 
Rhe8  D1      - - ---------------R.------Q---P R---...---  ---------......-----.. ..---------- K------- ---P......--- ---------- 
RheP  D1      - - ---------L------.------Q---P R---...---  ---------......-----.. ..---------A K------- ---P......--- ---------- 
 
Human D2        (G)WLLLQVSSRVFTE...GEPLALRCHAW KDKL...VYN  VLYYRNGKAF....KFFHWN.. ..SNLTILKTNI SHNGTYHC SGMGK....HRYT SAGISVTVKE 
Rhe9  D2        (D)-------------...----------- ----...---  -----Q----....----YR.. ..--Q------- -----A-- -----....---- ----V----- 
Rhe3  D2        (D)-------------...----------- ----...---  -----Q----....----YR.. ..--Q------- -----A-- -----....---- ----V----- 
Rhe8  D2        (D)-------------...----------- ----...---  -----Q----....----YR.. ..--Q------- -----A-- -----....---- ----V----- 
RheP  D2        (D)-------------...----------- ----...---  -----Q----....----YR.. ..--Q------- -----A-- -----....---- ----V----- 
 
Human D3      LFT APVLNASVTSPLLE...GNLVTLSCETK LLLQ..RPGL  QLYFSFYMGSKTL.RGRNTS.. ..SEYQILTARR EDSGLYWC EAATED.GNVLKR SPELELQVL 
Rhe9  D3    --- --------------...----------- ----..----  -------------.------.. ..---------- ----F--- --T---.------ --------- 
Rhe3  D3    --- --------------...----------- ----..----  -------------.------.. ..---------- ----F--- --T---.------ --------- 
Rhe8  D3    --- --------------...----------- ----..----  -------------.------.. ..---------- ----F--- --T---.------ --------- 
RheP  D3    --- --------------...----------- ----..----  -------------.------.. ..---------- ----F--- --T---.------ --------- 
 
Human CO-TM-CY  GLQLPTP VWFHVLFYLAVGIMFLVNTVLWV TIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRH 
Rhe9  CO-TM-CY  ------- --L------V------------- ------------N-------A-----T-------- 
Rhe3  CO-TM-CY  ------- --L------V------------- ------------N-------A-----T-------- 
Rhe8  CO-TM-CY  ------- --L------V------------- ------------N-------A-----T-------- 
RheP  CO-TM-CY  ------- --L------V------------- ------------N-------A-----T-------- 
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Fig. 3.9. Alignment of the deduced amino acid sequences of rhesus macaque CD64 (FcγRI) 
(GenBank accession numbers: HQ423394-HQ423396) (obtained by cloning and sequencing 
whole blood cDNAs) with a human CD64a representative (shown as “Human”; GenBank 
accession number: AK291451.1). The deduced amino acid sequences of the macaque CD64 are 
compared and residues that differ from the human CD64a sequence are shown. Included are only 
macaque sequences carrying independent allelic polymorphic amino acids (n=3), in which each 
allele has a single polymorphic site or a unique combination of polymorphic sites. A 
computationally predicted macaque CD64-“like” [“RhesusP”; GenBank accession number 
(updated 6/1/2010): XR_013029] was also counted in. Hyphens illustrate identical residues and 
dots represent the IMGT gaps (missing amino acids) inserted to maximize alignment. 
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                      A        AB     B         BC          C     CD      D          E          F         FG            G 
                   (1-15)          (16-26)    (27-38)    (39-45)       (77-84)    (85-96)    (97-104)  (105-117)    (118-128) 
               ———————————————>   ——————————>             ——————>       ——————> ———————————> ———————>              ——————————> 
               1         10  15   16  20 2326 27      36  3941 45       77 80 8485  89    96 97   104 105       117 118    127 
      87654321 | ........|....|123|...|..|..| |........|  |.|...|1234567|..|...||...|......| |......| |...........| |.........| 
Human D1  QA.A P PKAVLKLEPPWINVLQ.EDSVTLTCQGA RSPE...SDS  IQWFHNGNL.....IPTHTQ....PSYRFKANN. NDSGEYTC QTGQ......TSL SDPVHLTVLS 
Rhe9  D1  -TA- - ---------------R.--------G-- H--D...---  T--------.....------....---M-----. ------R- ---R......--- ---------- 
Rhe2  D1  -TA- - ---------------R.--------G-- H--D...---  T--------.....------....---------. ------R- ---R......--- ---I------ 
Rhe4  D1  -T.- - ---------------R.--------G-- H--D...---  T--------.....------....---------. ------R- ---R......--- ---------- 
Rhe6  D1  -T.- - ---------------R.--------G-- H--D...---  T--------.....------....---M-----. ------R- ---R......--- ---------- 
Rhe7  D1  -T.- - ---------------R.--------G-- H--D...---  T--------.....------....---------. ------R- ---R......--- ---------- 
RheP  D1  -T.- - ---------------R.--------G-- H--D...---  T--------.....------....---M-----. ------R- ---R......--- ---------- 
 
Human D2       (E)WLVLQTPHLEFQE...GETIMLRCHSW KDKP...LVK  VTFFQNGKSQ....KFSHLD....PTFSIPQANH SHSGDYHC TGNIG...YTLFS SKPVTITVQV 
Rhe9  D2        - --A---T----R-...----------- ----...-I-  -A-------K....N---MN....-N-------- -------- -----...--PY- ---------- 
Rhe2  D2        - --A---T----R-...----------- ----...-I-  -A-----I-K....----MN....-N----R--- -------- -----...--PY- ---------- 
Rhe4  D2        - --A--------R-...----------- ----...-I-  -A-----I-K....----M-....-N----R--- -------- -----...--PY- ---------- 
Rhe6  D2        - --A---T----R-...----------- ----...-I-  -A-----I-K....----M-....-N----R--- -------- -----...--PY- ---------- 
Rhe7  D2        - --A--------R-...----------- ----...-I-  -------IAK....----M-....-N-------- -------- -----...--PY- ---------- 
RheP  D2        - --A---T----R-...----------- ----...-I-  -A-------K....N---MN....-N-------- -------- -----...--PY- ---------- 
 
Human CO-TM-CY  PSMGSSSPMG VIVAVVIATAVAAIVAAVVALI YCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDDKNIYLTLPPNDHV 
Rhe9  CO-TM-CY  --V------- I-----TGI--V---------- ------------------RN--L---T--L-------------------------------R---V--------  
Rhe2  CO-TM-CY  --V------- I-----TGI----V-------- ------------------RN--L---T--L-------------------------------R---M-------- 
Rhe4  CO-TM-CY  --V------- I-----TGI----V-------- ------------------RN--L---T--L-------------------------------R---V-------- 
Rhe6  CO-TM-CY  --V------- I-----TGI----V-------- ------------------RN--L---T--L-------------------------------R---M-------- 
Rhe7  CO-TM-CY  --V------- I-----TGI----V-------- ------------------RN--L---T--L-------------------------------R---M-------- 
RheP  CO-TM-CY  --V------- I-----TGI--V---------- ------------------RN--L---T--L-------------------------------R---M--S---YD 
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Fig. 3.10. Alignment of the deduced amino acid sequences of rhesus macaque CD32 (FcγRII) 
(GenBank accession numbers: HQ423389-HQ423393) obtained by cloning and sequencing 
whole blood cDNAs with a human CD32a representative (shown as “Human”; GenBank 
accession number: BC020823.1). The deduced amino acid sequences of macaque CD32 are 
compared and amino acids that differ from the human CD32a sequence are shown. Included are 
only macaque sequences carrying independent allelic polymorphic amino acids (n=5), in which 
each allele has a single polymorphic site or a unique combination of polymorphic sites. A 
computationally predicted macaque CD32 [“RhesusP”; GenBank accession number (updated 
6/1/2010): XM_001118066.2] was also counted in. Hyphens indicate identical residues and dots 
represent the IMGT gaps (missing amino acids) inserted to maximize alignment. The broken-line 
box represents the region where macaque polymorphic sites are clustered. The unbroken-line box 
indicates the eight-amino acid stretch bearing multiple N substitutions (see text for details).
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Thus, these results suggest a relatively high level of intra-species heterogeneity of CD32 
and, to a lesser extent, CD64 and CD16, in rhesus macaques. 
 
3.3.4. Susscessful generation of recombinant FcγR gene cDNA constructs as well as their 
cloning and expression vectors 
The cDNAs that encode the extracellular domains of rhesus macaque CD64, CD32, and 
CD16, were successfully annealed and amplified by PCRs or SOE-PCRs (Fig. 3.13). These 
cDNA constructs were subsequently ligated properly into pCR2.1 TOPO TA cloning. 
Sequencing-verified cloning vectors were digested with appropriate REs to release each FcγR, 
which was subsequently subcloned into pcDNA3.1(+) (Invitrogen, Carlsbad, CA) on HindIII and 
BamHI RE sites, downstream of and in-frame with the promoter sequence, yielding the 
constructs pcDNA3-FcγRs-Hind-Bam (Fig. 3.3). Similar procedures were carried out for 
pcDNA3.1(+) (Invitrogen, Carlsbad, CA) and NotI and XhoI REs, creating pcDNA3-FcγRs-Not-
Xho recombinant expression vectors (Fig. 3.4). Additional expression plasmids, termed 
P2561/2/3-FcγRs-Not-Xho, were also made by ligating the NotI-XhoI-digestive FcγR cDNAs 
into P2561/2/3 plasmids excised with the same REs (Fig. 3.4). 
The insert was verified for correct size and proper orientation by RE digestion (Fig. 
3.13). RE analysis using EcoRI, HindIII and BamHI pair, as well as NotI and XhoI pair, revealed 
agarose gel band(s) [a double band pattern was observed when the FcγR cDNAs also contained 
the same RE site(s)] corresponding to the expected molecular weight/size of about 1.1, 0.9, or 
0.8 kb for CD64, CD32, or CD16, respectively, indicating that each of the constructs has been 
inserted into the expression vectors (Fig. 3.13). Selected recombinant plasmids were 
subsequently produced in large quantities using EndoFree Plasmid Maxi kits (Qiagen Inc.,
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Fig. 3.11. Schematic representation illustrating the extracellular domain 1 ([D1], or EC1) 
putative secondary structure of a representative sequence from each of three rhesus macaque 
FcγR classes in alignment with those in humans: no variation at known human functional 
positions is found in the animal molecules. (A) FcγRI (CD64), (B) FcγRII (CD32), (C) FcγRIII 
(CD16). The black texts above each sequence secondary structure depict the variations found in 
rhesus macaques, with the vertical arrows showing their relative positioning. Blue boxes, 
residues involved in interdomain hinge packing; red boxes, putative Fc binding residues 
(contacting B chain of IgG); blue star, predicted N-linked glycosylation site (human only); black 
star, predicted N-linked glycosylation site. Rh, rhesus macaque; Hu, human. These 
representations were constructed based on Radaev et al., 2001;  Zhang et al., 2000; and Maxwell 
et al., 1999. 
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Fig. 3.12. Schematic representation illustrating the extracellular domain 2 ([D2], or EC2) 
putative secondary structure of a representative sequence from each of three rhesus macaque 
FcγR classes in alignment with those in humans: no variation at known human functional 
positions is found in the animal molecules. (A) FcγRI (CD64), (B) FcγRII (CD32), (C) FcγRIII 
(CD16). The black texts above each sequence secondary structure depict the variations found in 
rhesus macaques, with the vertical arrows showing their relative positioning. Blue boxes, 
residues involved in interdomain hinge packing; yellow boxes, putative Fc binding residues 
(contacting A chain of IgG); red boxes, putative Fc binding residues (contacting B chain of IgG); 
blue star, predicted N-linked glycosylation site (human only); black star, predicted N-linked 
glycosylation site. Rh, rhesus macaque; Hu, human. These representations were constructed 
based on Radaev et al., 2001;  Zhang et al., 2000; and Maxwell et al., 1999. 
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Fig. 3.13. Gel electrophoresis separation of DNA products resulting from PCR and SOE-PCR 
annealing and amplification or digestion of clones of recombinant gene constructs of FcγRI (A), 
FcγRII (B), and FcγRIII (C), as well as gel electrophoresis separation of DNA fragments 
resulting from digestions of clones of recombinant FcγR gene constructs in pCR2.1 TOPO TA 
cloning vector cut by EcoRI (D), in pCR2.1 TOPO TA cloning vector cut by NotI and XhoI (E), 
and in P2561/2/3 expression vector cut by NotI and XhoI (F). PCR- and SOE-PCR-generated 
products or fragments obtained from RE-digested DNA plasmids were separated on 1-2% 
agarose gels, adjacent to DNA molecular weight standards. The gels were stained with ethidium 
bromide and were visualized and photographed under UV light. RE digestions were used to 
confirm that the recombinant gene constructs had each been inserted into correct region of the 
vectors and in correct orientation (which were subsequently confirmed by DNA sequencing). 
Number of lanes corresponding to each construct varies, as indicated by the horizontal lines. For 
lanes with two bands, the above released band corresponds to the digested vector and the below 
released band corresponds to the inserted DNA fragment. Lanes showing only one band (with 
size similar to that of the relevant vector) correspond to clones without successful DNA ligation. 
The DNA molecular weight standards are represented by lanes with multiple bands. Only 
representative clones containing bands of the expected sizes are shown. The vertical arrows with 
short notations show lanes corresponding to the indicated constructs.
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Valencia, CA), to be used for cellular transfection. DNA sequencing analysis confirmed the 
accuracy and orientation of all these constructs in the expression vectors (data not shown). 
Taken together, these data indicate that the FcγR cDNA genes were successfully 
engineered into cloning and expression vector systems. 
 
3.4. Discussion 
The well-recognized protective nature of antibody responses in HIV-infection (Mascola 
and Montefiori, 2010), along with the need to test candidate vaccines in the SIV-infected rhesus 
macaque model, underscores the importance of characterizing Fc receptors in this species. 
Indeed, recent findings indicate the importance of exploiting antibody responses that depend on 
the interactions with Fc receptors to increase vaccine efficacy. Well-characterized anti-HIV 
neutralizing monoclonal antibodies and even some non neutralizing antibodies show markedly 
increased viral inhibitory activity when operating through an FcγR mediated mechanism (Forthal 
and Moog, 2009). Using a different host-pathogen model system, it has been shown that antigen-
antibody complexes enhance antiviral cytotoxic T cell responses through FcγR-mediated binding 
to dendritic cells (Michaud et al., 2010). Clearly, the breadth of FcγR functions appears more 
extensive than what initially assumed. Therefore, the characterization of Fc receptors in rhesus 
macaques is necessary to correctly and fully utilize this major animal model. 
Although the FcγRII and FcγRI-“like” sequences have recently been predicted 
computationally, results from our study provide the first analysis of FcγRII and FcγRI macaque 
homologues along with their intraspecies allelic polymorphisms. The predicted cDNA structure 
of the macaque CD32 and CD64 represents the typical primary structure of their human 
counterparts, suggesting similar nature interactions with IgG molecules. Macaque FcγR exhibit 
193 
 
 
characteristic FcγR structural features. In particular, the length of a domain and the number of 
amino acids present between cysteine pairs, both of which are responsible for the folding pattern, 
is shorter in FcγR (~88 and 42–44 residues, respectively) as compared to IG proteins (~110 and 
no fewer than 80 residues, respectively) (Maxwell et al., 1999; Williams and Barclay, 1988). The 
high amino acid sequence identity of the FcγR domains between humans and macaques is 
consistent with the highly conserved nature of the individual C-like FcγR binding domains. 
Nevertheless, not all amino acids from the Fc binding region and the interdomain region packing 
are completely conserved in the macaque CD32 or CD64 sequences. One example is the addition 
of two predicted N linked glycosylation sites at [D2] 77 and 88 in macaque CD32, and the lack 
of three of these sites at [D1] 97, [D2] 88 and 99 in CD64, as compared to their human 
counterparts. It is noteworthy that all these amino acid changes are recognized in the computer-
predicted sequences, as well as in every individual animal examined, except for the polymorphic 
[D2] 77. Given that N-glycosylation sites have the ability to affect structure/folding, cell-cell 
adhesion, leukocyte expression patterns, and ligand-binding properties of FcγR (Rogers et al., 
2006; van Sorge et al., 2003), it might be predicted that these inter-species variations in 
glycosylation pattern might have a functional consequence on macaque CD32 and CD64 
proteins. 
The majority of amino acids known to be crucial for CD32 ligand binding in humans 
(Maxwell et al., 1999) are conserved in rhesus macaques. However, the human [D2] L81 is 
substituted by M81 in all nine animals. As L and M are both amino acids with a hydrophobic 
side chain and both favor the formation and stabilization of domain structures, it is reasonable to 
speculate that no major alteration in the hydrophilic/hydrophobic profile results from this 
change. Nevertheless, it is noteworthy that this position is located downstream next to the 
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functionally polymorphic amino acid [D2] H/R80 (131). This residue defines the specificity of 
CD32 for IgG in humans (Warmerdam et al., 1991). Interestingly, all nine macaques investigated 
display H131, the IgG2 low-responder polymorphic allele. It remains to be seen, however, if this 
substitution affects IgG-binding affinity and/or specificity of the receptor. 
Because the C-terminal membrane-proximal [D2] domain is the principal IgG-binding 
domain, its polymorphisms may influence binding properties. The N-terminal membrane-distal 
[D1] domain, on the other hand, mainly plays a supporting role in domain–domain interaction; 
thus, its variations might only affect the orientation of the spatial domain (Radaev and Sun, 
2002). In macaque CD64 proteins, all four (including RhesusP) polymorphic amino acids occur 
in [D1] (three in A strand and AB turn and the fourth one at position 93) (at amino acid 6–60), 
whereas in CD32 proteins, most (seven of nine) allelic polymorphic sites are clustered on a short 
segment in the middle of D2 (at amino acid 120–140 segment). Thus, these regions might be 
capable of mutating easily, indicating the impact of the evolutionary forces and the active 
functions of the receptors. In CD32 molecules, this short segment represents the type of small-
region, broad variation occurrence that might render the CD32 amino acid 120–140 segment a 
mutation hot spot. Even more interesting is the presence of a shorter stretch of eight amino acids 
located within another segment (residues 128 to 135): four of the eight residues are polymorphic, 
three of these four polymorphic residues are N, and two of these three N residues are potential 
glycosylated ones, thus indicating that this segment/stretch represents the most actively 
functional and evolutionarily instable area of the molecule. Although the polymorphic variations 
identified in the present study, including the two novel CD16 variants, are entirely located in the 
ligand-binding regions, no single, specific variation is at a location known to be crucial for IgG 
binding in the corresponding human molecules. However, even a single amino acid change may 
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significantly alter the ligand-binding affinity of FcγR. IgG-FcγR interactions are complex and 
multi-facial, and therefore, until binding studies are carried out, it is difficult to predict the 
functional implications of these allelic variations. 
Under natural evolutionary selection, polymorphisms, when occurring co-locally in both 
FcγR molecules and their native Fc ligand within the binding areas, have the potential to 
optimize functional activity and increase the binding fitness of both interacting players (Kim et 
al., 2001). Also, because of the extensive contact surface and multiple interactive residues, 
interactions between different FcRs and homodimeric Fc fragment of IgG (ligand) subclasses are 
complex. For instance, both the CH2 and CH3 domains of IgGs are involved in binding, with 
participated amino acids bind with different affinity depending on particular IgG subclass and 
the corresponding FcγR class members (Shields et al., 2001; Burton and Woof, 1992). 
Additionally, these interactions are asymmetrical (i.e. overlapping but not identical residues in 
both Fc fragments may take part in binding). Recent work from our group demonstrates the 
existence in macaques of a high level of IgA and IgG intra-species polymorphisms, particularly 
in the IgG2 and IgG4 subclasses (Rogers et al., 2008; Scinicariello et al., 2004; Scinicariello and 
Attanasio, 2001). The amino acid changes are primarily located at CH2 domain or the hinge 
region, including the lower hinge where all FcγRs bind and are responsible for most of the IgG 
effector functions and properties (Radaev and Sun, 2002). Thus, as both FcγR and IgG are highly 
polymorphic in macaques, the binding fitness and effector functions associated with these 
molecules might vary from individual to individual (i.e. intra-species) and might differ from 
those present in humans (i.e. inter-species). In order to adequately assess the binding properties 
and the ability to mediate effector functions of NHP FcγRs, therefore, not only the 
polymorphism of FcγRs themselves are ascribed, but also their ligand IgG genetic heterogeneity 
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must also be taken into account. Whether or not the sequence differences in FcγRs in rhesus 
macques (compared to humans) might be compensated by substitutions in their corresponding 
IgGs, leading to the unique properties and functions of the monkey IgG molecules, is difficult to 
predict and remains to be experimentally determined. Additionally, since particular allelic 
variations can be associated with disease susceptibility and/or severity and may influence the 
outcome of treatment with monoclonal antibodies (van Sorge et al., 2003; Cartron et al., 2002), 
this high heterogeneity characteristics must be considered when designing studies and 
interpreting data obtained using macaques for assessing immunogenicity and protective efficacy 
of HIV vaccines or vaccines for other infectious diseases, for studying the genetic basis of IgG-
mediated human diseases, and for evaluating Ab- or FcγR-derived immunotherapeutic 
approaches. 
In this study, we have successfully constructed recombinant cDNAs for all three classes 
of rhesus macaque FcγRs through two expression vector systems. In the first system, each rhesus 
macaque FcγR class cDNA was amplified by RT-PCRs and annealed by SOE-PCRs using 
primers with restriction sites for HindIII and BamHI, followed by cloning into pCR2.1 TOPO 
TA vector, and subsequent RE digestion verification and DNA sequencing confirmation. The 
FcγR cDNA was then excised from pCR2.1 TOPO TA cloning vector with HindIII and BamHI 
REs and engineered into expression vector pcDNA 3.1(+) (pre-digested with HindIII and BamHI 
REs), which contains CMV promoter and poly(A) signal to drive FcγR expression. An 
alternative system, where instead of HindIII and BamHI sites, NotI and XhoI RE sites were used. 
This first system was applied for expression of rhesus macaque FcR genes recently identified in 
our laboratory, including those encoding CD16 (Rogers et al., 2006) or the FcR for IgA (CD89) 
(Rogers et al., 2008). Transfection with this vector into HeLa or COS-7 cells, however, failed to 
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yield cell clones stably and/or sufficiently expressing recombinant FcγRs (Nguyen, D.C, 
unpublished data). Therefore, we developed a second expression vector system, which was a 
“combined” vector derived from the retrovirus vector pLXSN, containing LTR (as previously 
described; Fig. 2.8), that allow for the inserted gene to integrate into the host cell chromosomes. 
This vector was created by transferring a portion of the vector consisting of the FcR gene – as 
well as pcDNA3.1(+) promoter and poly(A) signal – into the pLXSN vector. The use of this 
“combined” vector, termed P2561/2/3, has previously proved to be capable of stably expressing 
recombinant FcγRs (Rogers et al., 2008 and 2006). P2561/2/3 system used in the present study, 
however, differs from the system previously used in our laboratory (Rogers et al., 2008 and 
2006) by its unique RE sites. This improved expression vector system has also been used for 
generation of recombinant IgGs, as described in the previous chapter. 
Cloning procedures are often the “bottleneck” in the use of the recombinant DNA 
method. Although in this study, no transfected cell clones were created at this time for evaluation 
of production of recombinant FcγRs, the successful construction of expression vectors is an 
important step before further studies can be undertaken. The gene expression cDNA constructs 
created in this study, which were designed (through the design of the primers) to incorporate 
unique [i.e. those are not present in FcγR genes, and rare (Persic et al., 1997)] NotI-XhoI 
restriction sites outside the gene coding regions for FcγRs, capable of facilitating easy cloning 
and exchange of IgSF gene constructs, can be readily cloned into another particular expression 
plasmid vector using RE digestion-ligation. For instance, future studies using the vector systems 
created from this study (and once protein FcγRs are produced) include those for mapping of 
binding interaction with ligands (IgGs) to specific epitopes, for interactions of FcγRs with the 
signaling chains, and for comparative studies of rhesus macaque/human IgG/FcγR interactions. 
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CHAPTER 4                                                                                                                                
17β-ESTRADIOL RESTORES ANTIBODY RESPONSES                                                  
TO AN INFLUENZA VACCINE IN A POSTMENOPAUSAL MOUSE MODEL 
 
(PARTIAL CONTENT OF THIS CHAPTER WAS PUBLISHED AS: 
NGUYEN ET AL., VACCINE 2011;29:2515–8) 
 
4.1. Summary 
Post-menopausal women belong to an age group that is highly susceptible to influenza 
infection and its most serious complications. Data on the immunogenicity of influenza vaccines 
in these women is, however, limited. In this study, we assessed the antibody response to 
influenza vaccination in a postmenopausal mouse model. An inactivated-detergent-split vaccine 
from the A/New Caledonia/20/99 (H1N1) influenza virus strain was given to three groups of 
mice: ovariectomized (OVEX), OVEX with 17β-estradiol replacement (OVEX + E2), and sham-
OVEX. The OVEX+ E2 group produced influenza virus-specific serum antibodies, including 
neutralizing antibodies, at significantly higher levels (p < 0.001) than did OVEX mice. These 
levels matched those observed in the sham-OVEX group, indicating that ovariectomy negatively 
modulates the antibody response to the influenza vaccine, whereas 17β-estradiol replacement 
restores this response to levels observed in intact animals. Our findings suggest that 
immunogenicity and efficacy of influenza vaccines need to be evaluated in postmenopausal 
women, including those receiving hormone replacement therapy. 
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4.2. Introduction 
Influenza remains a serious public health problem, which generates heavy burdens by 
annual epidemics and sporadic pandemics (Fiore et al., 2010). In the United States, influenza-
associated hospitalizations increase with increasing age (Dao et al., 2010). Co-morbidities and 
serious complications, including pneumonia, respiratory failure, and sepsis, are common in older 
individuals (Lee et al., 2010). Post-menopausal women belong to the age group highly 
susceptible to influenza complications. Currently, the most effective method in influenza control 
and prevention is the use of vaccines (Fiore et al., 2010). In the elderly, because of poor immune 
responses due to immunosenescence, the rate of immunization failure for influenza vaccines may 
be as high as 50% (Gravenstein et al., 1989). Unlike other infections, such as bacterial infections 
and sepsis, in which females are more resistant than males (Straub, 2007), women are more 
susceptible than men to influenza virus infection (WHO, 2010). 
Sex hormones are known to modulate the development and function of the immune 
system (Karpuzoglu et al., 2009; Bouman et al., 2005). As compared to men and pre-menopausal 
women, postmenopausal women and women subjected to surgical menopause are more 
susceptible to some specific disorders, including infectious diseases, and exhibit T and B cell 
impairment (Kumru et al., 2004). The use of hormone replacement therapy and estrogen 
replacement therapy in postmenopausal women is associated with retaining or improving both B 
and T cell immune functions, as well as with partly preventing or restoring some of the immune 
impairments associated with the post-menopause status (Gameiro et al., 2010). However, the 
modulatory effect of estrogen on immunity to human recommended vaccines, particularly after 
menopause, is largely uncharacterized. 
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We hypothesized that estrogen modulates the antibody response to influenza vaccine 
preparations and tested this hypothesis in the present study. 
 
4.3. Materials and methods 
4.3.1. Mice, bilateral ovariectomy, and estrogen deliver 
Pathogen-free adult (8–12 weeks of age) female BALB/c mice (Charles River 
Laboratories, Inc., Wilmington, MA), were housed and maintained in a pathogen-free 
environment on a phytoestrogen-free diet. The animals were divided into three groups: OVEX 
(subjected to ovariectomy), OVEX+ E2 (supplemented with exogenous estrogen) and Intact 
(sham-OVEX, not subjected to ovariectomy) (Fig. 4.1). Each group consisted of 23–24 mice, in 
which half of the mice were immunized, and the other half served as control. Surgical 
ovariectomy was performed under anesthesia to remove both left and right ovaries and animals 
were allowed to recover for at least one week before initiation of the experiments. 17β-estradiol 
(E2) (Sigma–Aldrich Corp., St. Louis, MO) was dissolved in 100% ethanol and diluted to its 
final concentrations (1 nM) in phosphate-buffered saline (PBS). The animals received 1 nM E2 
in drinking water (Gordon et al., 1986). The continuous delivery of E2 began after surgeries and 
lasted until the conclusion of the experiment. All animals were housed and all experimental 
procedures were carried out according to local and federal guidelines. 
 
4.3.2. Immunization 
Mice were immunized subcutaneously with a primary (Day 0) and booster (Day 28) 3 μg 
dose of an inactivated-detergent split influenza vaccine containing 333 μg/ml of the surface 
protein hemagglutinin (HA) of A/New Caledonia/20/99 virus (H1N1) obtained from Dr. David 
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Burt (ID Biomedicals, now GlaxoSmithKline Biologicals, Canada). Serum samples were 
collected at weeks 2–3 pre-immunization, immediately before vaccination (Day 0), 3 weeks after 
the first (3
rd
 week post-prime) and the second (3
rd
 week post-booster) doses, and 3 (3
rd
 month) 
and 6 (6
th
 month) months after the second dose (Fig. 4.2). Animals were monitored for adverse 
reactions to immunization such as redness, swelling, or the formation of granulomas at the site of 
injection. 
 
4.3.3. Evaluation of specific serum antibody response 
Antibody responses were evaluated by performing a set of assays using serum samples 
collected at different time-points. The assays included enzyme-linked immunosorbent assay 
(ELISA), HA-specific hemagglutination inhibition (HI), micro-neutralization (MN), and single-
radial hemolysis (SRH). Individual serum samples were used for all assays, with the exception of 
MN assay, for which pooled serum samples were used. The whole live homologous A/New 
Caledonia/20/99 virus was used for HI and MN assays. Viruses were propagated in the allantoic 
cavity of 10-day-old embryonated hens’ eggs at 34oC for 2 days. Virus stocks were aliquoted and 
stored at −70 ◦C until use. ELISAs were performed to detect IgM, IgG, IgG1, and IgG2a specific 
for viral HA by standard end-point dilution as previously described (Katz et al., 1997). Test sera 
were treated with receptor-destroying enzyme (RDE; purified neuraminidase from Vibrio 
cholerae, Denka Seiken Co. Ltd., Tokyo, Japan). Control negative mouse sera (five to seven 
samples) were included in each ELISA to establish negative endpoint cut-offs. Titers for immune 
sera were calculated as the reciprocal of the highest dilution of test sera that gave an absorbance 
reading value greater than twice the mean absorbance with one standard deviation of the control 
sera at an equivalent dilution. A four-fold or two-fold increase in titer, for individual and pooled 
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Fig. 4.1. Grouping of animals. Numbers denote individual animal numbering (for label purpose). 
 
 
 
Fig. 4.2. Immunization and blood collection timeline.
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serum comparison, respectively, was considered statistically significant for specific 
enhancement. Sera were tested for HI antibody using whole live homologous A/New 
Caledonia/20/99 virus (8 HA units per 50 μl PBS), by a standard HI assay (Stephenson et al., 
2004). A four-fold or greater increase in HI titer was considered indicative of significant 
enhancement. 
Neutralizing antibody activity was determined according to the MN assay as previously 
described (Stephenson et al., 2004). The presence of viral protein was detected by ELISA with a 
monoclonal antibody to the influenza A NP (Katz et al., 1997). MN titers were expressed as 
reciprocal of the highest dilution of serum that gave 50% neutralization of 100 TCID50 of virus 
in Marbin Darby canine kidney cells. Sera were considered positive for antibody if titers of ≥80 
were obtained in both assays; a fourfold or greater increase in MN titer was considered indicative 
of specific enhancement. The SRH assay was performed using chicken red blood cells as 
previously described (Stephenson et al., 2004). A 25% erythrocyte suspension was coated with 
an amount of 5,000 HAU per ml of homologous A/New Caledonia/20/99 virus. Plates were 
prepared by incorporating 0.6 ml of virus-treated erythrocytes together with 8.4 ml of 1% melted 
agar (Sigma–Aldrich Co., St. Louis, MO). An SRH zone of 25mm2 was considered protective 
(to 50% subjects) and an increase of equal or greater than 50% in the zone represented a 
significant antibody rise. 
 
4.3.4. Data analysis 
Serum HI antibody titers underwent log 2 transformation; the initial serum dilution was 
1/10, and undetectable titers were assigned a value of 5. Comparison of Ig titers was referred to 
log10 transformation of ELISA end-point titers. The SPSS program (SPSS Inc., Chicago, IL) 
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version 12 was used for statistical analysis. Analysis among multi-group data was carried out 
using ANOVA, followed by Tukey’s honestly significant differences test, or Tamhane’s T2 test 
when the test of homogeneity of variances (Levene’s statistic) indicated that the variance 
between the groups was not equal. Non-parametric data were compared by Mann–Whitney U-
test after Kruskal–Wallis analysis of variance. The null hypothesis was rejected at p > 0.05. 
 
4.4. Results 
All immunized mice produced anti-HA specific IgG and IgM responses following the 
primary dose. Antibody titers substantially increased after the booster dose (Fig. 4.3), with IgG 
being the predominant antibody class observed. The rise in specific antibody titers of both Ig 
classes post-prime was specific (from four- to seven-fold and significantly higher with p < 0.001) 
in the OVEX+ E2 and Intact when compared to the OVEX mice. Antibody levels increased 
substantially post-booster immunization (p < 0.001). No significant difference (p = 0.557) in 
antibody titers was observed between the OVEX+ E2 and Intact mouse groups for both time 
points and for both Ig classes. Specific IgG1 and IgG2a subclass antibodies were substantially 
induced. IgG1 levels were in general higher than IgG2a levels, regardless of the presence of E2. 
No statistically significant change was observed in titer for all three groups of mice of the same 
time points within each subclass of Ig. 
Animals from all groups generated a limited, but detectable HI antibody titers 3 weeks 
post-primary immunization. After the boosting dose, however, serum HI antibody titers 
dramatically increased (up to 128-fold) for all groups (Fig. 4.3). At this time point, the titers from 
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Fig. 4.3. Specific protective antibodies were induced and restored in the presence of 17β-
estradiol (E2) through six months after the boosting immunization. Titers expressed as values of 
mean log2 (for HI titer) or mean log10 (for ELISA IgM/IgG titers)±standard deviation (SD); titers 
of 2.33 (mean log2) and 2.00 (mean log10) for HI titer and ELISA IgM/IgG titers, respectively, 
were the detection limit. 
¥
No statistically significant change was observed in titer for all three 
groups of mice at the same time points within each subclass of Ig. 
*
Changes in titer of the 
OVEX+ E2 and Intact groups of mice as compared to that of the OVEX group of mice 
[specifically increased, and with statistical significance (p < 0.05)] and of the OVEX+ E2 and 
Intact groups of mice as compared to each other [no statistically significant change (p > 0.5)]; all 
considered at the same time point. 
*/¥
Increase in titer with (p < 0.05; OVEX+ E2 group) and 
without (p > 0.05; Intact group) statistical significance as compared to the OVEX group of mice. 
§
Pooled sera (no SD and no statistical comparison).
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the OVEX+ E2 and Intact mouse groups were similar, and at least four-fold higher than those 
from the OVEX group (p = 0.001). As a four-fold increase in HI titer is considered protective, 
our results demonstrate a specific and significant elevation of HI antibody levels in the OVEX+ 
E2 and Intact mice as compared to the OVEX group. Results from the SRH assay show that the 
hemolytic areas produced by the OVEX+ E2 or Intact sera were 62% and 65% greater than those 
obtained with OVEX sera respectively, while these two former areas differed only by 2% and the 
unvaccinated sera yielded no hemolytic zone (Fig. 4.4). 
Together, these results show the presence of similar antibody levels in the OVEX+ E2 
and Intact groups, and the presence of significantly higher antibody levels in these groups as 
compared to the OVEX group. 
Maintenance of long-term vigorous immune responses is important for overall vaccine 
efficacy. Therefore, we evaluated anti HA antibody titers produced three and six months after the 
booster immunization using the same set of assays used to detect antibody levels at earlier time 
points. Fig. 4.3 and Table 4.1 show the level and kinetics of these responses. IgG levels peaked 
three months post boost for HI and MN antibodies, whereas IgM reached maximum levels three-
week post-boost, with no exceptions for all groups. Influenza virus-specific serum antibodies 
were present three and six months post-boost regardless of the presence of estrogen (Fig. 4.3). 
IgG1 and IgG2a levels were maintained through six months after the boosting immunization. 
Again, antibody responses were not significantly different (p > 0.05) between the OVEX+ E2 
and Intact groups, but were specifically and significantly higher (p < 0.001) than those in the 
OVEX group three and six months post-boost. Similarly, results from SRH assay showed a 
significantly higher antibody levels in the OVEX+ E2 and Intact groups as compared to the 
OVEX group: the hemolytic area produced by the OVEX+ E2 or Intact sera was greater than that 
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yielded by the OVEX sera by 66% and 68%, respectively (for the three-month time point), and 
by 74% and 87%, respectively (for the six-month time point); all these zones were greater than 
25 mm
2
 (data not shown). No significant differences between the OVEX+ E2 and the Intact 
groups (their hemolytic areas differed by 1% or 7% at three- and six-month, respectively) were 
seen. Results from the SRH assay cannot be used to obtain quantitative determinations. 
However, SRH results were used to confirm the finding that the OVEX+ E2 group produced 
antibody responses at levels produced by the Intact group. 
All tested serum antibody (IgG, IgM, HI, and MN) titers at all times points from all 
control (unvaccinated) mice of the three groups were below detectable level (data not shown). 
Together, these results suggest that exogenous administration of estrogen restores 
production of specific antibody responses, but does not influence the TH1/TH2 pattern, at least up 
to six months after administration of the booster dose. 
 
4.5. Discussion 
Gender dimorphism in responses against pathogens and in autoimmune diseases has been 
observed in both humans and rodent models (Klein et al., 2010; McCombe et al., 2009). Indeed, 
the presence of estrogen and androgen receptors on progenitor and mature cells of the immune 
system suggests an important role for sex hormones in hematopoiesis and development of innate 
and adaptive immunity (Cunningham and Gilkeson, 2010; Rahman and Christian, 2007). The 
influence of 17β-estradiol on B-cell activity and development of antibody-mediated autoimmune 
diseases has been characterized (Grimaldi et al., 2005). However, it is recognized that 
information on the role that 17β-estradiol play in the modulation of antibody responses to 
vaccines is limited (Klein et al., 2010). Results from our study directly indicate a modulatory role
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Fig. 4.4. Effect of 17β-estradiol (E2) on influenza-specific antibody production as measured by Single Radial Hemolysis (SRH) assay. 
Specific antibodies were restored in the presence of estrogen from three weeks through six months after the boosting immunization. 
BALB/c mice were s.c. immunized with monovalent influenza vaccine antigen of A/New Caledonia/20/99 (H1N1) virus strain. Serum 
samples were collected one-, three-, and six-months after the boost (Two-Dose Vaccination) immunization. Agarose gels were used 
and results are read directly by measuring diameter of lysis ring that is directly proportional to the concentration of antibodies in test 
sera. Each sample was tested in duplicate.
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Table 4.1. Neutralizing antibody titers in ovariectomized (OVEX) mice, OVEX mice subjected 
to 17β-estradiol (E2) replacement (OVEX + E2) and Intact mice. 
Mouse group
a
 
MN titer 
Three months post-
2
nd
 vaccine dose 
Six months post-
2
nd
 vaccine dose 
OVEX
b
 640
c
 320 
OVEX + E2
b
 5,120
d
 2,560
d
 
Intact
b
 5,120
d
 2,560
d
 
 
a
Each group of 11–12 BALB/c mice were s.c. immunized with 3 μg/dose of the HA antigen. 
b
All MN assays used pooled sera (no SD). 
c
Titers expressed as the reciprocal of the highest dilution of serum that gave 50% neutralization 
of 100 TCID50 of virus in MDCK cells. 
d
Increased in titer of equal or greater than fourfold as compared to the OVEX group of mice of 
the same time course and of less than fourfold as compared to each other indicated with this 
same note (
d
).
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for E2 replacement on the response to an influenza vaccine in a post-menopausal animal model. 
In a similar model, E2 replacement resulted in improved protection against herpes simplex virus-
2 (HSV-2) genital challenge as compared to placebo and progesterone (Bhavanam et al., 2008) 
and estrogen administered in conjunction with a specific vaccine HSV-2 improved protection 
(Pennock et al., 2009). Thus, it is reasonable to postulate that postmenopausal women might 
respond differently to vaccine administration and that E2 replacement might up-modulate 
responses to vaccines in these women. 
The ability of E2 to restore specific anti-influenza HA antibody responses, which provide 
the essential protective role in influenza infection, in ovariectomized animals could be related to 
up-modulation of TH2 activity, as estrogen is known to exhibit reciprocal regulatory effects on T 
helper cells by inhibiting TH1 cytokine production and promoting that of TH2 cells (Salem, 
2004). Alternatively, this finding could be a result of the skewed-TH2 responses that are known 
to be produced by Balb/c mice (Sacks et al., 2008). In our study, although anti-HA specific IgG1 
(TH2-related) was higher than IgG2a (TH1-related) and anti-HA specific IgG1 increased earlier 
than IgG2a in all groups of mice, neither ovariectomy nor E2 levels had an effect on IgG1/IgG2a 
levels. The mechanisms underlying the ability of estradiol to up-modulate the response to the 
influenza vaccine are most likely complex and may involve pathways mediated by estrogen 
receptors as well as receptor independent pathways. Clarification of these mechanisms, as well 
as assessment of protective efficacy through challenge studies, will provide insight for the design 
of estradiol-based intervention strategies to increase the efficacy of influenza vaccines in 
postmenopausal women. 
The incidence of influenza infection, as well as related morbidity and mortality, may 
differ between males and females, are often related to age and may vary between countries. For 
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example, the outcome of influenza virus infection is generally worse for females, but the 
magnitude of these differences varies across geographical regions (WHO, 2010). Most reports of 
cases of seasonal influenza do not analyze data for sex differences, and when sex differences are 
analyzed there is no assessment of the interaction between sex and age. Although humoral 
immune responses to influenza vaccines have been found to be consistently higher in women 
than in men, clinical studies focusing on the effectiveness of these vaccines do not assess neither 
the role of sex nor the interaction between sex and age (Klein et al., 2010). Thus, studies carried 
out in animal models provide needed insight to understand the role that menopause plays in the 
response to vaccines. As life expectancy increases worldwide, the size of the postmenopausal 
population will increase accordingly. At the same time, influenza epidemics and pandemics are 
expected to continue representing a major global health threat. Older individuals are known to be 
at risk of serious influenza-associated complications while, at the same time, responding poorly 
to vaccines. Postmenopausal women would have the added disadvantage of impaired responses 
caused by a changing hormonal environment. Therefore, results from our study highlight the 
importance of taking into account the postmenopausal status when evaluating vaccine efficacy 
and designing strategies to control epidemic and pandemic influenza. 
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CHAPTER V                                                                                                              
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Phylogenetically positioned closely to humans, rhesus macaques are being increasingly 
used as an animal model for studies involving a variety of human diseases, as well as for 
assessing Ab-based therapeutics and vaccines, especially for HIV/AIDS research (Staprans et 
al., 2010; Hérodin et al., 2005). The design and interpretation of experimental data related to 
these studies often require the evaluation of humoral responses and are typically based on the 
assumption that rhesus macaque Ab molecules and their interactions with Fc receptors mimic 
those present in humans. This assumption has not been fully evaluated. The information 
available on rhesus macaque Ab molecules and corresponding Ig Fc receptors is steadily 
increasing (Warncke et al., 2012; Jacobsen et al., 2011; Rogers et al., 2008, 2006a, and 2004; 
Scinicariello et al., 2004; Scinicariello and Attanasio, 2001; Calvas et al., 1999). The findings 
that rhesus macaques exhibit a high level of Ab constant region polymorphism (Rogers et al., 
2008; Scinicariello et al., 2004; Scinicariello and Attanasio, 2001) suggest that their 
interactions with corresponding FcRs might be heterogenous, and that the structural and 
functional properties of their Ab products may not be of direct equivalence of those in humans. 
Indeed, recent data demonstrated a direct correlation of key amino acid differences with distinct 
functional activities (including ADCC and CDC) and FcγR binding affinity of the human and 
cynomolgus IgG subclasses (Warncke et al., 2012; Jacobsen et al., 2011). However, the IgG 
effector functions and pathogen clearance mechanisms in this model are largly unexplored – 
mostly due to lack of specific Ab reagents. In this study, we have engineered and produced 
recombinant IgG chimeras that were able to specifically recognize the NIP and were bound by 
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affinity purified goat anti-monkey IgG(H+L) Abs. These recombinant Abs  would be powerful 
new tools for evaluation of various IgG functional properties, including activation of cell-
killing mechanisms through binding with FcγRs such as ADCC, CDC, and phagocytosis, as 
well as other Ig characteristics, such as their half-life and protease susceptibility. 
To assess their ability in triggering specific effector functions, these recombinant IgG 
molecules will be subjected to FcγR binding and other immune cell-related studies (Fig. 5.1). 
Such FcγR binding properties and effector functional activities of these NIP-rhIgG chimeras 
will be assessed in in vitro studies using methods established in our laboratory (Rogers et al., 
2006). For these purpose, we retained the murine Ig V gene directed against the NIP hapten, an 
established specificity for Ig effector functions studies. HeLa cell lines expressing rhesus 
macaque FcγRs already generated (Rogers et al., 2006; Rogers et al., 2004) or to be generated 
(using the expression vector systems described in this dissertation) will be used in these 
functional studies. We expect these rhesus macaque recombinant IgG subclasses to exhibit the 
effector functions of the related appropriate human IgG CH regions, including FcγR binding 
and activation of relevant immune effector cells. We also predict some binding affinity and 
effector functional differences that might result from distint amino acid sequences of IgG 
subclasses among these two species. Confirmation of the presence and potency of such IgG 
effector functions with these newly created chimeric recombinant Abs will allow for their 
better use in further studies. 
Monoclonal Abs capable of specifically recognizing each of the rhesus macaque IgG 
subclasses represent valuable tools for further characterization of Ab responses and vaccine 
efficacy in this model. The relative level of IgG subclasses synthesized and present in rhesus 
macaque serum, which provide insights into the mechanisms that drive Ab production in this
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Fig. 5.1. Future studies and directions. See texts for details. 
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model, remain unknown. Given the availability of the cloning and expression plasmids 
containing the CH2/CH3 exon cDNA constructs (coding for the Fc region) created in this study, 
murine mAbs able to specifically recognize rhesus macaque IgG subclass Fc regions may be 
rapidly generated. Such Ab generation can be completed through DNA immunization of mice, an 
approach previously described by our group (Attanasio et al., 1997) (Fig. 5.1). Resultant murine 
mAbs can then be utilized to define the relative IgG isotype expression levels in normal and 
SIV/SHIV-infected rhesus macaque individuals. 
In this study, we have developed a flexible vector system and strategies for cloning and 
expression of Ig genes in order to produce in mammalian cells functional Igs, including those 
from NHP animals. As presented in the present study, complete, fully assembled IgG Abs that 
retain original antigenic specificity can be created and produced from separate IgH and IgL 
chains. This Ig expression system is uselful for engineering Abs with desired properties to be 
used to assess the IgG structure-function relationship or to evaluate vaccines or Ab-based 
therapeutic development. For example, the system might be used to enable generation of novel 
Abs with V domains of particular specificity, including clinically relevant specificity – instead of 
the NIP, such as those specific to antigens originated from SIV, HIV, or influenza viruses 
[including the lethal H5N1 (Simmons et al., 2007)], as well as from Mycobacterium tuberculosis 
(Fig. 5.1). These agents can be simply created by exchanging the Ig V gene of interest with that 
of the system. Such recombinant IgG variants might even be used for passive transfer or 
SIV/HIV challenge studies in rhesus macaques. Such in vivo evaluation will provide insights not 
only to better define the interplay between the humoral immune system and the cell-based 
effector innate immunity, but also to clarify the role of specific Ab-dependent cell-killing 
effector functions in in vivo protection against these pathogens (including HIV, SIV, and 
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influenza virus antigens). Those studies would, in turn, provide insights related to the in vivo 
administration of therapeutic Abs. 
Through genetic manipulation of Ig (not necessarily IgG) CH region genes, the effector 
functions of recombinant Abs can be modified to allow for desired immune effector responses 
while retaining antigen binding potency and specificity. To this end, the recombinant plasmid 
constructs created in this study may be subjected to manipulation for IgG-related basic and 
applied research purposes, including evaluating the pharmacologic values of recombinant Abs in 
the rhesus macaque model. Modifications could also be adapted to generate recombinant Abs 
with additional V and/or C functional properties, as well as for optimization (enhancement or 
neutralization) of particular Fc-mediated effector functions or other functional activities, to be 
used in Ab–antigen interaction studies or as therapeutic agents (Fig. 5.1). Moreover, such 
materials and approaches can be utilized for studying IgG structure/function relationships, such 
as changes in FcγR binding affinity due to amino acid differences by intra-species allelic 
polymorphisms in CH domains or in the hinge region. These constructs might also be used for 
production of well-conserved, immunogenic protein antigens for vaccine studies as well. 
In light of the finding that despite the extensive sequence identity and almost complete 
overlap of amino acids involved in Ab Fc binding, human and macaque CD16 molecules differ 
as it relates to number of isoforms (no CD16b has been identified in macaques) and cell-type 
expression patterns (as compared to human neutrophils, known to express CD16, rhesus 
macaque neutrophils do not appear to express this protein) (Rogers et al., 2006b), and that distint 
FcγR expression patterns and different binding properties between cynomolgus and human 
FcγRs and IgGs molecules have been recently revealed (Warncke et al., 2012; Jacobsen et al., 
2011), further characterizations of FcγR classes in rhesus macaques are necessary. The cellular 
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expression patterns of the rhesus macaque FcγRs identified in this dissertation – including CD64 
and CD32 receptors – have been partially completed (Nguyen, D.C, unpublished data). As 
previously discussed, the results obtained with genetic characterization of FcγRs validate rhesus 
macaques as an animal model for vaccine development and Ab response studies, while at the 
same time, underscoring the need to take into account their high degree of genetic heterogeneity 
when designing experimental protocols for such studies. These results were also the basis for 
creation of recombinant FcγR cDNA molecules. 
A major application using a cloned (recombinant) DNA molecule is the expression of it 
into a recombinant protein product. Our long term goals upon identification of the rhesus 
macaque homologues of human FcγR molecules at the genetic level are to characterize those 
molecules at the protein level, including determining their expression patterns on leukocyte 
populations and binding properties to both human and rhesus macaques IgG subclasses. As 
discussed previously, FcγRs vary in their affinity for different IgG subclasses. Moreover, 
interspecies differences between Igs as well as between FcRs of NHP models as opposed to 
humans might lead to variation in types immune effector responses induced by immune 
complexes (ICs)-FcRs (Warncke et al., 2012; Jacobsen et al., 2011). These differences might be 
ascribed onto different host defense strategies and disease susceptibility or progression of the 
rhesus macaque model against invading pathogens. Better understanding of these responses 
would serve to improve interpretation of immunology-related studies conducted in these models, 
particularly in rhesus macaques. Such studies could provide valuable insight for development of 
therapeutic agents directed at Ig and their Fc cell surface receptors. Therefore, it is important to 
develop expression systems for FcγRs and assays for binding affinity of cell bound receptors 
(and possibly, secreted FcγR portions), particularly given the fact that it is currently unknown 
225 
 
 
whether or at what extent human IgGs bind rhesus macaque effector cells. Recombinant forms of 
rhesus macaque FcγRs must, thus, be engineered. The first step towards these goals is to create 
recombinant FcγR cDNA constructs and incorporated them into cloning and expression vectors. 
We have employed the expression system and strategies developed and validated in this study to 
successfully create such FcγR cDNA constructs and vectors. Indeed, our strategies can also be 
adapted to be used for other rhesus macaque or other NHP IgSF molecule members as well. 
The recombinant IgG chimeras, as well as the cDNA plasmid vectors of IgG subclasses 
and corresponding FcγR molecules created in this study, therefore, represent both the 
foundations and the fundamental tools for further studies about IgG effector functions and Ab 
structure-function relationship in the rhesus macaque model (Fig. 5.1). Such studies will further 
validate and improve the use of rhesus macaques as a valuable model for studies that require 
assessment of IgG and FcγR functional properties and their interactions.
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